表紙
市場調查報告書
商品編碼
1064478

皮下生物藥物、技術、給藥系統市場(第4版):生物藥物類型(抗體、核甘酸、蛋白質、疫苗等)、治療類型(單藥治療、聯合治療)

Subcutaneous Biologics, Technologies and Drug Delivery Systems Market (4th Edition) by Type of Biologic (Antibodies, Nucleotides, Proteins, Vaccines, Other Biologics), Type of Therapy (Monotherapies and Combination Therapies),

出版日期: | 出版商: Roots Analysis | 英文 786 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

洞察示例

目前,生物製藥是製藥行業發展最快的領域之一。由於皮下生物製劑的各種優勢,製藥行業正在轉向皮下給藥。目前,超過 330 種生物製劑的皮下製劑正在各個臨床階段進行評估。

本報告探討了皮下生物製藥、技術和給藥系統市場,以及市場概況、產品、方法、應用、最終用戶和區域趨勢,以及進入市場的公司。提供概況等。

目錄

第一章前言

第2章執行摘要

第三章介紹

第4章批准的皮下生物形態:市場情況

  • 章節概述
  • 批准的皮下生物形態:藥物清單
  • 批准的皮下生物形態:開發者名單

第5章臨床皮下生物形態:市場情況

  • 章節概述
  • 臨床階段皮下生物藥物:藥物清單
  • 臨床分期皮下生物製劑:開發商名單

第 6 章批准的皮下生物形態:成功協議分析

第7章皮下製藥技術:當前市場狀況

  • 章節概述
  • 皮下製藥技術:技術列表
  • 皮下製藥技術:開發者名單

第8章皮下製藥技術開發商:公司競爭力分析

  • 章節概述
  • 假設和關鍵參數
  • 調查方法
  • 技術基準
  • 夥伴關係活動的基準測試
  • 企業競爭力分析

第9章皮下藥物技術開發商:公司簡介概述

  • 章節概述
  • Adocia
  • Ajinomoto Bio-Pharma Services
  • Alteogen
  • Arecor
  • Ascendis Pharma
  • Avadel Pharmaceuticals
  • Camurus
  • Creative Biolabs
  • Creative BioMart
  • DURECT
  • Eagle Pharmaceuticals
  • Halozyme Therapeutics
  • MedinCell
  • Xeris Pharmaceuticals
  • Serina Therapeutics

第 10 章夥伴關係和合作

  • 章節概述
  • 合作模式
  • 皮下製藥技術開發商:合作夥伴名單

第11章皮下給藥市場狀況系統:當前市場狀況

  • 章節概述
  • 各類皮下給藥系統

第12章皮下給藥系統:產品競爭力

  • 大容量穿戴式註射器
  • 自動噴油器
  • 無針注射系統
  • 預充式註射器

第 13 章批准的皮下生物形態:市場預測

第十四章皮下製藥技術:市場預測

第15章皮下給藥系統:市場預測

  • 皮下給藥系統市場
  • 給藥系統1:大容量可穿戴注射器
  • 給藥系統2:自動注射器
  • 給藥系統3:預裝注射器
  • 給藥系統4:無針注射系統
  • 給藥系統5:新藥重構系統

第16章SWOT分析

第17章結論

第 18 章執行洞察力

第19章附錄1:聚合數據

第20章附錄2:公司和組織名單

目錄

Title:
Subcutaneous Biologics, Technologies and Drug Delivery
Systems Market (4th Edition)

by Type of Biologic (Antibodies, Nucleotides, Proteins, Vaccines, Other Biologics), Type of Therapy (Monotherapies and Combination Therapies), Therapeutic Area (Autoimmune Disorders, Blood Disorders, Bone Disorders, Genetic Disorders, Hormonal Disorders, Infectious Disorders, Inflammatory Disorders, Kidney Disorders, Metabolic Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders and Other Disorders), Type of Payment (Milestone Payments and Upfront Payments), Type of Drug Delivery System (Large Volume Wearable Injectors, Autoinjectors, Prefilled Syringes, Needle-Free Injection Systems and Novel Drug Reconstitution Systems) and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World), Industry Trends and Global Forecasts, 2022-2035.

Example Insights:

Overview

Currently, biologics represent one of the fastest growing classes of the pharmaceutical industry. In fact, the US Food and Drug Administration (USFDA) has approved more than 630 biologic products till date, while over 8,000 such drug candidates are being evaluated in clinical studies. Primarily, biologic candidates are being designed for delivery via the parenteral route. However, this route is associated with the need for frequent medication, administered by a professional, in clinics or hospitals. Such visits pose an additional financial burden and are also very time consuming, thereby, negatively impacting the medical adherence. Further, low adherence to prescribed medications is reported to result in a loss of approximately USD 188 billion per year, in the US alone. A number of the aforementioned challenges can be mitigated by delivering drugs via the subcutaneous route, as it enables self-medication by patients. Other benefits associated with the subcutaneous administration include highly effective delivery of biologics (including vaccines, growth hormones and insulin) and substantial cost saving opportunities. Considering the various advantages offered by the subcutaneous route for the delivery of biologics, a shift in the preference towards this route has been observed in the pharmaceutical industry.

Presently, more than 330 subcutaneous biologics formulations are being evaluated in different clinical stages. In addition, several approved intravenous therapeutics are being reformulated and evaluated for delivery via the subcutaneous route of administration. However, there are certain concerns associated with the subcutaneous route. For instance, most protein-based therapeutics, such as monoclonal antibodies, need to be administered in large quantities and have been demonstrated to form highly viscous formulations when reformulated for subcutaneous delivery. In order to overcome this challenge, companies have developed / are developing a number of novel technology platforms, intended to facilitate the delivery of viscous drug formulations. Such innovations are gradually facilitating a shift towards subcutaneous delivery of biologics, primarily driven by the rising demand for self-administrable therapeutics. In fact, several subcutaneous self-administration drug delivery solutions, equipped with a variety of user-friendly features, are already available in the market; examples include prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors. Over the past few years, the aforementioned drug-device combination products have witnessed a high adoption, as they enable substantial reductions in healthcare expenses (incurred by patients) and demonstrate improved therapy adherence. Therefore, considering the rising prevalence of chronic diseases and the ongoing efforts of therapy / device developers engaged in this field, the subcutaneous biologics market is anticipated to grow at a steady pace in the foreseen future.

Scope of the Report

The 'Subcutaneous Biologics, Technologies and Drug Delivery Systems (4th Edition) Market by Type of Biologic (Antibodies, Nucleotides, Proteins, Vaccines, Other Biologics), Type of Therapy (Monotherapies and Combination Therapies), Therapeutic Area (Autoimmune Disorders, Blood Disorders, Bone Disorders, Genetic Disorders, Hormonal Disorders, Infectious Disorders, Inflammatory Disorders, Kidney Disorders, Metabolic Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders and Other Disorders), Type of Payment (Milestone Payments and Upfront Payments), Type of Drug Delivery System (Large Volume Wearable Injectors, Autoinjectors, Prefilled Syringes, Needle-Free Injection Systems and Novel Drug Reconstitution Systems) and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World), Industry Trends and Global Forecasts, 2022-2035' report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of commercially available biologics that are designed for delivery via the subcutaneous route, based on several relevant parameters, such as approval year, type of molecule (antibody, nucleotide, protein, vaccine and others) , type of therapy (monotherapy and combination therapy), route of administration (subcutaneous, intravenous and intramuscular) , method of administration (infusion and injection) , dosing frequency, dose concentration (in mg / ml) , target disease indication(s) (anemia, arthritis, asthma, diabetes, growth failure, growth hormone deficiency, idiopathic short stature, immunodeficiency, infertility, multiple sclerosis, neutropenia, osteoporosis, psoriasis, rheumatoid arthritis and turner syndrome) , therapeutic area (autoimmune disorders, blood disorders, bone disorders, genetic disorders, hormonal disorders, infectious disorders, inflammatory disorders, kidney disorders, metabolic disorders, neurological disorders, oncological disorders, respiratory disorders and other disorders) and type of available formulation (vial, cartridge, prefilled syringe, pen-injector, auto-injector and other devices) . In addition, it provides details on the companies offering these approved subcutaneous biologics, along with information on their year of establishment, company size, geographical location and leading developers (in terms of number of approved subcutaneous biologics) .
  • A detailed assessment of the current market landscape of clinical-stage biologics that are designed for delivery via the subcutaneous route, based on several relevant parameters, such as phase of development (phase I, phase II, Phase III, and FDA registration) , mechanism of action (inhibition, modulation, stimulation and others) , type of molecule (antibody, antisense oligonucleotides, protein, small interfering RNA, vaccine and others) , type of therapy (monotherapy and combination therapy) , dosing frequency, target disease indication(s) (asthma, atopic dermatitis, breast cancer, Crohn's disease, lung cancer, myasthenia gravis, non-alcoholic steatohepatitis, prostate cancer, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, type I diabetes, type II diabetes and ulcerative colitis) , therapeutic area (autoimmune disorders, bone disorders, cardiovascular disorders, dermatological disorders, genetic disorders, hematological disorders, hormonal disorders, infectious disorders, inflammatory disorders, kidney disorders, metabolic disorders, neurological disorders, oncological disorders, respiratory disorders and other disorders) and special designation(s) awarded (if any). In addition, it provides details on the companies engaged in the development of clinical-stage subcutaneous biologics, based on year of establishment, company size, location of headquarters and leading players (in terms of number of clinical-stage drugs).
  • An insightful success protocol analysis of leading subcutaneous biologics (in terms of value creation), taking into consideration several relevant parameters, such as drug efficacy / success rate, target disease indication burden, global competition (with respect to industry players), therapy price, geographical reach and disease prevalence.
  • A detailed assessment of the current market landscape of various subcutaneous formulation technologies, based on several relevant parameters, such as fundamental principle of technology, type of molecule (biologics and small molecule), route of administration, therapeutic area and primary advantage(s) offered. In addition, it provides details on the subcutaneous formulation technologies providers, along with information on their year of establishment, company size and location of headquarters.
  • An in-depth company competitiveness analysis of subcutaneous formulation technology providers, based on several relevant parameters, such as the company's technology strength (taking into consideration years of experience, type of molecule, route of administration, therapeutic area and advantage(s) offered), and partnership strength (in terms of the number of partnerships inked and type of agreement) .
  • Elaborate profiles of key subcutaneous technology providers, featuring a brief overview of the company, details related to its financial information (if available), technology portfolio, drug portfolio, recent developments and an informed future outlook.
  • An analysis of several partnerships and collaborations inked by subcutaneous formulation technology providers, during the period pre-2016 - 2021, based on several relevant parameters, such as year of partnership, type of partnership, type of partner, therapeutic area, focus area and country wise distribution.
  • An in-depth review of the most advanced and popular subcutaneous drug delivery systems, including large volume wearable injectors, drug device combination products, autoinjectors, pen injectors, needle-free injectors, novel drug reconstitution systems, prefilled syringes and implants, providing information on their developer(s) and device specific features. Details of specific parameters captured for different device categories are mentioned as follows:
  • Large volume wearable injectors: These devices have been analyzed based on their phase of development, type of device, actuation mechanism, technology used, route of administration, method of administration, therapeutic area, type of dose, storage volume / capacity, usability, availability of prefilled drug reservoir, availability of connectivity, drug compatibility, type of drug container, combination insulin, non-interoperable devices, availability of continuous glucose monitoring / blood glucose monitoring systems, availability of automated delivery feature, availability of automatic insulin delivery / artificial pancreas, and device control features
  • Autoinjectors: These devices have been analyzed based on their actuation mechanism, route of administration, type of dose, storage volume / capacity, usability, type of primary container and type of feedback mechanism.
  • Pen injectors: These devices have been analyzed based on their type of dose, storage volume / capacity and usability.
  • Needle-free injection systems: These devices have been analyzed based on their phase of development, actuation mechanism, therapeutic area and usability
  • Drug reconstitution systems: These devices have been analyzed based on their storage volume / capacity, usability, type of device, type of chamber, physical state of drugs and container fabrication material
  • Prefilled syringes: These devices have been analyzed based on their storage volume / capacity, barrel fabrication material, number of barrel chambers and type of needle system
  • Implants: These devices have been analyzed based on their phase of development, therapeutic area, implant material, treatment duration and type of delivery system
  • An elaborate product competitiveness analysis of subcutaneous drug delivery systems, such as large volume wearable injectors, autoinjectors, needle-free injectors and pre-filled syringes, taking into consideration the supplier power and product specific information.
  • A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry evolution, under an elaborate SWOT framework; it also includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall subcutaneous products market.

One of the key objectives of this study was to understand the primary growth drivers and estimate the existing market size and the future growth potential associated with subcutaneous biologics, technologies and drug delivery systems. Based on historical trends and sales related information for subcutaneous biologics, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term.

The report also provides details on the likely distribution of the current and forecasted opportunity for [A] Approved Subcutaneous Biologics across following segments:

  • Type of Biologic (antibodies, nucleotides, proteins, vaccines and other biologics)
  • Type of Therapy (monotherapy and combination therapy)
  • Therapeutic Area (autoimmune disorders, blood disorders, bone disorders, genetic disorders, hormonal disorders, infectious disorders, inflammatory disorders, kidney disorders, metabolic disorders, neurological disorders, oncological disorders, respiratory disorders, and other disorders)
  • Geographical Region (North America, Europe, Asia, Middle East and North Africa, Latin America and rest of the world)

Further, we have forecasted the revenues generated by approved subcutaneous biologics; for this, we have included information from yearly company biologics sales, biologics peak sales and patents.

[B] Subcutaneous Formulation Technology Providers across following segments:

  • Type of Payment (milestone payments and upfront payments)
  • Fundamental Principle (amino acid interaction principles, complex formation principles, encapsulation principles and other fundamental principles)
  • End-User (biopharmaceutical companies, contract development and manufacturing organizations, educational institutes, investors, pharmaceutical companies, research institutes and other end users)
  • Therapeutic Area (autoimmune disorders, genetic disorders, infectious disorders, metabolic disorders, oncological disorders, ophthalmic disorders and other disorders) and V. region (North America, Europe and Asia)

[C] Subcutaneous Biologics Drug Delivery Systems across following segments:

  • Type of Drug Delivery Systems (large volume wearable injectors, autoinjectors, prefilled syringes, needle-free injection systems and novel drug reconstitution systems) . The opportunity has been segmented
  • Type of Large Volume Wearable Injectors (infusion pumps and patch pumps)
  • Usability of Large Volume Wearable Injectors (disposable and reusable)
  • Therapeutic Area of Large Volume Wearable Injectors (cardiovascular disorders, infectious diseases, neurological disorders oncological disorders and others)
  • Type of Autoinjector (disposable and reusable)
  • Therapeutic Indication of Autoinjector (anaphylaxis, multiple sclerosis, rheumatoid arthritis, migraine, diabetes, and others)
  • Type of Syringe Barrel Material for Prefilled Syringes (glass and plastic)
  • Type of Chamber System for Prefilled Syringes (single chamber and dual chamber)
  • Therapeutic Area for Prefilled Syringes (autoimmune disorders, infectious diseases, neurological disorders, blood disorders, oncological disorders, psychiatric disorders, respiratory disorders, cardiovascular disorders, metabolic disorders, ophthalmic diseases, orthopedic disorders and others)
  • Type of Needle-Free Injection Systems (disposable and re-usable)
  • Types of Actuation Mechanisms for Needle-Free Injection Systems (spring-based, gas powered and others)
  • Therapeutic Area for Needle-Free Injection System (infectious diseases, diabetes and others)
  • Type of Container Novel Drug Reconstitution System (cartridge, infusion bag and prefilled syringe)
  • Type of Fabrication Material Used for Novel Drug Reconstitution System (glass and plastic)
  • Physical State of Drug in Syringe and Cartridge for Novel Drug Reconstitution System (liquid / powder, liquid / liquid)
  • Physical State of Drug in Infusion Bag for Novel Drug Reconstitution System (liquid mixture, frozen mixture)
  • Volume of Novel Drug Reconstitution System (<1 ml, 1-2.5 ml, 2.5-5 ml, >5 ml for prefilled syringe and cartridge; <250 ml, 250-500 ml, 500-1,000 ml, >1,000 ml for infusion bag) and
  • Key Geographical Regions for Drug Delivery Systems (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and rest of the world) .

Finally, in order to account for future uncertainties and add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in the report were influenced by discussions held with several senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Steve Prestrelski (Chief Scientific Officer and Founder, Xeris Pharmaceuticals) , Hong Qi (Vice President, Product Development, Xeris Pharmaceuticals) and Scott Coleman (Former Sr. Scientist Formulation, Xeris Pharmaceuticals)
  • Patrick Anquetil (Chief Executive Officer, Portal Instruments)
  • Deborah Bitterfield (Chief Executive Officer and Founder, Lindy Biosciences)
  • David Daily (Chief Executive Officer and Co-Founder, DALI Medical Devices)
  • Poonam R Velagaleti (Co-Founder, i-novion)
  • Frederic Ors (Former Chief Executive Officer, Immunovaccine Technologies)
  • David Heuzé (Communication Leader, MedinCell)
  • Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)
  • Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services)
  • Michael Reilly (Chief Executive Officer and Co-Founder, Excelse Bio)
  • Michael Hooven (Chief Executive Officer, Enable Injections)
  • Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies)

All actual figures have been sourced and analyzed from publicly available information forums and secondary sources. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the key players that have marketed their proprietary subcutaneous biologics?
  • Who are the leading players currently engaged in the development of clinical-stage subcutaneous biologics?
  • Which popular therapeutic areas are being targeted by clinical-stage subcutaneous biologics?
  • What are the crucial factors that impact the sales of a subcutaneous biologic product?
  • Who are the leading players involved in the development of subcutaneous formulation technologies?
  • What type of drug delivery systems are being most commonly used for the delivery of subcutaneous biologics?
  • What type of partnership models are most commonly adopted by stakeholders engaged in this industry?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outlines

Chapter 2 is an executive summary of key insights captured during our research. It offers a high-level view on the likely evolution of subcutaneous biologics, formulation technologies and drug delivery systems market, in the short to mid and long term.

Chapter 3 provides a general introduction on different types of therapeutic molecules (biologics and small molecules) comparing their characteristics, such as molecular size, molecular weight, molecular structure, immunogenicity, stability and manufacturing. The chapter also highlights different types of biologically derived products that are currently being developed by several players in the industry. Additionally, it includes information on the various challenges associated with the parenteral route of drug delivery, specifically those related to the traditional intravenous (infusion) route. Further, this chapter discusses about subcutaneous formulations, which includes different approaches of delivery of such biologics, method of administration, advantages and limitations associated with this route, along with the relevant regulatory guidelines.

Chapter 4 includes information on around 120 subcutaneous biologic drug candidates that are currently approved. The chapter features an elaborate analysis of marketed biologics based on several relevant parameters, such as approval year, type of molecule (antibody, nucleotide, protein, vaccine and others), type of therapy (monotherapy and combination therapy) , route of administration (subcutaneous, intravenous and intramuscular) , method of administration (infusion and injection) , dosing frequency, dose concentration (in mg/ml) , target disease indication(s) (anemia, arthritis, asthma, diabetes, growth failure, growth hormone deficiency, idiopathic short stature, immunodeficiency, infertility, multiple sclerosis, neutropenia, osteoporosis, psoriasis, rheumatoid arthritis and turner syndrome) , therapeutic area (autoimmune disorders, blood disorders, bone disorders, genetic disorders, hormonal disorders, infectious disorders, inflammatory disorders, kidney disorders, metabolic disorders, neurological disorders, oncological disorders, respiratory disorders and other disorders) and type of drug delivery device (vial, cartridge, prefilled syringe, pen-injector, auto-injector and other devices) . In addition, it provides details on the companies offering these approved subcutaneous biologics, along with information on their year of establishment, company size, geographical location and leading developers (in terms of number of approved subcutaneous biologics) .

Chapter 5 includes information of over 340 subcutaneous biologics that are currently in clinical stage of development. The chapter features an elaborate analysis of clinical-stage biologics based on several relevant parameters, such as phase of development (phase I, phase II, Phase III, and FDA registration) , mechanism of action (inhibition, modulation, stimulation and others) , type of molecule (antibody, antisense oligonucleotides, protein, small interfering RNA, vaccine and others) , type of therapy (monotherapy and combination therapy) , dosing frequency, target disease indication(s) (asthma, atopic dermatitis, breast cancer, Crohn's disease, lung cancer, myasthenia gravis, non-alcoholic steatohepatitis, prostate cancer, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, type I diabetes, type II diabetes and ulcerative colitis) , therapeutic area (autoimmune disorders, bone disorders, cardiovascular disorders, dermatological disorders, genetic disorders, hematological disorders, hormonal disorders, infectious disorders, inflammatory disorders, kidney disorders, metabolic disorders, neurological disorders, oncological disorders, respiratory disorders and other disorders) and special designation(s) awarded (if any). In addition, it provides details on the several companies engaged in the development of clinical-stage subcutaneous biologics, based on the year of establishment, company size, location of headquarters and leading players (in terms of number of clinical-stage drugs).

Chapter 6 is an insightful success protocol analysis of the leading subcutaneous biologics, biologics (in terms of value creation), taking into consideration several relevant parameters, such as drug efficacy / success rate, target disease indication burden, global competition (with respect to industry players), therapy price, geographical reach and disease prevalence.

Chapter 7 includes information on over 30 subcutaneous formulation technologies. It features an elaborate analysis of clinical-stage biologics based on several relevant parameters, such as fundamental principle of technology (amino acid interaction, complex formation, encapsulation and others) , type of molecule (biologics and small molecule), route of administration (intramuscular, intraocular, intravenous, local (unspecified), oral, pulmonary, subcutaneous and others) , therapeutic area (autoimmune disorders, genetic disorders, isank-deficiency disorders, infectious disorders, inflammatory disorders, metabolic disorders, neurological disorders, oncological disorders, other disorders) and primary advantage(s) offered. In addition, it provides details on the subcutaneous formulation technologies providers along with information on their year of establishment, company size and location of headquarters.

Chapter 8 features an insightful company competitiveness analysis of the subcutaneous formulation technology developers, based on several relevant parameters, such as the company's technology strength (taking into consideration years of experience, type of molecule, route of administration, therapeutic area and advantage(s) offered) , and partnership strength (in terms of the number of partnerships inked and type of agreement) .

Chapter 9 provides detailed profiles of key subcutaneous formulation technology providers engaged in this domain. Each profile features a brief overview of the company (including information on the year of establishment, number of employees, location of headquarters and key executives) , details related to its financial information (if available), list of drug candidates developed using the formulation technology, details related to its recent developments, and an informed future outlook.

Chapter 10 features an analysis of recent partnerships and collaborations that have been inked by several stakeholders engaged in this domain, pre-2016-2021. The chapter includes a brief description of the partnership models (including licensing agreement, formulation development agreement, product development agreement, R&D agreement, manufacturing and supply agreement, product development and commercialization agreement, joint venture and other related agreements) . Additionally, it comprises of analysis based on the year of partnership, type of partnership, type of partner, therapeutics area and focus area. Further, it consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 11 features an elaborate discussion on subcutaneous delivery systems with special focus on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, novel drug reconstitution systems, prefilled syringes and implants. The chapter includes a detailed analysis based on specific parameters for each device category, namely [A] large volume wearable non-insulin biologics injectors based on their phase of development, type of device, actuation mechanism, technology used, route of administration, method of administration, therapeutic area, type of dose, storage volume / capacity, usability, availability of prefilled drug reservoir, availability of connectivity, drug compatibility, availability of drug containers and key players, [B] large volume wearable insulin biologics injectors based on their phase of development, type of device, type of dose, storage volume / capacity, usability, combination insulin, non-interoperable devices, availability of prefilled drug reservoir, availability of continuous glucose monitoring (CGM) / blood glucose meters (BGM) system, availability of automated insulin delivery (AID) feature, automatic insulin delivery (AID) / artificial pancreas, availability of connectivity, availability of device control features and key players, [C] drug device combination products based on their phase of development, type device, mechanisms of action, technology used, route of administration, method of administration, therapeutics area, type of dose, storage volume/ capacity, usability, drug compatibility, drug container and key players, [D] autoinjector, by actuation mechanism, route of administration, type of dose, storage volume / capacity, usability, type of primary container, type of feedback mechanisms, and key players [E] pen-injectors based on their type of dose, storage volume / capacity, usability, and key player, [F] needle-free injection systems based on their phase of development, actuation mechanisms, therapeutic area, usability and key players [G] novel drug reconstitution systems based on their volume of container, usability, type of device, type of chambers, physical state of drugs, container fabrication material and key player, [I] prefilled syringes based on their storage volume / capacity, barrel fabrication material, number of barrel chamber, type of needle system and key players and [J] implants based on their phase of development, therapeutic area, implant material, treatment duration, type of delivery system and key players.

Chapter 12 features an insightful product competitiveness analysis of the subcutaneous delivery system, such as large volume wearable injectors, autoinjectors, needle-free injectors and pre-filled syringes, taking into consideration the supplier power and product specific information.

Chapter 13 presents an elaborate market forecast analysis, highlighting the future potential of the approved subcutaneous biologics market till 2035. Additionally, the chapter includes future sales projections of various approved subcutaneous biologic drug candidates. The chapter presents a detailed market segmentation on the basis of type of biologic (antibodies, nucleotides, proteins, vaccines and other biologics), [B] type of therapy (monotherapy and combination therapy) , [C] therapeutic area (autoimmune disorders, blood disorders, bone disorders, genetic disorders, hormonal disorders, infectious disorders, inflammatory disorders, kidney disorders, metabolic disorders, neurological disorders, oncological disorders, respiratory disorders, and other disorders) and [D] geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World) .

Chapter 14 presents an elaborate market forecast analysis, highlighting the future potential of the subcutaneous formulation technology market till the year 2035. The chapter presents a detailed market segmentation on the basis of [A] type of payment (milestone payments and upfront payments) , [B] fundamental principle (amino acid interaction, complex formation, encapsulation and other fundamental principles) , [C] end user (biopharmaceutical companies, biotechnology companies, contract development and manufacturing organizations, educational institutes, investors and other end users) , [D] therapeutic area (autoimmune disorders, genetic disorders, infectious disorders, metabolic disorders, oncological disorders, ophthalmic disorders and other disorders) and [E] geographical regions (North America, Europe and Asia) .

Chapter 15 presents an elaborate market forecast analysis, highlighting the future potential of the approved subcutaneous biologics market till the year 2035. In addition, it provides a 14-year forecast of subcutaneous delivery systems, including large volume wearable injectors, autoinjectors, prefilled syringes, needle-free injection systems and novel drug reconstitution systems.

Chapter 16 provides a detailed analysis capturing the key parameters and trends that are likely to impact the industry's evolution, under an elaborate SWOT framework; it also includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall subcutaneous biologics market.

Chapter 17 is a summary of the overall report. In this chapter, we have provided a list of the key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 18 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Deborah Bitterfield (Chief Executive Officer and Founder, Lindy Biosciences) , Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies) , Steve Prestrelski (Chief Scientific Officer and Founder, Xeris Pharmaceuticals) , Hong Qi (Vice President, Product Development, Xeris Pharmaceuticals) , Scott Coleman (Former Sr. Scientist Formulation, Xeris Pharmaceuticals) , David Daily (Chief Executive Officer and Co-Founder, DALI Medical Devices) , Michael Reilly (Chief Executive Officer and Co-Founder, Excelse Bio) , Poonam R Velagaleti (Co-Founder, i-novion) , Michael Hooven (Chief Executive Officer, Enable Injections) , Frederic Ors (Former Chief Executive Officer, Immunovaccine Technologies) , Patrick Anquetil (Chief Executive Officer, Portal Instruments) , Menachem Zucker (Vice President and Chief Scientist, Elcam Medical) , Tiffany H Burke (Director, Global Communications, West Pharmaceutical Services) , Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services) and David Heuzé (Communication Leader, MedinCell).

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 20 is an appendix, which provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Different Types of Therapeutics Molecules
  • 3.3. Biologically Derived Therapeutics
    • 3.3.1. Types of Products
    • 3.3.2. Routes of Administration and Formulations
    • 3.3.3. Subcutaneous Administration
      • 3.3.3.1. Methods of Subcutaneous Administration
      • 3.3.3.2. Advantages of Subcutaneous Administration
      • 3.3.3.3. Limitations of Subcutaneous Administration
  • 3.4. Regulatory Considerations
    • 3.4.1. Guidelines for Medical Devices
    • 3.4.2. Guidelines for Drug Device Combination Products
  • 3.5. Future Perspectives

4. APPROVED SUBCUTANEOUS BIOLOGICS: MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Approved Subcutaneous Biologics: List of Drugs
    • 4.2.1. Analysis by Approval Year
    • 4.2.2. Analysis by Type of Molecule
    • 4.2.3. Analysis by Type of Therapy
    • 4.2.4. Analysis by Route of Administration
    • 4.2.5. Analysis by Method of Administration
    • 4.2.6. Analysis by Dosing Frequency
    • 4.2.7. Analysis by Dose Concentration
    • 4.2.8. Analysis by Target Disease Indication(s)
    • 4.2.9. Analysis by Therapeutic Area
    • 4.2.10. Analysis by Type of Available Formulation
  • 4.3. Approved Subcutaneous Biologics: List of Developers
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Location of Headquarters
    • 4.3.4. Leading Developers: Analysis by Number of Approved Subcutaneous Biologics

5. CLINICAL SUBCUTANEOUS BIOLOGICS: MARKET LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Clinical-Stage Subcutaneous Biologics: List of Drugs
    • 5.2.1. Analysis by Phase of Development
    • 5.2.2. Analysis by Mechanism of Action
    • 5.2.3. Analysis by Type of Molecule
    • 5.2.4. Analysis by Type of Therapy
    • 5.2.5. Analysis by Dosing Frequency
    • 5.2.6. Analysis by Target Disease Indication(s)
    • 5.2.7. Analysis by Therapeutic Area
    • 5.2.8. Analysis by Special Drug Designation(s) Awarded
  • 5.3. Clinical-Stage Subcutaneous Biologics: List of Developers
    • 5.3.1. Analysis by Year of Establishment
    • 5.3.2. Analysis by Company Size
    • 5.3.3. Analysis by Geographical Location
    • 5.3.4. Leading Developers: Analysis by Number of Clinical-Stage Biologics

6. APPROVED SUBCUTANEOUS BIOLOGICS: SUCCESS PROTOCOL ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Leading Approved Subcutaneous Biologics: Analysis by Value Creation Sales
  • 6.3. STELARA® (Janssen Biotech)
    • 6.3.1. Drug Overview
    • 6.3.2. Development History
    • 6.3.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
    • 6.3.4. Success Protocol Analysis
  • 6.4 DUPIXENT® (Regeneron Pharmaceuticals)
    • 6.4.1. Drug Overview
    • 6.4.2. Development History
    • 6.4.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
    • 6.4.4. Success Protocol Analysis
  • 6.5. Trulicity® (Eli Lilly)
    • 6.5.1. Drug Overview
    • 6.5.2. Development History
    • 6.5.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
    • 6.5.4. Success Protocol Analysis
  • 6.6. Enbrel® (Amgen)
    • 6.6.1. Drug Overview
    • 6.6.2. Development History
    • 6.6.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
    • 6.6.4. Success Protocol Analysis
  • 6.7. COSENTYX® (Novartis)
    • 6.7.1. Drug Overview
    • 6.7.2. Development History
    • 6.7.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
    • 6.7.4. Success Protocol Analysis
  • 6.8. BESREMi (PharmaEssentia)
    • 6.8.1. Drug Overview
    • 6.8.2. Development History
    • 6.8.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
    • 6.8.4. Success Protocol Analysis
  • 6.9. DARZALEX FASPRO® (Halozyme)
    • 6.9.1. Drug Overview
    • 6.9.2. Development History
    • 6.9.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
    • 6.9.4. Success Protocol Analysis
  • 6.10. Prolia® / Pralia® (Amgen)
    • 6.10.1. Drug Overview
    • 6.10.2. Development History
    • 6.10.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
    • 6.10.5. Success Protocol Analysis
  • 6.11. HEMLIBRA® (Roche)
    • 6.11.1. Drug Overview
    • 6.11.2. Development History
    • 6.11.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
    • 6.11.4. Success Protocol Analysis
  • 6.12. BENLYSTA® (Human Genome Sciences)
    • 6.12.1. Drug Overview
    • 6.12.2. Development History
    • 6.12.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
    • 6.12.4. Success Protocol Analysis
  • 6.13. Conclusion

7. SUBCUTANEOUS FORMULATION TECHNOLOGIES: CURRENT MARKET LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Subcutaneous Formulation Technologies: List of Technologies
    • 7.2.1. Analysis by Fundamental Principle of Technology
    • 7.2.2. Analysis by Type of Molecule
    • 7.2.3. Analysis by Type of Formulation
    • 7.2.4. Analysis by Therapeutic Area
    • 7.2.5. Analysis by Advantage(s) Offered
  • 7.3. Subcutaneous Formulation Technologies: List of Developers
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Location of Headquarters

8. SUBCUTANEOUS FORMULATION TECHNOLOGY DEVELOPERS: COMPANY COMPETITIVENESS ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Assumption and Key Parameters
  • 8.3. Methodology
  • 8.4. Benchmarking of Technology Strength
  • 8.5. Benchmarking of Partnership Activity
  • 8.6. Company Competitiveness Analysis
    • 8.6.1. Developers based in North America
    • 8.6.2. Developers based in Europe and Asia

9. SUBCUTANEOUS FORMULATION TECHNOLOGY DEVELOPERS: COMPANY PROFILES

  • 9.1. Chapter Overview
  • 9.2. Adocia
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Technology Overview
      • 9.2.3.1. Biochaperonen® Technology
    • 9.2.4. Drug Portfolio
    • 9.2.5. Recent Developments and Future Outlook
  • 9.3. Ajinomoto Bio-Pharma Services
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Technology Overview
      • 9.3.3.1. Crystalomics® Formulation Technology
    • 9.3.4. Drug Portfolio
    • 9.3.5. Recent Developments and Future Outlook
  • 9.4. Alteogen
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Technology Overview
      • 9.4.3.1. Hybrozyme Technology
    • 9.4.4. Drug Portfolio
    • 9.4.5. Recent Developments and Future Outlook
  • 9.5. Arecor
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Technology Overview
      • 9.5.3.1. Arestat™ Technology
    • 9.5.4. Drug Portfolio
    • 9.5.5. Recent Developments and Future Outlook
  • 9.6. Ascendis Pharma
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Technology Overview
      • 9.6.3.1. TransCon Technology
    • 9.6.4. Drug Portfolio
    • 9.6.5. Recent Developments and Future Outlook
  • 9.7. Avadel Pharmaceuticals
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Technology Overview
      • 9.7.3.1. Medusa™ Technology
    • 9.7.4. Drug Portfolio
    • 9.7.5. Recent Developments and Future Outlook
  • 9.8. Camurus
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Technology Overview
      • 9.8.3.1. FluidCrystal® Injection Depot Technology
    • 9.8.4. Drug Portfolio
    • 9.8.5. Recent Developments and Future Outlook
  • 9.9. Creative Biolabs
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Technology Overview
      • 9.9.3.1. Long-Acting Injectable Technology
    • 9.9.4. Drug Portfolio
    • 9.9.5. Recent Developments and Future Outlook
  • 9.10. Creative BioMart
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Technology Overview
      • 9.10.3.1. High Concentration Formulation Technology
    • 9.10.4. Drug Portfolio
    • 9.10.5. Recent Developments and Future Outlook
  • 9.11. DURECT
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Technology Overview
      • 9.11.3.1. SABER® Platform
      • 9.11.3.2. CLOUD™ Platform
    • 9.11.4. Drug Portfolio
    • 9.11.5. Recent Developments and Future Outlook
  • 9.12. Eagle Pharmaceuticals
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Technology Overview
      • 9.12.3.1. Unnamed Technology
    • 9.12.4. Drug Portfolio
    • 9.12.5. Recent Developments and Future Outlook
  • 9.13. Halozyme Therapeutics
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Technology Overview
      • 9.13.3.1. ENHANZE® Technology
    • 9.13.4. Drug Portfolio
    • 9.13.5. Recent Developments and Future Outlook
  • 9.14. MedinCell
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Technology Overview
      • 9.14.3.1. BEPO® Technology
    • 9.14.4. Drug Portfolio
    • 9.14.5. Recent Developments and Future Outlook
  • 9.15. Xeris Pharmaceuticals
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Technology Overview
      • 9.15.3.1. XeriJect™ Technology
      • 9.15.3.2. XeriSol™ Technology
    • 9.15.4. Drug Portfolio
    • 9.15.5. Recent Developments and Future Outlook
  • 9.16. Serina Therapeutics
    • 9.16.1. Company Overview
    • 9.16.2. Financial Performance
    • 9.16.3. Technology Overview
      • 9.16.3.1. POZ™ Drug Delivery Technology
    • 9.16.4. Drug Portfolio
    • 9.16.5. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS

  • 10.1. Chapter Overview
  • 10.2. Partnership Models
  • 10.3. Subcutaneous Formulation Technology Developers: List of Partnerships
    • 10.3.1. Analysis by Year of Partnership
    • 10.3.2. Analysis by Type of Partnership
    • 10.3.3. Analysis by Type of Partner
    • 10.3.4. Analysis by Therapeutic Area
    • 10.3.5. Analysis by Focus Area
    • 10.3.6. Analysis by Region
      • 10.3.6.1. Country-Wise Distribution
      • 10.3.6.2. Intercontinental and Intracontinental Distribution
    • 10.3.7. Most Active Developers: Analysis by Number of Partnerships

11. SUBCUTANEOUS DRUG DELIVERY SYSTEMS: CURRENT MARKET LANDSCAPE

  • 11.1. Chapter Overview
  • 11.2. Different Types of Subcutaneous Drug Delivery Systems
    • 11.2.1. Large Volume Wearable Injectors
      • 11.2.1.1. Current Market Landscape of Devices for Non-insulin Drugs
        • 11.2.1.1.1. Analysis by Phase of Development
        • 11.2.1.1.2. Analysis by Type of Device
        • 11.2.1.1.3. Analysis by Actuation Mechanism
        • 11.2.1.1.4. Analysis by Technology Used
        • 11.2.1.1.5. Analysis by Route of Administration
        • 11.2.1.1.6. Analysis by Method of Administration
        • 11.2.1.1.7. Analysis by Therapeutic Area
        • 11.2.1.1.8. Analysis by Type of Dose
        • 11.2.1.1.9. Analysis by Storage Volume / Capacity
        • 11.2.1.1.10. Analysis by Usability
        • 11.2.1.1.11. Analysis by Availability of Prefilled Drug Reservoir
        • 11.2.1.1.12. Analysis by Availability of Connectivity
        • 11.2.1.1.13. Analysis by Availability of Drug Compatibility
        • 11.2.1.1.14. Analysis by Availability of Drug Container
        • 11.2.1.1.15. Most Active Players: Analysis by Number of Large Volume Wearable Injectors for Non-insulin Drugs
      • 11.2.1.2. Current Market Landscape of Devices for Insulin Drugs
        • 11.2.1.2.1. Analysis by Phase of Development
        • 11.2.1.2.2. Analysis by Type of Device
        • 11.2.1.2.3. Analysis by Type of Dose
        • 11.2.1.2.4. Analysis by Storage Volume / Capacity
        • 11.2.1.2.5. Analysis by Usability
        • 11.2.1.2.6. Analysis by Combination Insulin
        • 11.2.1.2.7. Analysis by Non-Interoperable Device
        • 11.2.1.2.8. Analysis by Availability of Prefilled Drug Reservoir
        • 11.2.1.2.9. Analysis by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
        • 11.2.1.2.10. Analysis by Availability of Automated Insulin Delivery (AID) Feature
        • 11.2.1.2.11. Analysis by Automatic Insulin Delivery (AID) / Artificial Pancreas
        • 11.2.1.2.12. Analysis by Availability of Connectivity
        • 11.2.1.2.13. Analysis by Availability of Device Control Features
        • 11.2.1.2.14. Most Active Players: Analysis by Number of Large Volume Wearable Injectors for Insulin Drugs
      • 11.2.1.3. Current Market Landscape of Drug Device Combination Products
        • 11.2.1.3.1. Analysis by Phase of Development
        • 11.2.1.3.2. Analysis by Type of Device
        • 11.2.1.3.3. Analysis by Mechanism of Action
        • 11.2.1.3.4. Analysis by Technology Used
        • 11.2.1.3.5. Analysis by Route of Administration
        • 11.2.1.3.6. Analysis by Method of Administration
        • 11.2.1.3.7. Analysis by Therapeutic Area
        • 11.2.1.3.8. Analysis by Type of Dose
        • 11.2.1.3.9. Analysis by Storage Volume / Capacity
        • 11.2.1.3.10. Analysis by Usability
        • 11.2.1.3.11. Analysis by Drug Compatibility
        • 11.2.1.3.12. Analysis by Drug Container
        • 11.2.1.3.13. Most Active Players: Analysis by Number of Products Manufactured
    • 11.2.2. Autoinjectors
      • 11.2.2.1. Current Market Landscape
        • 11.2.2.1.1. Analysis by Actuation Mechanism
        • 11.2.2.1.2. Analysis by Route of Administration
        • 11.2.2.1.3. Analysis by Type of Dose
        • 11.2.2.1.4. Analysis by Storage Volume / Capacity
        • 11.2.2.1.5. Analysis by Usability
        • 11.2.2.1.6. Analysis by Type of Primary Container
        • 11.2.2.1.7. Analysis by Type of Feedback Mechanisms
        • 11.2.2.1.8. Most Active Players: Analysis by Number of Devices
    • 11.2.3. Pen Injectors
      • 11.2.3.1. Current Market Landscape
        • 11.2.3.1.1. Analysis by Type of Dose
        • 11.2.3.1.2. Analysis by Storage Volume / Capacity
        • 11.2.3.1.3. Analysis by Usability
        • 11.2.3.1.4. Most Active Players: Analysis by Number of Devices
      • 11.2.3.2. Drug Device Combination Products
    • 11.2.4. Needle-Free Injection Systems
      • 11.2.4.1. Current Market Landscape
        • 11.2.4.1.1. Analysis by Phase of Development
        • 11.2.4.1.2. Analysis by Actuation Mechanism
        • 11.2.4.1.3. Analysis by Therapeutic Area
        • 11.2.4.1.4. Analysis by Usability
        • 11.2.4.1.5. Most Active Players: Analysis by Number of Devices
      • 11.2.4.2. Drug Device Combination Products
    • 11.2.5. Novel Drug Reconstitution Delivery Systems
      • 11.2.5.1. Current Market Landscape
        • 11.2.5.1.1. Analysis by Volume of Container
        • 11.2.5.1.1. Analysis by Usability
        • 11.2.5.1.2 Analysis by Type of Device
        • 11.2.5.1.3. Analysis by Type of Chamber
        • 11.2.5.1.1. Analysis by Physical State of Drugs
        • 11.2.5.1.4. Analysis by Container Fabrication Material
        • 11.2.5.1.7. Most Active Players: Analysis by Number of Devices
    • 11.2.6. Prefilled Syringes
      • 11.2.6.1. Current Market Landscape
        • 11.2.6.1.1. Analysis by Storage Volume / Capacity
        • 11.2.6.1.2. Analysis by Barrel Fabrication Material
        • 11.2.6.1.3. Analysis by Number of Barrel Chambers
        • 11.2.6.1.4. Analysis by Type of Needle System
      • 11.2.6.1 5. Most Active Players: Analysis by Number of Devices
      • 11.2.6.2. Drug Device Combination Products
    • 11.2.7. Implants
      • 11.2.7.1. Current Market Landscape
        • 11.2.7.1.1. Analysis by Phase of Development
        • 11.2.7.1.2. Analysis by Therapeutic Area
        • 11.2.7.1.3. Analysis by Implant Material
        • 11.2.7.1.4. Analysis by Treatment Duration
        • 11.2.7.1.5. Analysis by Type of Delivery System
        • 11.2.7.1.6. Most Active Players: Analysis by Number of Devices
      • 11.2.7.2. Subcutaneous Implants Eluting Small Molecules

12. SUBCUTANEOUS DRUG DELIVERY SYSTEMS: PRODUCT COMPETITIVENESS

  • 12.1. Large Volume Wearable Injectors
    • 12.1.1. Methodology and Key Parameters
    • 12.1.2. Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Drugs
    • 12.1.3. Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin Drugs
    • 12.1.4. Product Competitiveness Analysis: Drug Device Combination Products
  • 12.2. Autoinjectors
    • 12.2.1. Methodology and Key Parameters
    • 12.2.1. Product Competitiveness Analysis: Disposable Autoinjectors
    • 12.2.2. Product Competitiveness Analysis: Reusable Autoinjectors
  • 12.3. Needle-Free Injection Systems
    • 12.3.1. Methodology and Key Parameters
    • 12.3.2. Product Competitiveness Analysis: Spring-Based Needle-Free Injection Systems
    • 12.3.3. Product Competitiveness Analysis: Gas-Powered Needle-Free Injection Systems
  • 12.4. Prefilled Syringes
    • 12.4.1. Methodology and Key Parameters
    • 12.4.2. Product Competitiveness Analysis: Glass Barrel Syringes
    • 12.4.3. Product Competitiveness Analysis: Plastic Barrel Syringes

13. APPORVED SUBCUTANEOUS BIOLOGICS: MARKET FORECAST

  • 13.1. Chapter Overview
  • 13.2. Scope and Limitations
  • 13.3. Forecast Methodology and Key Assumptions
  • 13.4. Global Approved Subcutaneous Biologics Market, 2022-2035
    • 13.4.1. Approved Subcutaneous Biologics Market: Distribution by Type of Biologic, 2022 and 2035
      • 13.4.1.1. Approved Subcutaneous Biologics Market for Antibodies, 2022-2035
      • 13.4.1.2. Approved Subcutaneous Biologics Market for Nucleotides, 2022-2035
      • 13.4.1.3. Approved Subcutaneous Biologics Market for Proteins, 2022-2035
      • 13.4.1.4. Approved Subcutaneous Biologics Market for Vaccines, 2022-2035
      • 13.4.1.5. Approved Subcutaneous Biologics Market for Other Biologics, 2022-2035
    • 13.4.2. Approved Subcutaneous Biologics Market: Distribution by Type of Therapy, 2022 and 2035
      • 13.4.2.1. Approved Subcutaneous Biologics Market for Monotherapies, 2022-2035
      • 13.4.2.2. Approved Subcutaneous Biologics Market for Combination Therapies, 2022-2035
      • 13.4.2.3. Approved Subcutaneous Biologics Market for Monotherapies and Combination Therapies, 2022-2035
    • 13.4.3. Approved Subcutaneous Biologics Market: Distribution by Therapeutic Area, 2022 and 2035
      • 13.4.3.1. Approved Subcutaneous Biologics Market for Autoimmune Disorders, 2022-2035
      • 13.4.3.2. Approved Subcutaneous Biologics Market for Blood Disorders, 2022-2035
      • 13.4.3.3. Approved Subcutaneous Biologics Market for Bone Disorders, 2022-2035
      • 13.4.3.4. Approved Subcutaneous Biologics Market for Cardiovascular Disorders, 2022-2035
      • 13.4.3.5. Approved Subcutaneous Biologics Market for Genetic Disorders, 2022-2035
      • 13.4.3.6. Approved Subcutaneous Biologics Market for Hormonal Disorders, 2022-2035
      • 13.4.3.7. Approved Subcutaneous Biologics Market for Hypoactive Sexual Desire Disorders, 2022-2035
      • 13.4.3.8. Approved Subcutaneous Biologics Market for Infectious Disorders, 2022-2035
      • 13.4.3.9. Approved Subcutaneous Biologics Market for Inflammatory Disorders, 2022-2035
      • 13.4.3.10. Approved Subcutaneous Biologics Market for Kidney Disorders, 2022-2035
      • 13.4.3.11. Approved Subcutaneous Biologics Market for Mental Health Disorders, 2022-2035
      • 13.4.3.12. Approved Subcutaneous Biologics Market for Metabolic Disorders, 2022-2035
      • 13.4.3.13. Approved Subcutaneous Biologics Market for Neurological Disorders, 2022-2035
      • 13.4.3.14. Approved Subcutaneous Biologics Market for Oncological Disorders, 2022-2035
      • 13.4.3.15. Approved Subcutaneous Biologics Market for Respiratory Disorders, 2022-2035
      • 13.4.3.16. Approved Subcutaneous Biologics Market for Women's Health, 2022-2035
      • 13.4.3.17. Approved Subcutaneous Biologics Market for Other Disorders, 2022-2035
    • 13.4.4. Approved Subcutaneous Biologics Market: Distribution by Geographical Region, 2022 and 2035
      • 13.4.4.1. Approved Subcutaneous Biologics Market in North America, 2022-2035
      • 13.4.4.2. Approved Subcutaneous Biologics Market in Europe, 2022-2035
      • 13.4.4.3. Approved Subcutaneous Biologics Market in Asia, 2022-2035
    • 13.4.5. Drug-wise Sales Forecast
      • 13.4.5.1. AIMOVIG (erenumab-aooe), Amgen
        • 13.4.5.1.1 Sales Forecast
      • 13.4.5.2. AJOVY (fremanezumab-vfrm), Teva Pharmaceuticals
        • 13.4.5.2.1 Sales Forecast
      • 13.4.5.3. Apidra® (insulin glulisine), Sanofi
        • 13.4.5.3.1. Sales Forecast
      • 13.4.5.4. Aranesp® / Nesp® (darbepoetin alfa), Amgen
        • 13.4.5.4.1. Sales Forecast
      • 13.4.5.5. Basaglar® / Abrasia (EU) (insulin glargine injection), Eli Lilly
        • 13.4.5.5.1. Sales Forecast
      • 13.4.5.6. BENLYSTA® (belimumab), Human Genome Sciences
        • 13.4.5.6.1. Sales Forecast
      • 13.4.5.7. BESREMi (ropeginterferon alfa-2b-njft), PharmaEssentia
        • 13.4.5.7.1. Sales Forecast
      • 13.4.5.8. BIOTHRAX® (Anthrax Vaccine Adsorbed), Emergent Biosolutions
        • 13.4.5.8.1. Sales Forecast
      • 13.4.5.9. CABLIVI (Caplacizumab), Abylnx
        • 13.4.5.9.1. Sales Forecast
      • 13.4.5.10. Cegfila®, Mundipharma Corporation
        • 13.4.5.10.1. Sales Forecast
      • 13.4.5.11. CIMZIA® (certolizumab pegol), UCB
        • 13.4.5.11.1. Sales Forecast
      • 13.4.5.12. COSENTYX® (secukinumab), Novartis
        • 13.4.5.12.1. Sales Forecast
      • 13.4.5.13. CRYSVITA® (burosumab-twza), Ultragenyx
        • 13.4.5.13.1. Sales Forecast
      • 13.4.5.14. Cuvitru™ (immune globulin subcutaneous [human], 20% solution), Shire
        • 13.4.5.14.1. Sales Forecast
      • 13.4.5.15. DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj / DARZALEX® SC, Halozyme
        • 13.4.5.15.1. Sales Forecast
      • 13.4.5.16. DENGVAXIA (Dengue Tetravalent Vaccine), Sanofi Pasteur
        • 13.4.5.16.1. Sales Forecast
      • 13.4.5.17. DUPIXENT® (dupilumab), Regeneron Pharmaceuticals
        • 13.4.5.17.1. Sales Forecast
      • 13.4.5.18. EMGALITY (galcanezumab-gnlm), Eli Lilly
        • 13.4.5.18.1. Sales Forecast
      • 13.4.5.19. EMPAVELI™ (pegcetacoplan), Apellis Pharmaceuticals
        • 13.4.5.19.1. Sales Forecast
      • 13.4.5.20. Enbrel® (etanercept), Amgen
        • 13.4.5.20.1. Sales Forecast
      • 13.4.5.21. ENSPRYNG™ (satralizumab), Genentech
        • 13.4.5.21.1. Sales Forecast
      • 13.4.5.22. EVENITY™ (romosozumab-aqqg), Amgen
        • 13.4.5.22.1. Sales Forecast
      • 13.4.5.23. EXTAVIA® (interferon beta-l b), Novartis
        • 13.4.5.23.1. Sales Forecast
      • 13.4.5.24. FASENRA® (benralizumab), AstraZeneca
        • 13.4.5.24.1. Sales Forecast
      • 13.4.5.25. Fertavid® (follitropin beta), Merck
        • 13.4.5.25.1. Sales Forecast
      • 13.4.5.26. FIASP® (Insulin Aspart), Novo Nordisk
        • 13.4.5.26.1. Sales Forecast
      • 13.4.5.27. Fulphila® (pegfilgrastim-jmdb), Mylan Pharmaceuticals
        • 13.4.5.27.1. Sales Forecast
      • 13.4.5.28. Gamunex-C® (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified), Grifols Therapeutics
        • 13.4.5.28.1. Sales Forecast
      • 13.4.5.29. GATTEX® / Revestive (teduglutide [rDNA origin]), NPS Pharmaceuticals
        • 13.4.5.29.1. Sales Forecast
      • 13.4.5.30. GIVLAARI (givosiran), Alnylam Pharmaceuticals
        • 13.4.5.30.1. Sales Forecast
      • 13.4.5.31. HAEGARDA®, CSL Behring
        • 13.4.5.31.1. Sales Forecast
      • 13.4.5.32. HEMLIBRA® (emicizumab-kxwh), Roche
        • 13.4.5.32.1. Sales Forecast
      • 13.4.5.33. Hepcludex® (Bulevirtide), Gilead Sciences
        • 13.4.5.33.1. Sales Forecast
      • 13.4.5.34. Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid), CSL Behring
        • 13.4.5.34.1. Sales Forecast
      • 13.4.5.35. HYQVIA (Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase), Baxalta
        • 13.4.5.35.1. Sales Forecast
      • 13.4.5.36. ILARIS® (canakinumab), Novartis
        • 13.4.5.36.1. Sales Forecast
      • 13.4.5.37. ILUMYA™ (tildrakizumab-asmn) / Ilumetri, Sun Pharma
        • 13.4.5.37.1. Sales Forecast
      • 13.4.5.38. Kalbitor (ecallantide), Dyax
        • 13.4.5.38.1. Sales Forecast
      • 13.4.5.39. Kesimpta® (ofatumumab), Novartis
        • 13.4.5.39.1. Sales Forecast
      • 13.4.5.40. KEVZARA® (sarilumab), Regeneron Pharmaceuticals
        • 13.4.5.40.1. Sales Forecast
      • 13.4.5.41. KINERET® (anakinra), Swedish Orphan Biovitrum
        • 13.4.5.41.1. Sales Forecast
      • 13.4.5.42. KIOVIG® / (Gammagard Liquid 10% (Immune Globulin Infusion), Baxalta
        • 13.4.5.42.1. Sales Forecast
      • 13.4.5.43. Kyntheum® / SILIQ™ / Lumicef® (brodalumab), AstraZeneca
        • 13.4.5.43.1. Sales Forecast
      • 13.4.5.44. Leqvio (Inclisiran), Alnylam Pharmaceuticals
        • 13.4.5.44.1. Sales Forecast
      • 13.4.5.45. Lonquex® (lipegfilgrastim), Teva Pharmaceuticals
        • 13.4.5.45.1. Sales Forecast
      • 13.4.5.46. Lyumjev (insulin lispro-aabc), Eli Lilly
        • 13.4.5.46.1. Sales Forecast
      • 13.4.5.47. Norditropin® (somatropin), Novo Nordisk
        • 13.4.5.47.1. Sales Forecast
      • 13.4.5.48. NPLATE® (romiplostim), Amgen
        • 13.4.5.48.1. Sales Forecast
      • 13.4.5.49. Nucala® (mepolizumab), GlaxoSmithKline
        • 13.4.5.49.1. Sales Forecast
      • 13.4.5.50. Nutropin AQ® (somatropin), Roche
        • 13.4.5.50.1. Sales Forecast
      • 13.4.5.51. OXLUMO™ (lumasiran), Alnylam Pharmaceuticals
        • 13.4.5.51.1. Sales Forecast
      • 13.4.5.52. PALYNZIQ (pegvaliase-pqpz), BioMarin Pharmaceutical
        • 13.4.5.52.1. Sales Forecast
      • 13.4.5.53. Pergoveris® (follitropin alfa / lutropin alfa), Merck
        • 13.4.5.53.1. Sales Forecast
      • 13.4.5.54. Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf), Roche
        • 13.4.5.54.1. Sales Forecast
      • 13.4.5.55. PLEGRIDY® (peginterferon beta-1a), Biogen
        • 13.4.5.55.1. Sales Forecast
      • 13.4.5.56. PRALUENT® (alirocumab), Regeneron Pharmaceuticals
        • 13.4.5.56.1. Sales Forecast
      • 13.4.5.57. Prolia® / Pralia® (denosumab), Amgen
        • 13.4.5.57.1. Sales Forecast
      • 13.4.5.58. REBLOZYL® (luspatercept-aamt), Acceleron Pharma
        • 13.4.5.58.1. Sales Forecast
      • 13.4.5.59. REKOVELLE® (follitropin delta), Ferring Pharmaceuticals
        • 13.4.5.59.1. Sales Forecast
      • 13.4.5.60. Repatha® (evolocumab), Amgen
        • 13.4.5.60.1. Sales Forecast
      • 13.4.5.61. RITUXAN HYCELA™ (rituximab and hyaluronidase human) / MabThera® SC (rituximab), Genentech
        • 13.4.5.61.1. Sales Forecast
      • 13.4.5.62. RYZODEG® 70/30 (insulin degludec and insulin aspart), Novo Nordisk
        • 13.4.5.62.1. Sales Forecast
      • 13.4.5.63. Skyrizi ( isankizumab), AbbVie
        • 13.4.5.63.1. Sales Forecast
      • 13.4.5.64. SKYTROFA™ (lonapegsomatropin-tcgd), Ascendis Pharma
        • 13.4.5.64.1. Sales Forecast
      • 13.4.5.65. SOLIQUA® 100/33 (insulin glargine & lixisenatide injection), Sanofi
        • 13.4.5.65.1. Sales Forecast
      • 13.4.5.66. STELARA® (ustekinumab), Janssen Biotech
        • 13.4.5.66.1. Sales Forecast
      • 13.4.5.67. Strensiq® (asfotase alfa), Alexion Pharmaceuticals
        • 13.4.5.67.1. Sales Forecast
      • 13.4.5.68. TAKHZYRO (lanadelumab-flyo), Takeda Pharmaceuticals
        • 13.4.5.68.1. Sales Forecast
      • 13.4.5.69. Taltz® (ixekizumab), Eli Lilly
        • 13.4.5.69.1. Sales Forecast
      • 13.4.5.70. TEGSEDI (inotersen), Ionis Pharmaceuticals
        • 13.4.5.70.1. Sales Forecast
      • 13.4.5.71. Toujeo® (insulin glargine injection) U-300, Sanofi
        • 13.4.5.71.1. Sales Forecast
      • 13.4.5.72. TREMFYA® (guselkumab), Janssen Biotech
        • 13.4.5.72.1. Sales Forecast
      • 13.4.5.73. TRESIBA® (insulin degludec injection), Novo Nordisk
        • 13.4.5.73.1. Sales Forecast
      • 13.4.5.74. Trulicity® (dulaglutide), Eli Lilly
        • 13.4.5.74.1. Sales Forecast
      • 13.4.5.75. TYMLOS™ (abaloparatide), Radius Health
        • 13.4.5.75.1. Sales Forecast
      • 13.4.5.76. Tysabri (Natalizumab), Biogen
        • 13.4.5.76.1. Sales Forecast
      • 13.4.5.77. Voxzogo (vosoritide), BioMarin Pharmaceutical
        • 13.4.5.77.1. Sales Forecast
      • 13.4.5.78. VYLEESI (bremelanotide injection), AMAG Pharmaceuticals
        • 13.4.5.78.1. Sales Forecast
      • 13.4.5.79. XEMBIFY (immune globulin subcutaneous, human - klhw), Grifols Therapeutics
        • 13.4.5.79.1. Sales Forecast
      • 13.4.5.80. Xgeva® / RANMARK® (denosumab), Amgen
        • 13.4.5.80.1. Sales Forecast
      • 13.4.5.81. XULTOPHY® / IdegLira (insulin degludec and liraglutide injection), Novo Nordisk
        • 13.4.5.81.1. Sales Forecast
      • 13.4.5.82. XYOSTED (testosterone enanthate), Antares Pharma
        • 13.4.5.82.1. Sales Forecast
      • 13.4.5.83. ZEGALOGUE (dasiglucagon), Zealand Pharma
        • 13.4.5.83.1. Sales Forecast

14. SUBCUTANEOUS FORMULATION TECHNOLOGIES: MARKET FORECAST

  • 14.1. Chapter Overview
  • 14.2. Forecast Methodology and Key Assumptions
  • 14.3. Global Subcutaneous Formulation Technologies Market, 2022-2035
    • 14.3.1. Subcutaneous Formulation Technologies Market: Distribution by Type of Payment, 2022 and 2035
      • 14.3.1.1. Subcutaneous Formulation Technologies Market for Milestone Payments, 2022-2035
      • 14.3.1.2. Subcutaneous Formulation Technologies Market for Upfront Payments, 2022-2035
    • 14.3.2. Subcutaneous Formulation Technologies Market: Distribution by Fundamental Principle, 2022 and 2035
      • 14.3.2.1. Subcutaneous Formulation Technologies Market for Amino Acid Interaction Principles, 2022-2035
      • 14.3.2.2. Subcutaneous Formulation Technologies Market for Complex Formation Principles, 2022-2035
      • 14.3.2.3. Subcutaneous Formulation Technologies Market for Encapsulation Principles, 2022-2035
      • 14.3.2.4. Subcutaneous Formulation Technologies Market for Other Fundamental Principles, 2022-2035
    • 14.3.3. Subcutaneous Formulation Technologies Market: Distribution by End User, 2022 and 2035
      • 14.3.3.1. Subcutaneous Formulation Technologies Market for Biopharmaceutical Companies, 2022-2035
      • 14.3.3.2. Subcutaneous Formulation Technologies Market for Biotechnology Companies, 2022-2035
      • 14.3.3.3. Subcutaneous Formulation Technologies Market for Contract Development and Manufacturing Organizations, 2022-2035
      • 14.3.3.4. Subcutaneous Formulation Technologies Market for Educational Institutes, 2022-2035
      • 14.3.3.5. Subcutaneous Formulation Technologies Market for Investors, 2022-2035
      • 14.3.3.6. Subcutaneous Formulation Technologies Market for Pharmaceutical Companies, 2022-2035
      • 14.3.3.7. Subcutaneous Formulation Technologies Market for Research Institutes, 2022-2035
      • 14.3.3.8. Subcutaneous Formulation Technologies Market for Other End Users, 2022-2035
    • 14.3.4. Subcutaneous Formulation Technologies Market: Distribution by Therapeutic Area, 2022 and 2035
      • 14.3.4.1. Subcutaneous Formulation Technologies Market for Autoimmune Disorders, 2022-2035
      • 14.3.4.2. Subcutaneous Formulation Technologies Market for Genetic Disorders, 2022-2035
      • 14.3.4.3. Subcutaneous Formulation Technologies Market for Infectious Disorders, 2022-2035
      • 14.3.4.4. Subcutaneous Formulation Technologies Market for Metabolic Disorders, 2022-2035
      • 14.3.4.5. Subcutaneous Formulation Technologies Market for Oncological Disorders, 2022-2035
      • 14.3.4.6. Subcutaneous Formulation Technologies Market for Ophthalmic Disorders, 2022-2035
      • 14.3.4.7. Subcutaneous Formulation Technologies Market for Other Disorders, 2022-2035
    • 14.3.5. Subcutaneous Formulation Technologies Market: Distribution by Geographical Regions, 2022 and 2035
      • 14.3.5.1. Subcutaneous Formulation Technologies Market in North America, 2022-2035
      • 14.3.5.2. Subcutaneous Formulation Technologies Market in Europe, 2022-2035
      • 14.3.5.3. Subcutaneous Formulation Technologies Market in Asia, 2022-2035

15. SUBCUTANEOUS DRUG DELIVERY SYSTEMS: MARKET FORECAST

  • 15.1. Subcutaneous Drug Delivery Systems Market
  • 15.2. Drug Delivery System 1: Large Volume Wearable Injectors
    • 15.2.1. Forecast Methodology and Key Assumptions
    • 15.2.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2021-2035 (By Value)
      • 15.2.2.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2021-2035 (By Value)
      • 15.2.2.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2021-2035 (By Value)
      • 15.2.2.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2021-2035 (By Value)
      • 15.2.2.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2021-2035 (By Value)
        • 15.2.2.4.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2021-2035 (By Value)
        • 15.2.2.4.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2021-2035 (By Value)
        • 15.2.2.4.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2021-2035 (By Value)
      • 15.2.2.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2021-2035 (By Value)
        • 15.2.2.5.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2021-2035 (By Value)
        • 15.2.2.5.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2021-2035 (By Value)
        • 15.2.2.5.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2021-2035 (By Value)
      • 15.2.2.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2021-2035 (By Value)
        • 15.2.2.6.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific:Distribution by Type of Device, 2021-2035 (By Value)
        • 15.2.2.6.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific:Distribution by Usability, 2021-2035 (By Value)
        • 15.2.2.6.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific:Distribution by Therapeutic Area, 2021-2035 (By Value)
      • 15.2.2.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, 2021-2035 (By Value)
        • 15.2.2.7.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, 2021-2035 (By Value)
        • 15.2.2.7.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, 2021-2035 (By Value)
        • 15.2.2.7.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, 2021-2035 (By Value)
      • 15.2.2.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, 2021-2035 (By Value)
        • 15.2.2.8.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (By Value)
        • 15.2.2.8.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (By Value)
        • 15.2.2.8.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (By Value)
        • 15.2.2.8.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (By Value)
        • 15.2.2.8.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (By Value)
        • 15.2.2.8.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (By Value)
    • 15.2.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2021-2035 (By Volume)
      • 15.2.3.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2021-2035 (By Volume)
      • 15.2.3.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2021-2035 (By Volume)
      • 15.2.3.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2021-2035 (By Volume)
      • 15.2.3.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2021-2035 (By Volume)
        • 15.2.3.4.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2021-2035 (By Volume)
        • 15.2.3.4.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2021-2035 (By Volume)
        • 15.2.3.4.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2021-2035 (By Volume)
      • 15.2.3.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2021-2035 (By Volume)
        • 15.2.3.5.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe:Distribution by Type of Device, 2021-2035 (By Volume)
        • 15.2.3.5.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe:Distribution by Usability, 2021-2035 (By Volume)
        • 15.2.3.5.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe:Distribution by Therapeutic Area, 2021-2035 (By Volume)
      • 15.2.3.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2021-2035 (By Volume)
        • 15.2.3.6.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific:Distribution by Type of Device, 2021-2035 (By Volume)
        • 15.2.3.6.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific:Distribution by Usability, 2021-2035 (By Volume)
        • 15.2.3.6.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific:Distribution by Therapeutic Area, 2021-2035 (By Volume)
      • 15.2.3.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, 2021-2035 (By Volume)
        • 15.2.3.7.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America:Distribution by Type of Device, 2021-2035 (By Volume)
        • 15.2.3.7.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America:Distribution by Usability, 2021-2035 (By Volume)
        • 15.2.3.7.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America:Distribution by Therapeutic Area, 2021-2035 (By Volume)
      • 15.2.3.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, 2021-2035 (By Volume)
        • 15.2.3.8.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (By Volume)
        • 15.2.3.8.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (By Volume)
        • 15.2.3.8.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (By Volume)
    • 15.2.4. Global Large Volume Wearable Injectors Market for Insulin, 2021-2035
      • 15.2.4.1. Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2021-2035
      • 15.2.4.2. Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2021-2035
      • 15.2.4.3. Large Volume Wearable Injectors Market for Insulin in North America, 2021-2035 (By Value)
        • 15.2.4.3.1. Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2021-2035
        • 15.2.4.3.2. Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2021-2035
      • 15.2.4.4. Large Volume Wearable Injectors Market for Insulin in Europe, 2021-2035
        • 15.2.4.4.1. Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2021-2035
        • 15.2.4.4.2. Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2021-2035
      • 15.2.4.5. Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2021-2035
        • 15.2.4.5.1. Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2021-2035
        • 15.2.4.5.2. Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2021-2035
      • 15.2.4.6. Large Volume Wearable Injectors Market for Insulin in Latin America, 2021-2035
        • 15.2.4.6.1. Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Type of Device, 2021-2035
        • 15.2.4.6.2. Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Usability, 2021-2035
      • 15.2.4.7. Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, 2021-2035
        • 15.2.4.7.1. Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Type of Device, 2021-2035
        • 15.2.4.7.2. Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Usability, 2021-2035
  • 15.3. Drug Delivery System 2: Autoinjectors
    • 15.3.1. Forecast Methodology and Key Assumptions
    • 15.3.2. Global Autoinjectors Market, 2021-2035 (By Value)
      • 15.3.2.1. Global Autoinjectors Market for Anaphylaxis, 2021-2035 (By Value)
        • 15.3.2.1.1. Global Autoinjectors Market for Anaphylaxis: Distribution by Usability, 2021-2035 (By Value)
          • 15.3.2.1.1.1. Global Disposable Autoinjectors Market for Anaphylaxis, 2021-2035 (By Value)
        • 15.3.2.1.2. Global Autoinjectors Market for Anaphylaxis: Distribution by Route of Administration, 2021-2035 (By Value)
          • 15.3.2.1.2.1. Global Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (By Value)
          • 15.3.2.1.2.2. Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (By Value)
        • 15.3.2.1.3. Global Autoinjectors Market for Anaphylaxis: Distribution by Type of Molecule, 2021-2035 (By Value)
          • 15.3.2.1.3.1. Global Small Molecule-based Autoinjectors Market for Anaphylaxis, 2021-2035 (By Value)
        • 15.3.2.1.4. Global Autoinjectors Market for Anaphylaxis: Distribution by Geography, 2021-2035 (By Value)
          • 15.3.2.1.4.1. Autoinjectors Market for Anaphylaxis in North America, 2021-2035 (By Value)
          • 15.3.2.1.4.2. Autoinjectors Market for Anaphylaxis in Europe, 2021-2035 (By Value)
          • 15.3.2.1.4.3. Autoinjectors Market for Anaphylaxis in Asia-Pacific, 2021-2035 (By Value)
          • 15.3.2.1.4.4. Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2035 (By Value)
      • 15.3.2.2. Global Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)
        • 15.3.2.2.1. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Usability, 2021- 2035 (By Value)
          • 15.3.2.2.1.1. Global Disposable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (ByValue)
          • 15.3.2.2.1.2. Global Reusable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)
        • 15.3.2.2.2. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Route ofAdministration, 2021-2035 (By Value)
          • 15.3.2.2.2.1. Global Intramuscular Autoinjectors Market for Multiple Sclerosis, 2021-2035 (ByValue)
          • 15.3.2.2.2.2. Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, 2021-2035 (ByValue)
        • 15.3.2.2.3. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Type of Molecule, 2021-2035 (By Value)
          • 15.3.2.2.3.1. Global Protein-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)
          • 15.3.2.2.3.2. Global Peptide-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)
          • 15.3.2.2.3.3. Global Antibody-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)
        • 15.3.2.2.4. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Geography, 2021-2035 (By Value)
          • 15.3.2.2.4.1. Autoinjectors Market for Multiple Sclerosis in North America, 2021-2035 (By Value)
          • 15.3.2.2.4.2. Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2035 (By Value)
          • 15.3.2.2.4.3. Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, 2021-2035 (By Value)
          • 15.3.2.2.4.4. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2035 (By Value)
      • 15.3.2.3. Global Autoinjectors Market for Migraine, 2021-2035 (By Value)
        • 15.3.2.3.1. Global Autoinjectors Market for Migraine: Distribution by Usability, 2021-2035 (By Value)
          • 15.3.2.3.1.1. Global Disposable Autoinjectors Market for Migraine, 2021-2035 (By Value)
        • 15.3.2.3.2. Global Autoinjectors Market for Migraine: Distribution by Route of Administration, 2021-2035 (By Value)
          • 15.3.2.3.2.1. Global Subcutaneous Autoinjectors Market for Migraine, 2021-2035 (By Value)
        • 15.3.2.3.3. Global Autoinjectors Market for Migraine: Distribution by Type of Molecule, 2021-2035 (By Value)
          • 15.3.2.3.3.1. Global Antibody-based Autoinjectors Market for Migraine, 2021-2035 (By Value)
          • 15.3.2.3.3.2. Global Small Molecule-based Autoinjectors Market for Migraine, 2021-2035 (By Value)
        • 15.3.2.3.4. Global Autoinjectors Market for Migraine: Distribution by Geography, 2021-2035 (By Value)
          • 15.3.2.3.4.1. Autoinjectors Market for Migraine in North America, 2021-2035 (By Value)
          • 15.3.2.3.4.2. Autoinjectors Market for Migraine in Europe, 2021-2035 (By Value)
          • 15.3.2.3.4.3. Autoinjectors Market for Migraine in Asia-Pacific, 2021-2035 (By Value)
          • 15.3.2.3.4.4. Autoinjectors Market for Migraine in Rest of the World, 2021-2035 (By Value)
      • 15.3.2.4. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)
        • 15.3.2.4.1. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Usability, 2021-2035 (By Value)
          • 15.3.2.4.1.1. Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)
          • 15.3.2.4.1.2. Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)
        • 15.3.2.4.2. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Route of Administration, 2021-2035 (By Value)
          • 15.3.2.4.2.1. Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)
          • 15.3.2.4.2.2. Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)
        • 15.3.2.4.3. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Type of Molecule, 2021-2035 (By Value)
          • 15.3.2.4.3.1. Global Antibody-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)
          • 15.3.2.4.3.2. Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis,2021-2035 (By Value)
          • 15.3.2.4.3.3. Global Small Molecule-based Autoinjectors Market for Rheumatoid and PsoriaticArthritis, 2021-2035 (By Value)
        • 15.3.2.4.4. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Geography, 2021-2035 (By Value)
          • 15.3.2.4.4.1. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America, 2021-2035 (By Value)
          • 15.3.2.4.4.2. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, 2021-2035 (By Value)
          • 15.3.2.4.4.3. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, 2021-2035 (By Value)
          • 15.3.2.4.4.4. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World, 2021-2035 (By Value)
      • 15.3.2.5. Global Autoinjectors Market for Diabetes, 2021-2035 (By Value)
        • 15.3.2.5.1. Global Autoinjectors Market for Diabetes: Distribution by Usability, 2021-2035 (By Value)
          • 15.3.2.5.1.1. Global Disposable Autoinjectors Market for Diabetes, 2021-2035 (By Value)
        • 15.3.2.5.2. Global Autoinjectors Market for Diabetes: Distribution by Route of Administration, 2021-2035 (By Value)
          • 1.3.2.5.2.1. Global Subcutaneous Autoinjectors Market for Diabetes, 2021-2035 (By Value)
        • 15.3.2.5.3. Global Autoinjectors Market for Diabetes: Distribution by Type of Molecule, 2021-2035 (By Value)
          • 15.3.2.5.3.1. Global Protein-based Autoinjectors Market for Diabetes, 2021-2035 (By Value)
          • 15.3.2.5.3.2. Global Peptide-based Autoinjectors Market for Diabetes, 2021-2035 (By Value)
        • 15.3.2.5.4. Global Autoinjectors Market for Diabetes: Distribution by Geography, 2021-2035 (By Value)
          • 15.3.2.5.4.1. Autoinjectors Market for Diabetes in North America, 2021-2035 (By Value)
          • 15.3.2.5.4.2. Autoinjectors Market for Diabetes in Europe, 2021-2035 (By Value)
          • 15.3.2.5.4.3. Autoinjectors Market for Diabetes in Asia-Pacific, 2021-2035 (By Value)
          • 15.3.2.5.4.4. Autoinjectors Market for Diabetes in Rest of the World, 2021-2035 (By Value)
      • 15.3.2.6. Global Autoinjectors Market for Other Indications, 2021-2035 (By Value)
        • 15.3.2.6.1. Global Autoinjectors Market for Other Indications: Distribution by Usability, 2021-2035 (By Value)
          • 15.3.2.6.1.1. Global Disposable Autoinjectors Market for Other Indications, 2021-2035 (By Value)
        • 15.3.2.6.2. Global Autoinjectors Market for Other Indications: Distribution by Route of Administration, 2021-2035 (By Value)
          • 15.3.2.6.2.1. Global Subcutaneous Autoinjectors Market for Other Indications, 2021-2035 (By Value)
          • 15.3.2.6.2.2. Global Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (By Value)
          • 15.3.2.6.2.3. Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (By Value)
        • 15.3.2.6.3. Global Autoinjectors Market for Other Indications: Distribution by Type of Molecule, 2021-2035 (By Value)
          • 15.3.2.6.3.1. Global Protein-based Autoinjectors Market for Other Indications, 2021-2035 (By Value)
          • 15.3.2.6.3.2. Global Antibody-based Autoinjectors Market for Other Indications, 2021-2035 (By Value)
          • 15.3.2.6.3.3. Global Small Molecule-based Autoinjectors Market for Other Indications, 2021-2035 (By Value)
        • 15.3.2.6.4. Global Autoinjectors Market for Other Indications: Distribution by Geography, 2021-2035 (By Value)
          • 15.3.2.6.4.1. Autoinjectors Market for Other Indications in North America, 2021-2035 (By Value)
          • 15.3.2.6.4.2. Autoinjectors Market for Other Indications in Europe, 2021-2035 (By Value)
          • 15.3.2.6.4.3. Autoinjectors Market for Other Indications in Asia-Pacific, 2021-2035 (By Value)
          • 15.3.2.6.4.4. Autoinjectors Market for Other Indications in Rest of the World, 2021-2035 (By Value)
    • 15.3.3. Global Autoinjectors Market, 2021-2035 (By Volume)
      • 15.3.3.1. Global Autoinjectors Market for Anaphylaxis, 2021-2035 (By Volume)
        • 15.3.3.1.1. Global Autoinjectors Market for Anaphylaxis: Distribution by Usability, 2021-2035 (By Volume)
          • 15.3.3.1.1.1. Global Disposable Autoinjectors Market for Anaphylaxis, 2021-2035 (By Volume)
        • 15.3.3.1.2. Global Autoinjectors Market for Anaphylaxis: Distribution by Route of Administration, 2021-2035 (By Volume)
          • 15.3.3.1.2.1. Global Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (By Volume)
          • 15.3.3.1.2.2. Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (By Volume)
        • 15.3.3.1.3. Global Autoinjectors Market for Anaphylaxis: Distribution by Type of Molecule, 2021-2035 (By Volume)
          • 15.3.3.1.3.1. Global Small Molecule-based Autoinjectors Market for Anaphylaxis, 2021-2035 (By Volume)
        • 15.3.3.1.4. Global Autoinjectors Market for Anaphylaxis: Distribution by Geography, 2021-2035 (By Volume)
          • 15.3.3.1.4.1. Autoinjectors Market for Anaphylaxis in North America, 2021-2035 (By Volume)
          • 15.3.3.1.4.2. Autoinjectors Market for Anaphylaxis in Europe, 2021-2035 (By Volume)
          • 15.3.3.1.4.3. Autoinjectors Market for Anaphylaxis in Asia-Pacific, 2021-2035 (By Volume)
          • 15.3.3.1.4.4. Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2035 (By Volume)
      • 15.3.3.2. Global Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
        • 15.3.3.2.1. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Usability, 2021-2035 (By Volume)
          • 15.3.3.2.1.1. Global Disposable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
          • 15.3.3.2.1.2. Global Reusable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
        • 15.3.3.2.2. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Route of Administration, 2021-2035 (By Volume)
          • 15.3.3.2.2.1. Global Intramuscular Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
          • 15.3.3.2.2.2. Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
        • 15.3.3.2.3. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Type of Molecule, 2021-2035 (By Volume)
          • 15.3.3.2.3.1. Global Protein-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
          • 15.3.3.2.3.2. Global Peptide-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
          • 15.3.3.2.3.3. Global Antibody-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
        • 15.3.3.2.4. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Geography, 2021-2035 (By Volume)
          • 15.3.3.2.4.1. Autoinjectors Market for Multiple Sclerosis in North America, 2021-2035 (By Volume)
          • 15.3.3.2.4.2. Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2035 (By Volume)
          • 15.3.3.2.4.3. Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, 2021-2035 (By Volume)
          • 15.3.3.2.4.4. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2035 (By Volume)
      • 15.3.3.3. Global Autoinjectors Market for Migraine, 2021-2035 (By Volume)
        • 15.3.3.3.1. Global Autoinjectors Market for Migraine: Distribution by Usability, 2021-2035 (By Volume)
          • 15.3.3.3.1.1. Global Disposable Autoinjectors Market for Migraine, 2021-2035 (By Volume)
        • 15.3.3.3.2. Global Autoinjectors Market for Migraine: Distribution by Route of Administration, 2021-2035 (By Volume)
          • 15.3.3.3.2.1. Global Subcutaneous Autoinjectors Market for Migraine, 2021-2035 (By Volume)
        • 15.3.3.3.3. Global Autoinjectors Market for Migraine: Distribution by Type of Molecule, 2021-2035 (By Volume)
          • 15.3.3.3.3.1. Global Antibody-based Autoinjectors Market for Migraine, 2021-2035 (By Volume)
          • 15.3.3.3.3.2. Global Small Molecule-based Autoinjectors Market for Migraine, 2021-2035 (By Volume)
        • 15.3.3.3.4. Global Autoinjectors Market for Migraine: Distribution by Geography, 2021-2035 (By Volume)
          • 15.3.3.3.4.1. Autoinjectors Market for Migraine in North America, 2021-2035 (By Volume)
          • 15.3.3.3.4.2. Autoinjectors Market for Migraine in Europe, 2021-2035 (By Volume)
          • 15.3.3.3.4.3. Autoinjectors Market for Migraine in Asia-Pacific, 2021-2035 (By Volume)
          • 15.3.3.3.4.4. Autoinjectors Market for Migraine in Rest of the World, 2021-2035 (By Volume)
      • 15.3.3.4. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
        • 15.3.3.4.1. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Usability, 2021-2035 (By Volume)
          • 15.3.3.4.1.1. Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
          • 15.3.3.4.1.2. Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
        • 15.3.3.4.2. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Route of Administration, 2021-2035 (By Volume)
          • 15.3.3.4.2.1. Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
          • 15.3.3.4.2.2. Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
        • 15.3.3.4.3. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Type of Molecule, 2021-2035 (By Volume)
          • 15.3.3.4.3.1. Global Antibody-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
          • 15.3.3.4.3.2. Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
          • 15.3.3.4.3.3. Global Small Molecule-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
        • 15.3.3.4.4. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Geography, 2021-2035 (By Volume)
          • 15.3.3.4.4.1. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America, 2021-2035 (By Volume)
          • 15.3.3.4.4.2. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, 2021-2035 (By Volume)
          • 15.3.3.4.4.3. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, 2021-2035 (By Volume)
          • 15.3.3.4.4.4. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World, 2021-2035 (By Volume)
      • 15.3.3.5. Global Autoinjectors Market for Diabetes, 2021-2035 (By Volume)
        • 15.3.3.5.1. Global Autoinjectors Market for Diabetes: Distribution by Usability, 2021-2035 (By Volume)
          • 15.3.3.5.1.1. Global Disposable Autoinjectors Market for Diabetes, 2021-2035 (By Volume)
        • 15.3.3.5.2. Global Autoinjectors Market for Diabetes: Distribution by Route of Administration, 2021-2035 (By Volume)
          • 15.3.3.5.2.1. Global Subcutaneous Autoinjectors Market for Diabetes, 2021-2035 (By Volume)
        • 15.3.3.5.3. Global Autoinjectors Market for Diabetes: Distribution by Type of Molecule, 2021-2035 (By Volume)
          • 15.3.3.5.3.1. Global Protein-based Autoinjectors Market for Diabetes, 2021-2035 (By Volume)
          • 15.3.3.5.3.2. Global Peptide-based Autoinjectors Market for Diabetes, 2021-2035 (By Volume)
        • 15.3.3.5.4. Global Autoinjectors Market for Diabetes: Distribution by Geography, 2021-2035 (By Volume)
          • 15.3.3.5.4.1. Autoinjectors Market for Diabetes in North America, 2021-2035 (By Volume)
          • 15.3.3.5.4.2. Autoinjectors Market for Diabetes in Europe, 2021-2035 (By Volume)
          • 15.3.3.5.4.3. Autoinjectors Market for Diabetes in Asia-Pacific, 2021-2035 (By Volume)
          • 15.3.3.5.4.4. Autoinjectors Market for Diabetes in Rest of the World, 2021-2035 (By Volume)
      • 15.3.3.6. Global Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
        • 15.3.3.6.1. Global Autoinjectors Market for Other Indications: Distribution by Usability, 2021-2035 (By Volume)
          • 15.3.3.6.1.1. Global Disposable Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
        • 15.3.3.6.2. Global Autoinjectors Market for Other Indications: Distribution by Route of Administration, 2021-2035 (By Volume)
          • 15.3.3.6.2.1. Global Subcutaneous Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
          • 15.3.3.6.2.2. Global Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
          • 15.3.3.6.2.3. Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
        • 15.3.3.6.3. Global Autoinjectors Market for Other Indications: Distribution by Type of Molecule, 2021-2035 (By Volume)
          • 15.3.3.6.3.1. Global Protein-based Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
          • 15.3.3.6.3.2. Global Antibody-based Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
          • 15.3.3.6.3.3. Global Small Molecule-based Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
        • 15.3.3.6.4. Global Autoinjectors Market for Other Indications: Distribution by Geography, 2021-2035 (By Volume)
          • 15.3.3.6.4.1. Autoinjectors Market for Other Indications in North America, 2021-2035 (By Volume)
          • 15.3.3.6.4.2. Autoinjectors Market for Other Indications in Europe, 2021-2035 (By Volume)
          • 15.3.3.6.4.3. Autoinjectors Market for Other Indications in Asia-Pacific, 2021-2035 (By Volume)
          • 15.3.3.6.4.4. Autoinjectors Market for Other Indications in Rest of the World, 2021-2035 (By Volume)
  • 15.4. Drug Delivery System 3: Prefilled Syringes
    • 15.4.1. Forecast Methodology and Key Assumptions
    • 15.4.2. Global Prefilled Syringes Market, 2020-2030
      • 15.4.2.1. Global Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, 2020-2030
      • 15.4.2.2. Global Prefilled Syringes Market: Distribution by Type of Chamber System, 2020-2030
      • 15.4.2.3. Global Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, 2020-2030
      • 15.4.2.4. Global Prefilled Syringes Market: Distribution by Target Therapeutic Area, 2020-2030
  • 15.5. Drug Delivery System 4: Needle-Free Injection Systems
    • 15.5.1. Forecast Methodology and Key Assumptions
    • 15.5.2. Global Needle-Free Injection Systems Market, 2020-2030
      • 15.5.2.1. Global Needle-Free Injection Systems Market: Distribution by Usability, 2020-2030
      • 15.5.2.2. Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, 2020-2030
      • 15.5.2.3. Global Needle-Free Injection Systems Market: Distribution by Target Therapeutic Area, 2020-2030
  • 15.6. Drug Delivery System 5: Novel Drug Reconstitution Systems
    • 15.6.1. Forecast Methodology and Key Assumptions
    • 15.6.2. Global Novel Drug Reconstitution Systems Market, 2021-2030
      • 15.6.2.1. Global Dual Chamber Prefilled Syringes Market, 2021-2030
        • 15.6.2.1.1. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Physical State of Drug
          • 15.6.2.1.1.1. Dual Chamber Prefilled Syringes Market for Liquid / Powder Drugs, 2021-2030
          • 15.6.2.1.1.2. Dual Chamber Prefilled Syringes Market for Liquid / Liquid Drugs, 2021-2030
        • 15.6.2.1.2. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Type of Fabrication Material Used
          • 15.6.2.1.2.1. Glass Dual Chamber Prefilled Syringes Market, 2021-2030
          • 15.6.2.1.2.2. Plastic Dual Chamber Prefilled Syringes Market, 2021-2030
        • 15.6.2.1.3. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Volume
          • 15.6.2.1.3.1. Dual Chamber Prefilled Syringes Market for <1 mL Syringes, 2021-2030
          • 15.6.2.1.3.2. Dual Chamber Prefilled Syringes Market for 1-2.5 mL Syringes, 2021-2030
          • 15.6.2.1.3.3. Dual Chamber Prefilled Syringes Market for 2.6-5 mL Syringes, 2021-2030
          • 15.6.2.1.3.4. Dual Chamber Prefilled Syringes Market for >5 mL Syringes, 2021-2030
        • 15.6.2.1.4. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Geography
          • 15.6.2.1.4.1. Dual Chamber Prefilled Syringes Market in North America, 2021-2030
          • 15.6.2.1.4.2. Dual Chamber Prefilled Syringes Market in Europe, 2021-2030
          • 15.6.2.1.4.3. Dual Chamber Prefilled Syringes Market in Asia-Pacific, 2021-2030
          • 15.6.2.1.4.4. Dual Chamber Prefilled Syringes Market in Latin America, 2021-2030
          • 15.6.2.1.4.5. Dual Chamber Prefilled Syringes Market in Middle East and Africa, 2021-2030
      • 15.6.2.2. Global Dual Chamber Cartridges Market, 2021-2030
        • 15.6.2.2.1. Dual Chamber Cartridges Market, 2021-2030: Distribution by Physical State of Drug
          • 15.6.2.2.1.1. Dual Chamber Cartridges Market for Liquid / Powder Drugs, 2021-2030
          • 15.6.2.2.1.2. Dual Chamber Cartridges Market for Liquid / Liquid Drugs, 2021-2030
        • 15.6.2.2.2. Dual Chamber Cartridges Market, 2021-2030: Distribution by Type of Fabrication Material Used
          • 15.6.2.2.2.1. Glass Dual Chamber Cartridges Market, 2021-2030
          • 15.6.2.2.2.2. Plastic Dual Chamber Cartridges Market, 2021-2030
        • 15.6.2.2.3. Dual Chamber Cartridges Market, 2021-2030: Distribution by Volume
          • 15.6.2.2.3.1. Dual Chamber Cartridges Market for <1 mL Cartridges, 2021-2030
          • 15.6.2.2.3.2. Dual Chamber Cartridges Market for 1-2.5 mL Cartridges, 2021-2030
          • 15.6.2.2.3.3. Dual Chamber Cartridges Market for 2.6-5 mL Cartridges, 2021-2030
          • 15.6.2.2.3.4. Dual Chamber Cartridges Market for >5 mL Cartridges, 2021-2030
        • 15.6.2.2.4. Dual Chamber Cartridges Market, 2021-2030: Distribution by Geography
          • 15.6.2.2.4.1. Dual Chamber Cartridges Market in North America, 2021-2030
          • 15.6.2.2.4.2. Dual Chamber Cartridges Market in Europe, 2021-2030
          • 15.6.2.2.4.3. Dual Chamber Cartridges Market in Asia-Pacific, 2021-2030
          • 15.6.2.2.4.4. Dual Chamber Cartridges Market in Latin America, 2021-2030
          • 15.6.2.2.4.5. Dual Chamber Cartridges Market in Middle East and Africa, 2021-2030
      • 15.6.2.3. Global Dual / Multi Chamber Infusion Bags Market, 2021-2030
        • 15.6.2.3.1. Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Physical State of Drug
          • 15.6.2.3.1.1. Dual / Multi Chamber Infusion Bags Market for Liquid Mixture, 2021-2030
          • 15.6.2.3.1.2. Dual / Multi Chamber Infusion Bags Market for Frozen Mixture, 2021-2030
        • 15.6.2.3.2. Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Type of Plastic
          • 15.6.2.3.2.1. Dual / Multi Chamber Infusion Bags Market for Ethylene Vinyl Acetate, 2021-2030
          • 15.6.2.3.2.2. Dual / Multi Chamber Infusion Bags Market for Polypropylene, 2021-2030
          • 15.6.2.3.2.3. Dual / Multi Chamber Infusion Bags Market for Polyvinyl Chloride, 2021-2030
          • 15.6.2.3.2.4. Dual / Multi Chamber Infusion Bags Market for Other Plastic Materials, 2021-2030
        • 15.6.2.3.3. Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Volume
          • 15.6.2.3.3.1. Dual / Multi Chamber Infusion Bags Market for <250 mL Infusion Bags, 2021-2030
          • 15.6.2.3.3.2. Dual / Multi Chamber Infusion Bags Market for 250-500 mL Infusion Bags, 2021-2030
          • 15.6.2.3.3.3. Dual / Multi Chamber Infusion Bags Market for 501-1,000 mL Infusion Bags, 2021-2030
          • 15.6.2.3.3.4. Dual / Multi Chamber Infusion Bags Market for >1,000 mL Infusion Bags, 2021-2030
        • 15.6.2.3.4. Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Geography
          • 15.6.2.3.4.1. Dual / Multi Chamber Infusion Bags Market in North America, 2021-2030
          • 15.6.2.3.4.2. Dual / Multi Chamber Infusion Bags Market in Europe, 2021-2030
          • 15.6.2.3.4.3. Dual / Multi Chamber Infusion Bags Market in Asia-Pacific, 2021-2030
          • 15.6.2.3.4.4. Dual / Multi Chamber Infusion Bags Market in Latin America, 2021-2030
          • 14.6.2.3.4.5. Dual / Multi Chamber Infusion Bags Market in Middle East and Africa, 2021-2030

16. SWOT ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Comparison of SWOT Factors
    • 16.2.1. Strengths
    • 16.2.2. Weaknesses
    • 16.2.3. Opportunities
    • 16.2.4. Threats

17. CONCLUDING REMARKS

18. EXECUTIVE INSIGHTS

  • 18.1. Chapter Overview
  • 18.2. Lindy Biosciences
    • 18.2.1. Company Snapshot
    • 18.2.2. Interview Transcript: Deborah Bitterfield, Chief Executive Officer and Founder
  • 18.3. Oval Medical Technologies
    • 18.3.1. Company Snapshot
    • 18.3.2. Interview Transcript: Matthew Young, Chief Technology Officer and Founder
  • 18.4. Xeris Pharmaceuticals
    • 18.4.1. Company Snapshot
    • 18.4.2. Interview Transcript: Steve Prestrelski, Chief Scientific Officer and Founder; Hong Qi, Vice President, Product Development; and Scott Coleman, Ex Sr. Scientist Formulation)
  • 18.5. DALI Medical Devices
    • 18.5.1. Company Snapshot
    • 18.5.2. Interview Transcript: David Daily, Chief Executive Officer and Co-Founder
  • 18.6. Excelse Bio
    • 18.6.1. Company Snapshot
    • 18.6.2. Interview Transcript: Michael Reilly, Chief Executive Officer and Co-Founder
  • 18.7. i-novion
    • 18.7.1. Company Snapshot
    • 18.7.2. Interview Transcript: Poonam R Velagaleti, Co-Founder
  • 18.8. Enable Injections
    • 18.8.1. Company Snapshot
    • 18.8.2. Interview Transcript: Michael Hooven, Chief Executive Officer
  • 18.9. Immunovaccine Technologies
    • 18.9.1. Company Snapshot
    • 18.9.2. Interview Transcript: Frederic Ors, Ex Chief Executive Officer
  • 18.10. Portal Instruments
    • 18.10.1. Company Snapshot
    • 18.10.2. Interview Transcript: Patrick Anquetil, Chief Executive Officer
  • 18.11. Elcam Medical
    • 18.11.1. Company Snapshot
    • 18.11.2. Interview Transcript: Menachem Zucker, Vice President and Chief Scientist
  • 18.12. West Pharmaceutical Services
    • 18.12.1. Company Snapshot
    • 18.12.2. Interview Transcript: Tiffany H Burke, Director, Global Communications and Graham Reynolds, Vice President and General Manager, Global Biologics
  • 18.13. MedinCell
    • 18.13.1. Company Snapshot
    • 18.13.2. Interview Transcript: David Heuzé, Communication Leader

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

  • Figure 3.1 Types of Biologically Derived Therapeutics
  • Figure 3.2 Steps Involved in Subcutaneous Drug Delivery
  • Figure 4.1 Approved Subcutaneous Biologics: Distribution by Approval Year
  • Figure 4.2 Approved Subcutaneous Biologics: Distribution by Type of Molecule
  • Figure 4.3 Approved Subcutaneous Biologics: Distribution by Approval Year and Type ofMolecule
  • Figure 4.4 Approved Subcutaneous Biologics: Distribution by Type of Therapy
  • Figure 4.5 Approved Subcutaneous Biologics: Distribution by Route of Administration
  • Figure 4.6 Approved Subcutaneous Biologics: Distribution by Method of Administration
  • Figure 4.7 Approved Subcutaneous Biologics: Distribution by Route of Administration andMethod of Administration
  • Figure 4.8 Approved Subcutaneous Biologics: Distribution by Dosing Frequency
  • Figure 4.9 Approved Subcutaneous Biologics: Distribution by Dose Concentration
  • Figure 4.10 Approved Subcutaneous Biologics: Distribution by Target Disease(s) Indication
  • Figure 4.11 Approved Subcutaneous Biologics: Distribution by Therapeutic Area
  • Figure 4.12 Approved Subcutaneous Biologics: Distribution by Approval Year and Therapeutic Area
  • Figure 4.13 Approved Subcutaneous Biologics: Distribution by Type of Available Formulation
  • Figure 4.14 Approved Subcutaneous Biologics: Distribution by Route of Administration andType of Available Formulation
  • Figure 4.15 Approved Subcutaneous Biologics Developers: Distribution by Year ofEstablishment
  • Figure 4.16 Approved Subcutaneous Biologics Developers: Distribution by Company Size
  • Figure 4.17 Approved Subcutaneous Biologics Developers: Distribution by Location ofHeadquarters
  • Figure 4.18 Leading Developers: Distribution by Number of Approved Subcutaneous Biologics
  • Figure 5.1 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development
  • Figure 5.2 Clinical-Stage Subcutaneous Biologics: Distribution by Mechanism of Action
  • Figure 5.3 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule
  • Figure 5.4 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development and Type of Molecule
  • Figure 5.5 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Therapy
  • Figure 5.6 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule and Type of Therapy
  • Figure 5.7 Clinical-Stage Subcutaneous Biologics: Distribution by Dosing Frequency
  • Figure 5.8 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule andDosing Frequency
  • Figure 5.9 Clinical-Stage Subcutaneous Biologics: Distribution by Target Disease Indication(s)
  • Figure 5.10 Clinical-Stage Subcutaneous Biologics: Distribution by Therapeutic Area
  • Figure 5.11 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development and Therapeutic Area
  • Figure 5.12 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule andTherapeutic Area
  • Figure 5.13 Clinical-Stage Subcutaneous Biologics: Distribution by Special Drug Designation(s) Awarded
  • Figure 5.14 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Year ofEstablishment
  • Figure 5.15 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Company Size
  • Figure 5.16 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Location ofHeadquarters
  • Figure 5.17 Leading Developers: Distribution by Number of Clinical-Stage SubcutaneousBiologics
  • Figure 6.1 Leading Approved Subcutaneous Biologics: Distribution by Value Creation Sales
  • Figure 6.2 STELARA® (Janssen Biotech): Development History
  • Figure 6.3 STELARA® (Janssen Biotech): Success Protocol Analysis
  • Figure 6.4 DUPIXENT® (Regeneron Pharmaceuticals): Development History
  • Figure 6.5 DUPIXENT® (Regeneron Pharmaceuticals): Success Protocol Analysis
  • Figure 6.6 Trulicity® (Eli Lilly): Development History
  • Figure 6.7 Trulicity® (Eli Lilly): Success Protocol Analysis
  • Figure 6.8 Enbrel® (Amgen): Development History
  • Figure 6.9 Enbrel® (Amgen): Success Protocol Analysis
  • Figure 6.10 COSENTYX® (Novartis): Development History
  • Figure 6.11 COSENTYX® (Novartis): Success Protocol Analysis
  • Figure 6.12 BESREMi (PharmaEssentia): Development History
  • Figure 6.13 BESREMi (PharmaEssentia): Success Protocol Analysis
  • Figure 6.14 DARZALEX FASPRO® (Halozyme): Development History
  • Figure 6.15 DARZALEX FASPRO® (Halozyme): Success Protocol Analysis
  • Figure 6.16 Prolia® / Pralia® (Amgen): Development History
  • Figure 6.17 Prolia® / Pralia® (Amgen): Success Protocol Analysis
  • Figure 6.18 HEMLIBRA® (Roche): Development History
  • Figure 6.19 HEMLIBRA® (Roche): Success Protocol Analysis
  • Figure 6.20 BENLYSTA® (Roche): Development History
  • Figure 6.21 BENLYSTA® (Roche): Success Protocol Analysis
  • Figure 6.22 Success Protocol Analysis: Conclusion
  • Figure 7.1 High Concentration Biologic Formulations: Advantages
  • Figure 7.2 High Concentration Biologic Formulations: Challenges
  • Figure 7.3 Subcutaneous Formulation Technologies: Distribution by Fundamental Principle of Technology
  • Figure 7.4 Subcutaneous Formulation Technologies: Distribution by Type of Molecule
  • Figure 7.5 Subcutaneous Formulation Technologies: Distribution by Type of Formulation
  • Figure 7.6 Subcutaneous Formulation Technologies: Distribution by Type of Molecule and Type of Formulation
  • Figure 7.7 Subcutaneous Formulation Technologies: Distribution by Therapeutic Area
  • Figure 7.8 Subcutaneous Formulation Technologies: Distribution by Advantage(s) Offered
  • Figure 7.9 Subcutaneous Formulation Technology Developers: Distribution by Year ofEstablishment
  • Figure 7.10 Subcutaneous Formulation Technology Developers: Distribution by Company Size
  • Figure 7.11 Subcutaneous Formulation Technology Developers: Distribution by Location of Headquarters (Region Wise)
  • Figure 7.12 Subcutaneous Formulation Technology Developers: Distribution by Location of Headquarters (Country-Wise)
  • Figure 7.13 Subcutaneous Formulation Technology Developers: Distribution by Company Size and Location of Headquarters (Region-Wise)
  • Figure 7.14 Subcutaneous Formulation Technologies: Distribution by Number of Advantages Offered
  • Figure 8.1 Company Competitiveness Analysis: Benchmarking of Technology Strength
  • Figure 8.2 Company Competitiveness Analysis: Benchmarking of Partnership Activity
  • Figure 8.3 Company Competitiveness Analysis: Developers based in North America
  • Figure 8.4 Company Competitiveness Analysis: Developers based in Europe and Asia
  • Figure 9.1 Adocia: Annual Revenues, 2015 - H1 2021 (EUR Million)
  • Figure 9.2 Ajinomoto Bio-Pharma Services: Service Portfolio
  • Figure 9.3 Ajinomoto: Annual Revenues, 2016 - H1 2021 (JPY Billion)
  • Figure 9.4 Ajinomoto Bio-Pharma Services: Crystalomics Technology
  • Figure 9.7 Alteogen: Annual Revenues, 2016 - H1 2021 (USD Million)
  • Figure 9.6 Arecor: Annual Revenues, 2018 - H1 2021 (USD Million)
  • Figure 9.7 Arecor: Arestat Technology
  • Figure 9.8 Ascendis Pharma: Annual Revenues, 2015-H1 2021 (USD Million)
  • Figure 9.9 Avadel Pharmaceuticals: Annual Revenues, 2015 - 2020 (USD Million)
  • Figure 9.10 Avadel Pharmaceuticals: Medusa Technology
  • Figure 9.11 Camurus: Annual Revenues, 2015- H1 2021 (SEK)
  • Figure 9.12 Camurus: FluidCrystal Injection Depot Technology
  • Figure 9.13 DURECT: Annual Revenues, 2015-H1 2021 (USD Million)
  • Figure 9.14 DURECT: CLOUD Platform
  • Figure 9.15 Eagle Pharmaceuticals: Annual Revenues, 2015-H1 202 (USD Million)
  • Figure 9.16 Halozyme Therapeutics: Annual Revenues, 2015 - H1 2021 (USD Million)
  • Figure 9.17 MedinCell: Annual Revenues, 2015 - Q3 2021 (Euro Million)
  • Figure 9.18 MedinCell: BEPO Technology
  • Figure 9.19 Xeris Pharmaceuticals: Annual Revenues, 2016 - H1 2021 (USD Million)
  • Figure 9.20 Xeris Pharmaceuticals: XeriJect Technology
  • Figure 9.21 Xeris Pharmaceuticals: XeriSol Technology
  • Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2016-2021
  • Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 10.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
  • Figure 10.5 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 10.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Figure 10.7 Partnerships and Collaborations: Distribution by Type of Partner and Partnership
  • Figure 10.8 Partnerships and Collaborations: Distribution Type of Partner and Company Size
  • Figure 10.9 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 10.10 Partnerships and Collaborations: Focus Area (Word Cloud)
  • Figure 10.11 Partnerships and Collaborations: Country-wise Distribution
  • Figure 10.12 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements Distribution
  • Figure 10.13 Most Active Players: Distribution by Number of Partnerships
  • Figure 11.1 Different Types of Subcutaneous Drug Delivery Systems
  • Figure 11.2 Large Volume Wearable Injectors: Overall Market Landscape
  • Figure 11.3 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Phase of Development
  • Figure 11.4 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type ofDevice
  • Figure 11.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Actuation Mechanism
  • Figure 11.6 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Technology Used
  • Figure 11.7 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Route ofAdministration
  • Figure 11.8 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Methodof Administration
  • Figure 11.9 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic Area
  • Figure 11.10 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type ofDose
  • Figure 11.11 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by StorageVolume / Capacity (in mL)
  • Figure 11.12 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
  • Figure 11.13 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution byAvailability of Prefilled Drug Reservoir
  • Figure 11.14 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Connectivity
  • Figure 11.15 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Drug Compatibility
  • Figure 11.16 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Drug Container
  • Figure 11.17 Most Active Players: Distribution by Number of Large Volume Wearable Injectors for Non-Insulin Drugs
  • Figure 11.18 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Phase ofDevelopment
  • Figure 11.19 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Device
  • Figure 11.20 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Dose
  • Figure 11.21 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Storage Volume / Capacity (in mL)
  • Figure 11.22 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Usability
  • Figure 11.23 Large Volume Wearable Injectors for Insulin Drugs: Distribution by CombinationInsulin
  • Figure 11.24 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Non-Interoperable Device
  • Figure 11.25 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Prefilled Drug Reservoir
  • Figure 11.26 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
  • Figure 11.27 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type ofAutomated Insulin Delivery (AID) Features
  • Figure 11.28 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
  • Figure 11.29 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Connectivity
  • Figure 11.30 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Device Control Features
  • Figure 11.31 Most Active Players: Distribution by Number of Large Volume Wearable Injector for Insulin Drugs
  • Figure 11.32 Large Volume Drug Device Combinations: Distribution by Phase of Development
  • Figure 11.33 Large Volume Drug Device Combinations: Distribution by Type of Device
  • Figure 11.34 Large Volume Drug Device Combinations: Distribution by Mechanism of Action
  • Figure 11.35 Large Volume Drug Device Combinations: Distribution by Technology
  • Figure 11.36 Large Volume Drug Device Combinations: Distribution by Route of Administration
  • Figure 11.37 Large Volume Drug Device Combinations: Distribution by Method of Administration
  • Figure 11.38 Large Volume Drug Device Combinations: Distribution by Therapeutic Area
  • Figure 11.39 Large Volume Drug Device Combinations: Distribution by Type of Dose
  • Figure 11.40 Large Volume Drug Device Combinations: Distribution by Storage Volume /Capacity (in mL)
  • Figure 11.41 Large Volume Drug Device Combinations: Distribution by Usability
  • Figure 11.42 Large Volume Drug Device Combinations: Distribution by Drug Compatibility
  • Figure 11.43 Large Volume Drug Device Combinations: Distribution by Drug Container
  • Figure 11.44 Most Active Players: Distribution by Number of Products Manufactured
  • Figure 11.45 Autoinjectors: Distribution by Actuation Mechanism
  • Figure 11.46 Autoinjectors: Distribution by Route of Administration
  • Figure 11.47 Autoinjectors: Distribution by Type of Dose
  • Figure 11.48 Autoinjectors: Distribution by Storage Volume / Capacity (in ml)
  • Figure 11.49 Autoinjectors: Distribution by Usability
  • Figure 11.50 Autoinjectors: Distribution by Type of Primary Container
  • Figure 11.51 Autoinjectors: Distribution by Type of Feedback Mechanism
  • Figure 11.52 Most Active players: Distribution by Number of Devices
  • Figure 11.53 Pen Injectors: Distribution by Type of Dose
  • Figure 11.54 Pen Injectors: Distribution by Storage Volume / Capacity (in ml)
  • Figure 11.55 Pen Injectors: Distribution by Usability
  • Figure 11.56 Most Active Players: Distribution by Number of Devices
  • Figure 11.57 Needle Free Injection Systems: Distribution by Phase of Development
  • Figure 11.58 Needle Free Injection Systems: Distribution by Actuation Mechanism
  • Figure 11.59 Needle Free Injection Systems: Distribution by Therapeutic Area
  • Figure 11.60 Needle Free Injection Systems: Distribution by Usability
  • Figure 11.61 Most Active Players: Distribution by Number of Devices
  • Figure 11.62 Novel Drug Reconstitution Systems: Distribution by Volume Storage / Capacity (mL)
  • Figure 11.63 Novel Drug Reconstitution Systems: Distribution by Usability
  • Figure 11.64 Novel Drug Reconstitution Systems: Distribution by Type of Device
  • Figure 11.65 Novel Drug Reconstitution Systems: Distribution by Type of Chamber
  • Figure 11.66 Novel Drug Reconstitution Systems: Distribution by Type of Device andChamber
  • Figure 11.67 Novel Drug Reconstitution Systems: Distribution by Physical State of Drug
  • Figure 11.68 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material
  • Figure 11.69 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material and Usability
  • Figure 11.70 Most Active Players: Distribution by Number of Devices
  • Figure 11.71 Prefilled Syringes: Distribution by Storage Volume / Capacity (ml)
  • Figure 11.72 Prefilled Syringes: Distribution by Barrel Fabrication Material
  • Figure 11.73 Prefilled Syringes: Distribution by Number of Barrel Chambers
  • Figure 11.74 Prefilled Syringes: Distribution by Type of Needle System
  • Figure 11.75 Most Active Players: Distribution by Number of Devices
  • Figure 11.76 Implants: Distribution by Phase of Development
  • Figure 11.77 Implants: Distribution by Therapeutic Area
  • Figure 11.78 Implants: Distribution by Implant Material
  • Figure 11.79 Implants: Distribution by Treatment Duration
  • Figure 11.80 Implants: Distribution by Type of Delivery System
  • Figure 11.81 Most Active Players: Distribution By number of Devices
  • Figure 12.1 Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Drugs
  • Figure 12.2 Product Competitiveness Analysis: Large Volume Wearable Injectors for InsulinDrugs
  • Figure 12.3 Product Competitiveness Analysis: Drug Device Combinations Products
  • Figure 12.4 Product Competitiveness Analysis: Disposable Autoinjectors
  • Figure 12.5 Product Competitiveness Analysis: Reusable Autoinjectors
  • Figure 12.6 Product Competitiveness Analysis: Spring-based Needle-Free Injection Systems
  • Figure 12.7 Product Competitiveness Analysis: Compressed Gas-powered Needle-Free Injection Systems
  • Figure 12.8 Product Competitiveness Analysis: Glass Barrel Prefilled Syringes
  • Figure 12.9 Product Competitiveness Analysis: Plastic Barrel Prefilled Syringes
  • Figure 13.1 Global Approved Subcutaneous Biologics Market, 2022-2035
  • Figure 13.2 Approved Subcutaneous Biologics Market: Distribution by Type of Biologic, 2022 and 2035
  • Figure 13.3 Approved Subcutaneous Biologics Market for Antibodies, 2022-2035
  • Figure 13.4 Approved Subcutaneous Biologics Market for Nucleotides, 2022-2035
  • Figure 13.5 Approved Subcutaneous Biologics Market for Proteins, 2022-2035
  • Figure 13.6 Approved Subcutaneous Biologics Market for Vaccines, 2022-2035
  • Figure 13.7 Approved Subcutaneous Biologics Market for Other Biologics, 2022-2035
  • Figure 13.8 Approved Subcutaneous Biologics Market: Distribution by Type of Therapy, 2022 and 2035
  • Figure 13.9 Approved Subcutaneous Biologics Market for Monotherapies, 2022-2035
  • Figure 13.10 Approved Subcutaneous Biologics Market for Combination Therapies, 2022-2035
  • Figure 13.11 Approved Subcutaneous Biologics Market for Monotherapies and Combination Therapies, 2022-2035
  • Figure 13.12 Approved Subcutaneous Biologics Market: Distribution by Therapeutic Area, 2022 and 2035
  • Figure 13.13 Approved Subcutaneous Biologics Market for Autoimmune Disorders, 2022-2035
  • Figure 13.14 Approved Subcutaneous Biologics Market for Blood Disorders, 2022-2035
  • Figure 13.15 Approved Subcutaneous Biologics Market for Bone Disorders, 2022-2035
  • Figure 13.16 Approved Subcutaneous Biologics Market for Cardiovascular Disorders, 2022-2035
  • Figure 13.17 Approved Subcutaneous Biologics Market for Genetic Disorders, 2022-2035
  • Figure 13.18 Approved Subcutaneous Biologics Market for Hormonal Disorders, 2022-2035
  • Figure 13.19 Approved Subcutaneous Biologics Market for Hypoactive Sexual Desire Disorders, 2022-2035
  • Figure 13.20 Approved Subcutaneous Biologics Market for Infectious Disorders, 2022-2035
  • Figure 13.21 Approved Subcutaneous Biologics Market for Inflammatory Disorders, 2022-2035
  • Figure 13.22 Approved Subcutaneous Biologics Market for Kidney Disorders, 2022-2035
  • Figure 13.23 Approved Subcutaneous Biologics Market for Mental Health Disorders, 2022-2035
  • Figure 13.24 Approved Subcutaneous Biologics Market for Metabolic Disorders, 2022-2035
  • Figure 13.25 Approved Subcutaneous Biologics Market for Neurological Disorders, 2022-2035
  • Figure 13.26 Approved Subcutaneous Biologics Market for Oncological Disorders, 2022-2035
  • Figure 13.27 Approved Subcutaneous Biologics Market for Respiratory Disorders, 2022-2035
  • Figure 13.28 Approved Subcutaneous Biologics Market for Women's Health, 2022-2035
  • Figure 13.29 Approved Subcutaneous Biologics Market for Other Disorders, 2022-2035
  • Figure 13.30 Approved Subcutaneous Biologics Market: Distribution by Geographical Region,2022 and 2035
  • Figure 13.31 Approved Subcutaneous Biologics Market in North America, 2022-2035
  • Figure 13.32 Approved Subcutaneous Biologics Market in Europe, 2022-2035
  • Figure 13.33 Approved Subcutaneous Biologics Market in Asia, 2022-2035
  • Figure 13.34 AIMOVIG Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.35 AJOVY Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.36 Apidra® (insulin glulisine), Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.37 Aranesp® / Nesp® (darbepoetin alfa) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.38 Basaglar® / Abrasia (EU) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.39 BENLYSTA®(belimumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.40 BESREMi (ropeginterferon alfa-2b-njft) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.41 BIOTHRAX® (Anthrax Vaccine Adsorbed) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.42 CABLIVI (Caplacizumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.43 Cegfila® Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.44 CIMZIA® (certolizumab pegol) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.45 COSENTYX® (secukinumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.46 CRYSVITA® (burosumab-twza) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.47 Cuvitru™ (immune globulin subcutaneous [human], 20% solution) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.48 DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj / DARZALEX®SC Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.49 DENGVAXIA (Dengue Tetravalent Vaccine) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.50 DUPIXENT® (dupilumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.51 EMGALITY (galcanezumab-gnlm) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.52 EMPAVELI™ (pegcetacoplan) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.53 Enbrel® (etanercept) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.54 ENSPRYNG™ (satralizumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.55 EVENITY™ (romosozumab-aqqg) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.56 EXTAVIA® (interferon beta-l b) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.57 FASENRA® (benralizumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.58 Fertavid® (follitropin beta) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.59 FIASP® (Insulin Aspart) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.60 Fulphila® (pegfilgrastim-jmdb) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.61 Gamunex-C® (Immune Globulin Injection [Human], 10%Caprylate/Chromatography Purified) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.62 GATTEX® / Revestive (teduglutide [rDNA origin]) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.63 GIVLAARI (givosiran) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.64 HAEGARDA® Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.65 HEMLIBRA® (emicizumab-kxwh) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.66 Hepcludex® (Bulevirtide) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.67 Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.68 HYQVIA (Immune Globulin Infusion 10% (Human) with Recombinant HumanHyaluronidase) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.69 ILARIS® (canakinumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.70 ILUMYA™ (tildrakizumab-asmn) / Ilumetri Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.71 Kalbitor (ecallantide) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.72 Kesimpta® (ofatumumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.73 KEVZARA® (sarilumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.74 KINERET® (anakinra) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.75 KIOVIG® / (Gammagard Liquid 10% (Immune Globulin Infusion) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.76 Kyntheum® / SILIQ™ / Lumicef® (brodalumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.77 Leqvio (Inclisiran) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.78 Lonquex® (lipegfilgrastim) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.79 Lyumjev (insulin lispro-aabc) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.80 Norditropin® (somatropin) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.81 NPLATE® (romiplostim) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.82 Nucala® (mepolizumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.83 Nutropin AQ® (somatropin) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.84 OXLUMO™ (lumasiran) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.85 PALYNZIQ (pegvaliase-pqpz) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.86 Pergoveris® (follitropin alfa / lutropin alfa) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.87 Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.88 PLEGRIDY® (peginterferon beta-1a) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.89 PRALUENT® (alirocumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.90 Prolia® / Pralia® (denosumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.91 REBLOZYL® (luspatercept-aamt) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.92 REKOVELLE® (follitropin delta) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.93 Repatha® (evolocumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.94 RITUXAN HYCELA™ (rituximab and hyaluronidase human) / MabThera® SC(rituximab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.95 RYZODEG® 70/30 (insulin degludec and insulin aspart) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.96 Skyrizi (risankizumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.97 SKYTROFA™ (lonapegsomatropin-tcgd) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.98 SOLIQUA® 100/33 (insulin glargine & lixisenatide injection) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.99 STELARA® (ustekinumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.100 Strensiq® (asfotase alfa) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.101 TAKHZYRO (lanadelumab-flyo) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.102 Taltz® (ixekizumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.103 TEGSEDI (inotersen) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.104 Toujeo® (insulin glargine injection) U-300 Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.105 TREMFYA® (guselkumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.106 TRESIBA® (insulin degludec injection) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.107 Trulicity® (dulaglutide) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.108 TYMLOS™ (abaloparatide) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.109 Tysabri (Natalizumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.110 Voxzogo (vosoritide) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.111 VYLEESI (bremelanotide injection) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.112 XEMBIFY (immune globulin subcutaneous, human - klhw) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.113 Xgeva® / RANMARK® (denosumab) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.114 XULTOPHY® / IDegLira (insulin degludec and liraglutide injection) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.115 XYOSTED (testosterone enanthate) Sales Forecast, 2022-2035 (USD Million)
  • Figure 13.116 ZEGALOGUE (dasiglucagon) Sales Forecast, 2022-2035 (USD Million)
  • Figure 14.1 Global Subcutaneous Formulation Technologies Market, 2022-2035
  • Figure 14.2 Subcutaneous Formulation Technologies Market: Distribution by Type of Payment, 2022 and 2035
  • Figure 14.3 Subcutaneous Formulation Technologies Market for Milestone Payments, 2022-2035
  • Figure 14.4 Subcutaneous Formulation Technologies Market for Upfront Payments, 2022-2035
  • Figure 14.5 Subcutaneous Formulation Technologies Market: Distribution by Fundamental Principle, 2022 and 2035
  • Figure 14.6 Subcutaneous Formulation Technologies Market for Amino Acid Interaction, 2022-2035
  • Figure 14.7 Subcutaneous Formulation Technologies Market for Complex Formation, 2022-2035
  • Figure 14.8 Subcutaneous Formulation Technologies Market for Encapsulation, 2022-2035
  • Figure 14.9 Subcutaneous Formulation Technologies Market for Other Fundamental Principles, 2022-2035
  • Figure 14.10 Subcutaneous Formulation Technologies Market: Distribution by End Users, 2022 and 2035
  • Figure 14.11 Subcutaneous Formulation Technologies Market for Biopharmaceutical Companies, 2022-2035
  • Figure 14.12 Subcutaneous Formulation Technologies Market for Biotechnology Companies, 2022-2035
  • Figure 14.13 Subcutaneous Formulation Technologies Market for Contract Development and Manufacturing Organizations, 2022-2035
  • Figure 14.14 Subcutaneous Formulation Technologies Market for Educational Institutes, 2022-2035
  • Figure 14.15 Subcutaneous Formulation Technologies Market for Investors, 2022-2035
  • Figure 14.16 Subcutaneous Formulation Technologies Market for Pharmaceutical Companies, 2022-2035
  • Figure 14.17 Subcutaneous Formulation Technologies Market for Research Institutes, 2022-2035
  • Figure 14.18 Subcutaneous Formulation Technologies Market for Other End Users, 2022-2035
  • Figure 14.19 Subcutaneous Formulation Technologies Market: Distribution by Therapeutic Area, 2022 and 2035
  • Figure 14.20 Subcutaneous Formulation Technologies Market for Autoimmune Disorders, 2022-2035
  • Figure 14.21 Subcutaneous Formulation Technologies Market for Genetic Disorders, 2022-2035
  • Figure 14.22 Subcutaneous Formulation Technologies Market for Infectious Disorders, 2022-2035
  • Figure 14.23 Subcutaneous Formulation Technologies Market for Metabolic Disorders, 2022-2035
  • Figure 14.24 Subcutaneous Formulation Technologies Market for Oncological Disorders, 2022-2035
  • Figure 14.25 Subcutaneous Formulation Technologies Market for Ophthalmic Disorders, 2022-2035
  • Figure 14.26 Subcutaneous Formulation Technologies Market for Other Disorders, 2022-2035
  • Figure 14.27 Subcutaneous Formulation Technologies Market: Distribution by Geographical Regions, 2022 and 2035
  • Figure 14.28 Subcutaneous Formulation Technologies Market in North America, 2022-2035
  • Figure 14.29 Subcutaneous Formulation Technologies Market in Europe, 2022-2035
  • Figure 14.30 Subcutaneous Formulation Technologies Market in Asia, 2022-2035
  • Figure 15.1 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2021-2035 (USD Million)
  • Figure 15.2 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2021-2035 (USD Million)
  • Figure 15.3 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2021-2035 (USD Million)
  • Figure 15.4 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2021-2035 (USD Million)
  • Figure 15.5 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2021-2035 (USD Million)
  • Figure 15.6 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2021-2035 (USD Million)
  • Figure 15.7 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2021-2035 (USD Million)
  • Figure 15.8 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2021-2035 (USD Million)
  • Figure 15.9 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2021-2035 (USD Million)
  • Figure 15.10 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe:Distribution by Type of Device, 2021-2035 (USD Million)
  • Figure 15.11 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe:Distribution by Usability, 2021-2035 (USD Million)
  • Figure 15.12 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe:Distribution by Therapeutic Area, 2021-2035 (USD Million)
  • Figure 15.13 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific,2021-2035 (USD Million)
  • Figure 15.14 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2021-2035 (USD Million)
  • Figure 15.15 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2021-2035 (USD Million)
  • Figure 15.16 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2021-2035 (USD Million)
  • Figure 15.17 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America,2021-2035 (USD Million)
  • Figure 15.18 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, 2021-2035 (USD Million)
  • Figure 15.19 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, 2021-2035 (USD Million)
  • Figure 15.20 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, 2021-2035 (USD Million)
  • Figure 15.21 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, 2021-2035 (USD Million)
  • Figure 15.22 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle Eastand North Africa: Distribution by Type of Device, 2021-2035 (USD Million)
  • Figure 15.23 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (USD Million)
  • Figure 15.24 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (USD Million)
  • Figure 15.25 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2021-2035 (Million Units)
  • Figure 15.26 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs:Distribution by Type of Device, 2021-2035 (Million Units)
  • Figure 15.27 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs:Distribution by Usability, 2021-2035 (Million Units)
  • Figure 15.28 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs:Distribution by Therapeutic Area, 2021-2035 (Million Units)
  • Figure 15.29 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2021-2035 (Million Units)
  • Figure 15.30 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2021-2035 (Million Units)
  • Figure 15.31 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2021-2035 (Million Units)
  • Figure 15.32 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2021-2035 (Million Units)
  • Figure 15.33 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2021-2035 (Million Units)
  • Figure 15.34 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe:Distribution by Type of Device, 2021-2035 (Million Units)
  • Figure 15.35 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe:Distribution by Usability, 2021-2035 (Million Units)
  • Figure 15.36 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe:Distribution by Therapeutic Area, 2021-2035 (Million Units)
  • Figure 15.37 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific,2021-2035 (Million Units)
  • Figure 15.38 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2021-2035 (Million Units)
  • Figure 15.39 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2021-2035 (Million Units)
  • Figure 15.40 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific:Distribution by Therapeutic Area, 2021-2035 (Million Units)
  • Figure 15.41 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America,2021-2035 (Million Units)
  • Figure 15.42 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America:Distribution by Type of Device, 2021-2035 (Million Units)
  • Figure 15.43 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America:Distribution by Usability, 2021-2035 (Million Units)
  • Figure 15.44 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America:Distribution by Therapeutic Area, 2021-2035 (Million Units)
  • Figure 15.45 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, 2021-2035 (Million Units)
  • Figure 15.46 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (Million Units)
  • Figure 15.47 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (Million Units)
  • Figure 15.48 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (Million Units)
  • Figure 15.49 Global Large Volume Wearable Injectors Market for Insulin, 2021-2035 (USDBillion)
  • Figure 15.50 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Typeof Device, 2021-2035 (USD Million)
  • Figure 15.51 Global Large Volume Wearable Injectors Market for Insulin: Distribution byUsability, 2021-2035 (USD Million)
  • Figure 15.52 Large Volume Wearable Injectors Market for Insulin in North America, 2021-2035(USD Million)
  • Figure 15.53 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2021-2035 (USD Million)
  • Figure 15.54 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2021-2035 (USD Million)
  • Figure 15.55 Large Volume Wearable Injectors Market for Insulin in Europe, 2021-2035 (USDMillion)
  • Figure 15.56 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution byType of Device, 2021-2035 (USD Million)
  • Figure 15.57 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution byUsability, 2021-2035 (USD Million)
  • Figure 15.58 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2021-2035(USD Million)
  • Figure 15.59 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distributionby Type of Device, 2021-2035 (USD Million)
  • Figure 15.60 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distributionby Usability, 2021-2035 (USD Million)
  • Figure 15.61 Large Volume Wearable Injectors Market for Insulin in Latin America, 2021-2035(USD Million)
  • Figure 15.62 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Type of Device, 2021-2035 (USD Million)
  • Figure 15.63 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Usability, 2021-2035 (USD Million)
  • Figure 15.64 Large Volume Wearable Injectors Market for Insulin in Middle East and NorthAfrica, 2021-2035 (USD Million)
  • Figure 15.65 Large Volume Wearable Injectors Market for Insulin in Middle East and NorthAfrica: Distribution by Type of Device, 2021-2035 (USD Million)
  • Figure 15.66 Large Volume Wearable Injectors Market for Insulin in Middle East and NorthAfrica: Distribution by Usability, 2021-2035 (USD Million)
  • Figure 15.67 Global Autoinjectors Market, 2021-2035 (USD Billion)
  • Figure 15.68 Global Autoinjectors Market for Anaphylaxis, 2021-2035 (USD Billion)
  • Figure 15.69 Global Disposable Autoinjectors Market for Anaphylaxis, 2021-2035 (USD Billion)
  • Figure 15.70 Global Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (USDBillion)
  • Figure 15.71 Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (USD Billion)
  • Figure 15.72 Global Small Molecule-based Autoinjectors Market for Anaphylaxis, 2021-2035(USD Billion)
  • Figure 15.73 Autoinjectors Market for Anaphylaxis in North America, 2021-2035 (USD Billion)
  • Figure 15.74 Autoinjectors Market for Anaphylaxis in Europe, 2021-2035 (USD Billion)
  • Figure 15.75 Autoinjectors Market for Anaphylaxis in Asia-Pacific, 2021-2035 (USD Billion)
  • Figure 15.76 Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2035 (USDBillion)
  • Figure 15.77 Global Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
  • Figure 15.78 Global Disposable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USDBillion)
  • Figure 15.79 Global Reusable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USDBillion)
  • Figure 15.80 Global Intramuscular Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
  • Figure 15.81 Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
  • Figure 15.82 Global Protein-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
  • Figure 15.83 Global Peptide-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
  • Figure 15.84 Global Antibody-based Autoinjectors Market for Multiple Sclerosis, 2021-2035(USD Billion)
  • Figure 15.85 Autoinjectors Market for Multiple Sclerosis in North America, 2021-2035 (USDBillion)
  • Figure 15.86 Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2035 (USD Billion)
  • Figure 15.87 Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, 2021-2035 (USDBillion)
  • Figure 15.88 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2035 (USDBillion)
  • Figure 15.89 Global Autoinjectors Market for Migraine, 2021-2035 (USD Billion)
  • Figure 15.90 Global Disposable Autoinjectors Market for Migraine, 2021-2035 (USD Billion)
  • Figure 15.91 Global Subcutaneous Autoinjectors Market for Migraine, 2021-2035 (USD Billion)
  • Figure 15.92 Global Antibody-based Autoinjectors Market for Migraine, 2021-2035 (USDBillion)
  • Figure 15.93 Global Small Molecule-based Autoinjectors Market for Migraine, 2021-2035 (USD Billion)
  • Figure 15.94 Autoinjectors Market for Migraine in North America, 2021-2035 (USD Billion)
  • Figure 15.95 Autoinjectors Market for Migraine in Europe, 2021-2035 (USD Billion)
  • Figure 15.96 Autoinjectors Market for Migraine in Asia-Pacific, 2021-2035 (USD Billion)
  • Figure 15.97 Autoinjectors Market for Migraine in Rest of the World, 2021-2035 (USD Billion)
  • Figure 15.98 Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035(USD Billion)
  • Figure 15.99 Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis,2021-2035 (USD Billion)
  • Figure 15.100 Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis,2021-2035 (USD Billion)
  • Figure 15.101 Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis,2021-2035 (USD Billion)
  • Figure 15.102 Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid andPsoriatic Arthritis, 2021-2035 (USD Billion)
  • Figure 15.103 Global Antibody-based Autoinjectors Market for Rheumatoid and PsoriaticArthritis, 2021-2035 (USD Billion)
  • Figure 15.104 Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis,2021-2035 (USD Billion)
  • Figure 15.105 Global Small Molecule-based Autoinjectors Market for Rheumatoid and PsoriaticArthritis, 2021-2035 (USD Billion)
  • Figure 15.106 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America,2021-2035 (USD Billion)
  • Figure 15.107 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, 2021-2035(USD Billion)
  • Figure 15.108 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, 2021-2035 (USD Billion)
  • Figure 15.109 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World,2021-2035 (USD Billion)
  • Figure 15.110 Global Autoinjectors Market for Diabetes, 2021-2035 (USD Billion)
  • Figure 15.111 Global Disposable Autoinjectors Market for Diabetes, 2021-2035 (USD Billion)
  • Figure 15.112 Global Subcutaneous Autoinjectors Market for Diabetes, 2021-2035 (USD Billion)
  • Figure 15.113 Global Protein-based Autoinjectors Market for Diabetes, 2021-2035 (USD Billion)
  • Figure 15.114 Global Peptide-based Autoinjectors Market for Diabetes, 2021-2035 (USD Billion)
  • Figure 15.115 Autoinjectors Market for Diabetes in North America, 2021-2035 (USD Billion)
  • Figure 15.116 Autoinjectors Market for Diabetes in Europe, 2021-2035 (USD Billion)
  • Figure 15.117 Autoinjectors Market for Diabetes in Asia-Pacific, 2021-2035 (USD Billion)
  • Figure 15.118 Autoinjectors Market for Diabetes in Rest of the World, 2021-2035 (USD Billion)
  • Figure 15.119 Global Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
  • Figure 15.120 Global Disposable Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
  • Figure 15.121 Global Subcutaneous Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
  • Figure 15.122 Global Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
  • Figure 15.123 Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications,2021-2035 (USD Billion)
  • Figure 15.124 Global Protein-based Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
  • Figure 15.125 Global Antibody-based Autoinjectors Market for Other Indications, 2021-2035(USD Billion)
  • Figure 15.126 Global Small Molecule-based Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
  • Figure 15.127 Autoinjectors Market for Other Indications in North America, 2021-2035 (USD Billion)
  • Figure 15.128 Autoinjectors Market for Other Indications in Europe, 2021-2035 (USD Billion)
  • Figure 15.129 Autoinjectors Market for Other Indications in Asia-Pacific, 2021-2035 (USD Billion)
  • Figure 15.130 Autoinjectors Market for Other Indications in Rest of the World, 2021-2035 (USD Billion)
  • Figure 15.131 Global Autoinjectors Market, 2021-2035 (Million Units)
  • Figure 15.132 Global Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
  • Figure 15.133 Global Disposable Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
  • Figure 15.134 Global Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
  • Figure 15.135 Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
  • Figure 15.136 Global Small Molecule-based Autoinjectors Market for Anaphylaxis, 2021-2035(Million Units)
  • Figure 15.137 Autoinjectors Market for Anaphylaxis in North America, 2021-2035 (Million Units)
  • Figure 15.138 Autoinjectors Market for Anaphylaxis in Europe, 2021-2035 (Million Units)
  • Figure 15.139 Autoinjectors Market for Anaphylaxis in Asia-Pacific, 2021-2035 (Million Units)
  • Figure 15.140 Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2035 (Million Units)
  • Figure 15.141 Global Autoinjectors Market for Multiple Sclerosis, 2021-2035 (Million Units)
  • Figure 15.142 Global Disposable Autoinjectors Market for Multiple Sclerosis, 2021-2035(Million Units)
  • Figure 15.143 Global Reusable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (Million Units)
  • Figure 15.144 Global Intramuscular Autoinjectors Market for Multiple Sclerosis, 2021-2035(USD Billion)
  • Figure 15.145 Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, 2021-2035(Million Units)
  • Figure 15.146 Global Protein-based Autoinjectors Market for Multiple Sclerosis, 2021-2035(Million Units)
  • Figure 15.147 Global Peptide-based Autoinjectors Market for Multiple Sclerosis, 2021-2035(Million Units)
  • Figure 15.148 Global Antibody-based Autoinjectors Market for Multiple Sclerosis, 2021-2035(Million Units)
  • Figure 15.149 Autoinjectors Market for Multiple Sclerosis in North America, 2021-2035 (MillionUnits)
  • Figure 15.150 Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2035 (Million Units)
  • Figure 15.151 Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, 2021-2035 (Million Units)
  • Figure 15.152 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2035(Million Units)
  • Figure 15.153 Global Autoinjectors Market for Migraine, 2021-2035 (Million Units)
  • Figure 15.154 Global Disposable Autoinjectors Market for Migraine, 2021-2035 (Million Units)
  • Figure 15.155 Global Subcutaneous Autoinjectors Market for Migraine, 2021-2035 (MillionUnits)
  • Figure 15.156 Global Antibody-based Autoinjectors Market for Migraine, 2021-2035 (MillionUnits)
  • Figure 15.157 Global Small Molecule-based Autoinjectors Market for Migraine, 2021-2035(Million Units)
  • Figure 15.158 Autoinjectors Market for Migraine in North America, 2021-2035 (Million Units)
  • Figure 15.159 Autoinjectors Market for Migraine in Europe, 2021-2035 (Million Units)
  • Figure 15.160 Autoinjectors Market for Migraine in Asia-Pacific, 2021-2035 (Million Units)
  • Figure 15.161 Autoinjectors Market for Migraine in Rest of the World, 2021-2035 (Million Units)
  • Figure 15.162 Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035(Million Units)
  • Figure 15.163 Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis,2021-2035 (Million Units)
  • Figure 15.164 Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis,2021-2035 (Million Units)
  • Figure 15.165 Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis,2021-2035 (Million Units)
  • Figure 15.166 Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid andPsoriatic Arthritis, 2021-2035 (Million Units)
  • Figure 15.167 Global Antibody-based Autoinjectors Market for Rheumatoid and PsoriaticArthritis, 2021-2035 (Million Units)
  • Figure 15.168 Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis,2021-2035 (Million Units)
  • Figure 15.169 Global Small Molecule-based Autoinjectors Market for Rheumatoid and PsoriaticArthritis, 2021-2035 (Million Units)
  • Figure 15.170 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America,2021-2035 (Million Units)
  • Figure 15.171 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, 2021-2035(Million Units)
  • Figure 15.172 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, 2021-2035 (USD Billion)
  • Figure 15.173 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World,2021-2035 (Million Units)
  • Figure 15.174 Global Autoinjectors Market for Diabetes, 2021-2035 (Million Units)
  • Figure 15.175 Global Disposable Autoinjectors Market for Diabetes, 2021-2035 (Million Units)
  • Figure 15.176 Global Subcutaneous Autoinjectors Market for Diabetes, 2021-2035 (MillionUnits)
  • Figure 15.177 Global Protein-based Autoinjectors Market for Diabetes, 2021-2035 (MillionUnits)
  • Figure 15.178 Global Peptide-based Autoinjectors Market for Diabetes, 2021-2035 (MillionUnits)
  • Figure 15.179 Autoinjectors Market for Diabetes in North America, 2021-2035 (Million Units)
  • Figure 15.180 Autoinjectors Market for Diabetes in Europe, 2021-2035 (Million Units)
  • Figure 15.181 Autoinjectors Market for Diabetes in Asia-Pacific, 2021-2035 (Million Units)
  • Figure 15.182 Autoinjectors Market for Diabetes in Rest of the World, 2021-2035 (Million Units)
  • Figure 15.183 Global Autoinjectors Market for Other Indications, 2021-2035 (Million Units)
  • Figure 15.184 Global Disposable Autoinjectors Market for Other Indications, 2021-2035 (USDBillion)
  • Figure 15.185 Global Subcutaneous Autoinjectors Market for Other Indications, 2021-2035(Million Units)
  • Figure 15.186 Global Intramuscular Autoinjectors Market for Other Indications, 2021-2035(Million Units)
  • Figure 15.187 Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications,2021-2035 (Million Units)
  • Figure 15.188 Global Protein-based Autoinjectors Market for Other Indications, 2021-2035(Million Units)
  • Figure 15.189 Global Antibody-based Autoinjectors Market for Other Indications, 2021-2035(Million Units)
  • Figure 15.190 Global Small Molecule-based Autoinjectors Market for Other Indications, 2021-2035 (Million Units)
  • Figure 15.191 Autoinjectors Market for Other Indications in North America, 2021-2035 (MillionUnits)
  • Figure 15.192 Autoinjectors Market for Other Indications in Europe, 2021-2035 (Million Units)
  • Figure 15.193 Autoinjectors Market for Other Indications in Asia-Pacific, 2021-2035 (MillionUnits)
  • Figure 15.194 Autoinjectors Market for Other Indications in Rest of the World, 2021-2035(Million Units)
  • Figure 15.195 Prefilled Syringes Price, 2020-2030: Conservative, Base and Optimistic Scenarios(USD per unit)
  • Figure 15.196 Global Prefilled Syringes Market, 2020-2030 (USD Million)
  • Figure 15.197 Global Prefilled Syringes Market, 2020-2030 (Million, Units)
  • Figure 15.198 Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, 2020,2025 and 2030 (USD Million)
  • Figure 15.199 Prefilled Syringes Market: Distribution by Type of Chamber System, 2020, 2025and 2030 (USD Million)
  • Figure 15.200 Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule,2020, 2025 and 2030 (USD Million)
  • Figure 15.201 Prefilled Syringes Market: Distribution by Target Therapeutic Area, 2020-2030
  • Figure 15.202 Global Needle-free Injection Systems Market, 2020-2030 (USD Million)
  • Figure 15.203 Global Needle-free Injection Systems Market: Distribution by Product Usability,2020-2030, (USD Million)
  • Figure 15.204 Global Needle-free Injection Systems Market: Distribution by ActuationMechanism, 2020-2030 (USD Million)
  • Figure 15.205 Global Needle-free Injection Systems Market: Distribution by Target TherapeuticArea, 2020-2030 (USD Million)
  • Figure 15.206 Global Novel Drug Reconstitution Systems Market, 2021-2030 (USD Billion)
  • Figure 15.207 Global Dual Chamber Prefilled Syringes Market, 2021-2030 (USD Billion)
  • Figure 15.208 Dual Chamber Prefilled Syringes Market, 2021 and 2030: Distribution by PhysicalState of Drug
  • Figure 15.209 Dual Chamber Prefilled Syringes Market for Liquid / Powder Drugs, 2021-2030(USD Billion)
  • Figure 15.210 Dual Chamber Prefilled Syringes Market for Liquid / Liquid Drugs, 2021-2030(USD Billion)
  • Figure 15.211 Dual Chamber Prefilled Syringes Market, 2021 and2030: Distribution by Type ofFabrication Material Used
  • Figure 15.212 Glass Dual Chamber Prefilled Syringes Market, 2021-2030 (USD Billion)
  • Figure 15.213 Plastic Dual Chamber Prefilled Syringes Market, 2021-2030 (USD Billion)
  • Figure 15.214 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Volume
  • Figure 15.215 Dual Chamber Prefilled Syringes Market for <1 mL Syringes, 2021-2030 (USDBillion)
  • Figure 15.216 Dual Chamber Prefilled Syringes Market for 1-2.5 mL Syringes, 2021-2030 (USDBillion)
  • Figure 15.217 Dual Chamber Prefilled Syringes Market for 2.5-5 mL Syringes, 2021-2030 (USDBillion)
  • Figure 15.218 Dual Chamber Prefilled Syringes Market for >5 mL Syringes, 2021-2030 (USDBillion)
  • Figure 15.219 Dual Chamber Prefilled Syringes Market, 2021 and 2030: Distribution by Geography
  • Figure 15.220 Dual Chamber Prefilled Syringes Market in North America, 2021-2030 (USDBillion)
  • Figure 15.221 Dual Chamber Prefilled Syringes Market in Europe, 2021-2030 (USD Billion)
  • Figure 15.222 Dual Chamber Prefilled Syringes Market in Asia-Pacific, 2021-2030 (USD Billion)
  • Figure 15.223 Dual Chamber Prefilled Syringes Market in Latin America, 2021-2030 (USDBillion)
  • Figure 15.224 Dual Chamber Prefilled Syringes Market in Middle East and Africa, 2021-2030(USD Billion)
  • Figure 15.225 Global Dual Chamber Cartridges Market, 2021-2030 (USD Billion)
  • Figure 15.226 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Physical Stateof Drug
  • Figure 15.227 Dual Chamber Cartridges Market for Liquid / Powder Drugs, 2021-2030 (USD Billion)
  • Figure 15.228 Dual Chamber Cartridges Market for Liquid / Liquid Drugs, 2021-2030 (USD Billion)
  • Figure 15.229 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Type ofFabrication Material Used
  • Figure 15.230 Glass Dual Chamber Cartridges Market, 2021-2030 (USD Billion)
  • Figure 15.231 Plastic Dual Chamber Cartridges Market, 2021-2030 (USD Billion)
  • Figure 15.232 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Volume
  • Figure 15.233 Dual Chamber Cartridges Market for <1 mL Cartridges, 2021-2030 (USD Billion)
  • Figure 15.234 Dual Chamber Cartridges Market for 1-2.5 mL Cartridges, 2021-2030 (USD Billion)
  • Figure 15.235 Dual Chamber Cartridges Market for 2.5-5 mL Cartridges, 2021-2030 (USD Billion)
  • Figure 15.236 Dual Chamber Cartridges Market for >5 mL Cartridges, 2021-2030 (USD Billion)
  • Figure 15.237 Dual Chamber Cartridges Market, 2021-2030: Distribution by Geography
  • Figure 15.238 Dual Chamber Cartridges Market in North America, 2021-2030 (USD Billion)
  • Figure 15.239 Dual Chamber Cartridges Market in Europe, 2021-2030 (USD Billion)
  • Figure 15.240 Dual Chamber Cartridges Market in Asia-Pacific, 2021-2030 (USD Billion)
  • Figure 15.241 Dual Chamber Cartridges Market in Latin America, 2021-2030 (USD Billion)
  • Figure 15.242 Dual Chamber Cartridges Market in Middle East and Africa, 2021-2030 (USDBillion)
  • Figure 15.243 Global Dual / Multi Chamber Infusion Bags Market, 2021-2030 (USD Billion)
  • Figure 15.244 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by PhysicalState of Drug
  • Figure 15.245 Dual / Multi Chamber Infusion Bags Market for Liquid Drugs, 2021-2030 (USD Billion)
  • Figure 15.246 Dual / Multi Chamber Infusion Bags Market for Frozen Drugs, 2021-2030 (USDBillion)
  • Figure 15.247 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Type of Plastic Bags
  • Figure 15.248 Dual / Multi Chamber Infusion Bags Market for Ethylene Vinyl Acetate Bags,2021-2030 (USD Billion)
  • Figure 15.249 Dual / Multi Chamber Infusion Bags Market for Polypropylene Bags, 2021-2030 (USD Billion)
  • Figure 15.250 Dual / Multi Chamber Infusion Bags Market for Polyvinyl Chloride Bags, 2021-2030 (USD Billion)
  • Figure 15.251 Dual / Multi Chamber Infusion Bags Market for Other Plastic Materials Bags, 2021-2030 (USD Billion)
  • Figure 15.252 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Volume
  • Figure 15.253 Dual / Multi Chamber Infusion Bags Market for <250 mL Bags, 2021-2030 (USD Billion)
  • Figure 15.254 Dual / Multi Chamber Infusion Bags Market for 250-500 mL Bags, 2021-2030 (USD Billion)
  • Figure 15.255 Dual / Multi Chamber Infusion Bags Market for 501-1,000 mL Bags, (USD Billion) 2021-2030
  • Figure 15.256 Dual / Multi Chamber Infusion Bags Market for >1,000 mL Bags, 2021- 2030 (USD Billion)
  • Figure 15.257 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Geography
  • Figure 15.258 Dual / Multi Chamber Infusion Bags Market in North America, 2021-2030 (USD Billion)
  • Figure 15.259 Dual / Multi Chamber Infusion Bags Market in Europe, 2021-2030 (USD Billion)
  • Figure 15.260 Dual / Multi Chamber Infusion Bags Market in Asia-Pacific, 2021-2030 (USD Billion)
  • Figure 15.261 Dual / Multi Chamber Infusion Bags Market in Latin America, 2021-2030 (USD Billion)
  • Figure 15.266 Dual / Multi Chamber Infusion Bags Market in Middle East and Africa, 2021-2030 (USD Billion)
  • Figure 16.1 Subcutaneous Biologics SWOT Analysis: Overview
  • Figure 16.2 SWOT Analysis: Harvey Ball Analysis
  • Figure 16.3 Number of Biologics Approved by the USFDA, 2011-2020
  • Figure 17.1 Concluding Remarks: Approve Subcutaneous Biologics Market Landscape
  • Figure 17.2 Concluding Remarks: Clinical Subcutaneous Biologics Market Landscape
  • Figure 17.3 Concluding Remarks: Formulation Technology Market Landscape
  • Figure 17.4 Concluding Remarks: Partnerships and Collaborations
  • Figure 17.5 Concluding Remarks: Approved Subcutaneous Biologics Market Forecast
  • Figure 17.5 Concluding Remarks: Subcutaneous Drug Delivery Systems Market Forecast

List Of Tables

  • Table 3.1 Comparison of Characteristics of Small Molecules and Biologics
  • Table 3.2 Parenteral Routes of Administration
  • Table 3.3 Parenteral Drug Formulations: Associated Physical and Chemical Instabilities
  • Table 3.4 Parenteral Drug Formulations: Key Excipients
  • Table 4.1 List of Approved Subcutaneous Biologics
  • Table 4.2 Approved Subcutaneous Biologics: Information on Targeted Indication and Therapeutic Area
  • Table 4.3 Approved Subcutaneous Biologics: Information on Dosing Frequency, Dose Concentration and Therapeutic Area
  • Table 4.4 Approved Subcutaneous Biologics: Information on Available Formulation
  • Table 4.5 Subcutaneous Biologics: List of Companies
  • Table 5.1 List of Clinical Subcutaneous Biologics
  • Table 5.2 Clinical Subcutaneous Biologics: Information on Type of Therapy, Dosing Frequency, Therapeutic Area, Special Drug Designation(s) Awarded
  • Table 5.3 Clinical Subcutaneous Biologics: List of Companies
  • Table 6.1 STELARA® (Janssen Biotech): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
  • Table 6.2 DUPIXENT® (Regeneron Pharmaceuticals): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
  • Table 6.3 Trulicity® (Eli Lilly): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
  • Table 6.4 Enbrel® (Amgen): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
  • Table 6.5 COSENTYX® (Novartis): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
  • Table 6.6 BESREMi (PharmaEssentia): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
  • Table 6.7 DARZALEX FASPRO® (Halozyme): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
  • Table 6.8 Prolia® / Pralia® (Amgen): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
  • Table 6.9 HEMLIBRA® (Roche): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
  • Table 6.10 BENLYSTA® (Human Genome Sciences): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
  • Table 7.1 Subcutaneous Formulation Technologies: List of Technology Developers
  • Table 7.2 Subcutaneous Formulation Technologies: Information on Fundamental Principle and Type of Molecule
  • Table 7.3 Subcutaneous Formulation Technologies: Information on Route of Administration
  • Table 7.4 Subcutaneous Formulation Technologies: Information on Therapeutics Area and Key Characteristics
  • Table 8.1 Company Competitiveness Analysis: Benchmarking of Technology Strength
  • Table 8.2 Company Competitiveness Analysis: Benchmarking of Partnership Activity
  • Table 8.3 Company Competitiveness Analysis: Players Based in North America
  • Table 8.4 Company Competitiveness Analysis: Players Based in Europe and Asia
  • Table 9.1 Subcutaneous Formulation Technologies Developers: List of Companies Profiled
  • Table 9.2 Adocia: Company Overview
  • Table 9.3 Adocia: Product Portfolio
  • Table 9.4 Adocia: Recent Developments and Future Outlook
  • Table 9.5 Ajinomoto: Company Overview
  • Table 9.6 Ajinomoto Biopharma: Recent Developments and Future Outlook
  • Table 9.7 Alteogen: Company Overview
  • Table 9.8 Alteogen: Product Portfolio
  • Table 9.9 Alteogen: Recent Developments and Future Outlook
  • Table 9.10 Arecor: Company Overview
  • Table 9.11 Arecor: Product Portfolio
  • Table 9.12 Arecor: Recent Developments and Future Outlook.
  • Table 9.13 Ascendis Pharma: Company Overview
  • Table 9.14 Ascendis Pharma: Product Portfolio
  • Table 9.15 Ascendis Pharma: Recent Developments and Future Outlook.
  • Table 9.16 Avadel Pharmaceutical: Company Overview
  • Table 9.17 Avadel Pharmaceuticals: Product Portfolio
  • Table 9.18 Avadel Pharmaceuticals: Recent Developments and Future Outlook.
  • Table 9.19 Camurus: Company Overview
  • Table 9.20 Camurus: Product Portfolio
  • Table 9.21 Camurus: Recent Developments and Future Outlook
  • Table 9.22 Creative Biolabs: Company Overview
  • Table 9.23 Creative Biomart: Company Overview
  • Table 9.24 DURECT: Company Overview
  • Table 9.25 DURECT: Product Portfolio
  • Table 9.26 DURECT: Recent Developments and Future Outlook
  • Table 9.27 Eagle Pharmaceutical: Company Overview
  • Table 9.28 Eagle Pharmaceutical: Recent Developments and Future Outlook
  • Table 9.29 Halozyme Therapeutics: Company Overview
  • Table 9.30 Halozyme Therapeutics: Product Portfolio
  • Table 9.31 Halozyme Therapeutics: Recent Developments and Future Outlook
  • Table 9.32 Medincell: Company Overview
  • Table 9.33 MedinCell: Product Portfolio
  • Table 9.34 MedinCell: Recent Developments and Future Outlook.
  • Table 9.35 Serina Therapeutics: Company Overview
  • Table 9.36 Serina Therapeutics: Product Portfolio
  • Table 9.37 Serina Therapeutics: Recent Developments and Future Outlook
  • Table 9.38 Xeris pharmaceutical: Company Overview
  • Table 9.39 Xeris Pharmaceuticals: Product Portfolio
  • Table 9.40 Xeris Pharmaceuticals: Recent Developments and Future Outlook
  • Table 10.1 Subcutaneous Formulation Technologies: List of Partnerships, Pre-2016-2021
  • Table 10.2 Subcutaneous Formulation Technologies: Information on Type of Agreement Region-wise and Geography-wise)
  • Table 11.1 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Development Status and Device Features
  • Table 11.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Administration Related Parameters
  • Table 11.3 Large Volume Wearable Injectors for Insulin Drugs: Information on Development Status and Device Features
  • Table 11.4 Large Volume Wearable Injectors for Insulin Drugs: Information on Device Monitoring and Connectivity Features
  • Table 11.5 Large Volume Drug Device Combinations: Information on Development Status and Device Features
  • Table 11.6 Large Volume Drug Device Combinations: Information on Drug Administration Related Parameters
  • Table 11.7 Autoinjectors: Development Pipeline
  • Table 11.8 Autoinjectors: List of Additional Parameters of Devices
  • Table 11.9 Pen Injectors: Development Landscape
  • Table 11.10 List of Smart Pen Injectors
  • Table 11.11 List of Drug and Pen Injector Combination Products
  • Table 11.12 Needle Free Injection Systems: Development Landscape
  • Table 11.13 Novel Drug Reconstitution Systems: Information on Type of Product, Number of Chambers, Physical State of Drug and Product Certifications
  • Table 11.14 Novel Drug Reconstitution Systems: Information on Container Fabrication Material, Volume, Drug Class, Device Usability and Provisions for Self-Administration
  • Table 11.15 Prefilled Syringes: List of Available / Under Development Devices
  • Table 11.16 Drugs Approved in Prefilled Syringes, 2013-2019
  • Table 11.17 Other Drugs Sold in Prefilled Syringes
  • Table 11.18 Implants: Development Landscape
  • Table 11.19 Implants: Information on Material Type, Treatment Duration and Type of Delivery System
  • Table 11.20 Implants: Subcutaneous Implants Eluting Small Molecules
  • Table 19.1 Approved Subcutaneous Biologics: Distribution by Approval Year
  • Table 19.2 Approved Subcutaneous Biologics: Distribution by Type of Molecule
  • Table 19.3 Approved Subcutaneous Biologics: Distribution by Approval Year and Type of Molecule
  • Table 19.4 Approved Subcutaneous Biologics: Distribution by Type of Therapy
  • Table 19.5 Approved Subcutaneous Biologics: Distribution by Route of Administration
  • Table 19.6 Approved Subcutaneous Biologics: Distribution by Method of Administration
  • Table 19.7 Approved Subcutaneous Biologics: Distribution by Route of Administration and Method of Administration
  • Table 19.8 Approved Subcutaneous Biologics: Distribution by Dosing Frequency
  • Table 19.9 Approved Subcutaneous Biologics: Distribution by Dose Concentration
  • Table 19.10 Approved Subcutaneous Biologics: Distribution by Therapeutic Area
  • Table 19.11 Approved Subcutaneous Biologics: Distribution by Approval Year and Therapeutic Area
  • Table 19.12 Approved Subcutaneous Biologics: Distribution by Type of Available Formulation
  • Table 19.13 Approved Subcutaneous Biologics: Distribution by Route of Administration andType of Available Formulations
  • Table 19.14 Approved Subcutaneous Biologics Developers: Distribution by Year of Establishment
  • Table 19.15 Approved Subcutaneous Biologics Developers: Distribution by Company Size
  • Table 19.16 Approved Subcutaneous Biologics Developers: Distribution by Location of Headquarters
  • Table 19.17 Leading Developers: Distribution by Number of Approved Subcutaneous Biologics
  • Table 19.18 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development
  • Table 19.19 Clinical-Stage Subcutaneous Biologics: Distribution by Mechanism of Action
  • Table 19.20 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule
  • Table 19.21 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development and Type of Molecule
  • Table 19.22 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Therapy
  • Table 19.23 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule and Type of Therapy
  • Table 19.24 Clinical-Stage Subcutaneous Biologics: Distribution by Dosing Frequency
  • Table 19.25 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule and Dosing Frequency
  • Table 19.26 Clinical-Stage Subcutaneous Biologics: Distribution by Target Disease Indication(s)
  • Table 19.27 Clinical-Stage Subcutaneous Biologics: Distribution by Therapeutics Area
  • Table 19.28 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development and Therapeutics Area
  • Table 19.29 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule and Therapeutics Area
  • Table 19.30 Clinical-Stage Subcutaneous Biologics: Distribution by Special Drug Designation(s) Awarded
  • Table 19.31 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Year of Establishment
  • Table 19.32 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Company Size
  • Table 19.33 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Location of Headquarters
  • Table 19.34 Leading Developers: Distribution by Number of Clinical-Stage SubcutaneousBiologics
  • Table 19.35 Subcutaneous Formulation Technology: Distribution by Fundamental Principle of Technology
  • Table 19.36 Subcutaneous Formulation Technology: Distribution by Type of Molecule
  • Table 19.37 Subcutaneous Formulation Technologies: Distribution by Type of Formulation
  • Table 19.38 Subcutaneous Formulation Technologies: Distribution by Type of Molecule and Type of Formulation
  • Table 19.39 Subcutaneous Formulation Technologies: Distribution by Therapeutic Area
  • Table 19.40 Subcutaneous Formulation Technologies: Distribution by Advantage(s) Offered
  • Table 19.41 Subcutaneous Formulation Technology Developers: Distribution by Year ofEstablishment
  • Table 19.42 Subcutaneous Formulation Technology Developers: Distribution by Company Size
  • Table 19.43 Subcutaneous Formulation Technology Developers: Distribution by Location of Headquarters (Region Wise)
  • Table 19.44 Subcutaneous Formulation Technology Developers: Distribution by Location of Headquarters (Country-Wise)
  • Table 19.45 Subcutaneous Formulation Technology Developers: Distribution by Company Size and Location of Headquarters (Region Wise)
  • Table 19.46 Subcutaneous Formulation Technologies: Distribution by Number of Advantages Offered
  • Table 19.47 Adocia: Annual Revenues, 2015 - H1 2021 (EUR Million)
  • Table 19.48 Ajinomoto: Annual Revenues, 2016 - H1 2021 (JPY Billion)
  • Table 19.49 Alteogen : Annual Revenues, 2018 - H1 2021 (USD Million)
  • Table 19.50 Arecor: Annual Revenues, 2016 - H1 2021 (USD Million)
  • Table 19.52 Ascendis Pharma: Annual Revenues, 2015-H1 2021 (USD Million)
  • Table 19.53 Avadel Pharmaceuticals: Annual Revenues, 2015 - 2020 (USD Million)
  • Table 19.54 Camurus: Annual Revenues, 2015- H1 2021 (SEK)
  • Table 19.55 DURECT: Annual Revenues, 2015-H1 2021 (USD Million)
  • Table 19.56 Eagle Pharmaceuticals: Annual Revenues, 2015-H1 202 (USD Million)
  • Table 19.57 Halozyme Therapeutics: Annual Revenues, 2015 - H1 2021 (USD Million)
  • Table 19.58 MedinCell: Annual Revenues, 2015 - Q3 2021 (Euro Million)
  • Table 19.59 Xeris Pharmaceuticals: Annual Revenues, 2016 - H1 2021 (USD Million)
  • Table 19.60 Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2016-2021
  • Table 19.61 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 19.62 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 19.63 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
  • Table 19.64 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 19.65 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Table 19.66 Partnerships and Collaborations: Distribution by Type of Partner and Partnership
  • Table 19.67 Partnerships and Collaborations: Distribution Type of Partner and Company Size
  • Table 19.68 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 19.69 Partnerships and Collaborations: Country-wise Distribution
  • Table 19.70 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements Distribution
  • Table 19.71 Most Active Players: Distribution by Number of Partnerships
  • Table 19.72 Large Volume Wearable Injectors: Overall Market Landscape
  • Table 19.73 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Phase of Development
  • Table 19.74 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
  • Table 19.75 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Actuation Mechanism
  • Table 19.76 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Technology Used
  • Table 19.77 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Route of Administration
  • Table 19.78 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Method of Administration
  • Table 19.79 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic Area
  • Table 19.80 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
  • Table 19.81 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Storage Volume / Capacity (in mL)
  • Table 19.82 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
  • Table 19.83 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Prefilled Drug Reservoir
  • Table 19.84 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Connectivity
  • Table 19.85 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Drug Compatibility
  • Table 19.86 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Drug Container
  • Table 19.87 Most Active Players: Distribution by Number of Large Volume Wearable Injectors for Non-Insulin Drugs
  • Table 19.88 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Phase ofDevelopment
  • Table 19.89 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Device
  • Table 19.90 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Dose
  • Table 19.91 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Storage Volume / Capacity (in mL)
  • Table 19.92 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Usability
  • Table 19.93 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Combination Insulin
  • Table 19.94 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Non- Interoperable Device
  • Table 19.95 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Prefilled Drug Reservoir
  • Table 19.96 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
  • Table 19.97 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Automated Insulin Delivery (AID) Feature
  • Table 19.98 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
  • Table 19.99 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Connectivity
  • Table 19.100 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Device Control Features
  • Table 19.101 Most Active Players: Distribution by Number of Large Volume Wearable Injector for Insulin Drugs
  • Table 19.102 Large Volume Drug Device Combinations: Distribution by Phase of Development
  • Table 19.103 Large Volume Drug Device Combinations: Distribution by Type of Device
  • Table 19.104 Large Volume Drug Device Combinations: Distribution by Mechanism of Action
  • Table 19.105 Large Volume Drug Device Combinations: Distribution by Technology
  • Table 19.106 Large Volume Drug Device Combinations: Distribution by Route of Administration
  • Table 19.107 Large Volume Drug Device Combinations: Distribution by Method of Administration
  • Table 19.108 Large Volume Drug Device Combinations: Distribution by Therapeutic Area
  • Table 19.109 Large Volume Drug Device Combinations: Distribution by Type of Dose
  • Table 19.110 Large Volume Drug Device Combinations: Distribution by Storage Volume /Capacity (in mL)
  • Table 19.111 Large Volume Drug Device Combinations: Distribution by Usability
  • Table 19.112 Large Volume Drug Device Combinations: Distribution by Drug Compatibility
  • Table 19.113 Large Volume Drug Device Combinations: Distribution by Drug Container
  • Table 19.114 Most Active Players: Distribution by Number of Products Manufactured
  • Table 19.115 Autoinjectors: Distribution by Actuation Mechanism
  • Table 19.116 Autoinjectors: Distribution by Route of Administration
  • Table 19.117 Autoinjectors: Distribution by Type of Dose
  • Table 19.118 Autoinjectors: Distribution by Storage Volume / Capacity (in mL)
  • Table 19.119 Autoinjectors: Distribution by Usability
  • Table 19.120 Autoinjectors: Distribution by Type of Primary Container
  • Table 19.121 Autoinjectors: Distribution by Type of Feedback Mechanism
  • Table 19.122 Most Active players: Distribution by Number of Devices
  • Table 19.123 Pen Injectors: Distribution by Type of Dose
  • Table 19.124 Pen Injectors: Distribution by Storage Volume / Capacity (in ml)
  • Table 19.125 Pen Injectors: Distribution by Usability
  • Table 19.126 Most Active Players: Distribution by Number of Devices
  • Table 19.127 Needle Free Injection Systems: Distribution by Phase of Development
  • Table 19.128 Needle Free Injection Systems: Distribution by Actuation Mechanism
  • Table 19.129 Needle Free Injection Systems: Distribution by Therapeutic Area
  • Table 19.130 Needle Free Injection Systems: Distribution by Usability
  • Table 19.131 Most Active Players: Distribution by Number of Devices
  • Table 19.132 Novel Drug Reconstitution Systems: Distribution by Volume Storage / Capacity (in mL)
  • Table 19.133 Novel Drug Reconstitution Systems: Distribution by Usability
  • Table 19.134 Novel Drug Reconstitution Systems: Distribution by Type of Device
  • Table 19.135 Novel Drug Reconstitution Systems: Distribution by Type of Chamber
  • Table 19.136 Novel Drug Reconstitution Systems: Distribution by Type of Device and Chamber
  • Table 19.137 Novel Drug Reconstitution Systems: Distribution by Physical State of Drug
  • Table 19.138 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material
  • Table 19.139 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material and Usability
  • Table 19.140 Most Active Players: Distribution by Number of Devices
  • Table 19.141 Prefilled Syringes: Distribution by Storage Volume / Capacity (in ml)
  • Table 19.142 Prefilled Syringes: Distribution by Barrel Fabrication Material
  • Table 19.143 Prefilled Syringes: Distribution by Number of Barrel Chambers
  • Table 19.144 Prefilled Syringes: Distribution by Type of Needle System
  • Table 19.145 Most Active Players: Distribution by Number of Devices
  • Table 19.146 Implants: Distribution by Phase of Development
  • Table 19.147 Implants: Distribution by Therapeutic Area
  • Table 19.148 Implants: Distribution by Implant Material
  • Table 19.149 Implants: Distribution by Treatment Duration
  • Table 19.150 Implants: Distribution by Type of Delivery System
  • Table 19.151 Most Active Players: Distribution By number of Devices
  • Table 19.152 Global Approved Subcutaneous Biologics Market, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
  • Table 19.153 Approved Subcutaneous Biologics Market: Distribution by Type of Biologic, 2022 and 2035
  • Table 19.154 Approved Subcutaneous Biologics Market for Antibodies, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
  • Table 19.155 Approved Subcutaneous Biologics Market for Nucleotides, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
  • Table 19.156 Approved Subcutaneous Biologics Market for Proteins, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
  • Table 19.157 Approved Subcutaneous Biologics Market for Vaccines, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
  • Table 19.158 Approved Subcutaneous Biologics Market for Other Biologics, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
  • Table 19.159 Approved Subcutaneous Biologics Market: Distribution by Type of Therapy, 2022 and 2035
  • Table 19.160 Approved Subcutaneous Biologics Market for Monotherapies, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
  • Table 19.161 Approved Subcutaneous Biologics Market for Combination Therapies, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
  • Table 19.162 Approved Subcutaneous Biologics Market for Monotherapies and Combination Therapies, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
  • Table 19.163 Approved Subcutaneous Biologics Market: Distribution by Therapeutic Area, 2022 and 2035
  • Table 19.164 Approved Subcutaneous Biologics Market for Autoimmune Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
  • Table 19.165 Approved Subcutaneous Biologics Market for Blood Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
  • Table 19.166 Approved Subcutaneous Biologics Market for Bone Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
  • Table 19.167 Approved Subcutaneous Biologics Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
  • Table 19.168 Approved Subcutaneous Biologics Market for Genetic Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
  • Table 19.169 Approved Subcutaneous Biologics Market for Hormonal Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
  • Table 19.170 Approved Subcutaneous Biologics Market for Hypoactive Sexual Desires Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
  • Table 19.171 Approved Subcutaneous Biologics Market for Infectious Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
  • Table 19.172 Approved Subcutaneous Biologics Market for Inflammatory Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
  • Table 19.173 Approved Subcutaneous Biologics Market for Kidney Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
  • Table 19.174 Approved Subcutaneous Biologics Market for Mental Health Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
  • Table 19.175 Approved Subcutaneous Biologics Market for Metabolic Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
  • Table 19.176 Approved Subcutaneous Biologics Market for Neurological Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
  • Table 19.177 Approved Subcutaneous Biologics Market for Oncological Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
  • Table 19.178 Approved Subcutaneous Biologics Market for Respiratory Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
  • Table 19.179 Approved Subcutaneous Biologics Market for Women's Health, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
  • Table 19.180 Approved Subcutaneous Biologics Market for Other Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
  • Table 19.181 Approved Subcutaneous Biologics Market: Distribution by Geographical Region, 2022 and 2035
  • Table 19.182 Approved Subcutaneous Biologics Market in North America, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
  • Table 19.183 Approved Subcutaneous Biologics Market in Europe, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
  • Table 19.184 Approved Subcutaneous Biologics Market in Asia, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
  • Table 19.185 AIMOVIG Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.186 AJOVY Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.187 Apidra® (insulin glulisine), Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.188 Aranesp® / Nesp® Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.189 Basaglar® / Abrasia (EU) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.190 BENLYSTA® (belimumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.191 BESREMi (ropeginterferon alfa-2b-njft) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.192 BIOTHRAX® (Anthrax Vaccine Adsorbed) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.193 CABLIVI (Caplacizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.194 Cegfila® Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.195 CIMZIA® (certolizumab pegol) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.196 COSENTYX® (secukinumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.197 CRYSVITA® (burosumab-twza) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.198 Cuvitru™ (immune globulin subcutaneous [human], 20% solution) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.199 DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj / DARZALEX® SC Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.200 DENGVAXIA (Dengue Tetravalent Vaccine) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.201 DUPIXENT® (dupilumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.202 EMGALITY (galcanezumab-gnlm) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.203 EMPAVELI™ (pegcetacoplan) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.204 Enbrel® (etanercept) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.205 ENSPRYNG™ (satralizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.206 EVENITY™ (romosozumab-aqqg) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.207 EXTAVIA® (interferon beta-l b) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.208 FASENRA® (benralizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.209 Fertavid® (follitropin beta) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.210 FIASP® (Insulin Aspart) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.211 Fulphila® (pegfilgrastim-jmdb) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.212 Gamunex-C® (Immune Globulin Injection [Human], 10% Caprylate /Chromatography Purified) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.213 GATTEX® / Revestive (teduglutide [rDNA origin]) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.214 GIVLAARI (givosiran) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.215 HAEGARDA® Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.216 HEMLIBRA® (emicizumab-kxwh) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.217 Hepcludex® (Bulevirtide) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.218 Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.219 HYQVIA (Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.220 ILARIS® (canakinumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.221 ILUMYA™ (tildrakizumab-asmn) / Ilumetri Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.222 Kalbitor (ecallantide) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.223 Kesimpta® (ofatumumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.224 KEVZARA® (sarilumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.225 KINERET® (anakinra) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.226 KIOVIG® / (Gammagard Liquid 10% (Immune Globulin Infusion) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.227 Kyntheum® / SILIQ™ / Lumicef® (brodalumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.228 Leqvio (Inclisiran) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.229 Lonquex® (lipegfilgrastim) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.230 Lyumjev (insulin lispro-aabc) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.231 Norditropin® (somatropin) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.232 NPLATE® (romiplostim) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.233 Nucala® (mepolizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.234 Nutropin AQ® (somatropin) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.235 OXLUMO™ (lumasiran) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.236 PALYNZIQ (pegvaliase-pqpz) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.237 Pergoveris® (follitropin alfa / lutropin alfa) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.238 Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.239 PLEGRIDY® (peginterferon beta-1a) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.240 PRALUENT® (alirocumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.241 Prolia® / Pralia® (denosumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.242 REBLOZYL® (luspatercept-aamt) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.243 REKOVELLE® (follitropin delta) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.244 Repatha® (evolocumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.245 RITUXAN HYCELA™ (rituximab and hyaluronidase human) / MabThera® SC (rituximab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.246 RYZODEG® 70/30 (insulin degludec and insulin aspart) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.247 Skyrizi (risankizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.248 SKYTROFA™ (lonapegsomatropin-tcgd) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.249 SOLIQUA® 100/33 (insulin glargine & lixisenatide injection) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.250 STELARA® (ustekinumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.251 Strensiq® (asfotase alfa) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.252 TAKHZYRO (lanadelumab-flyo) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.253 Taltz® (ixekizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.254 TEGSEDI (inotersen) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.255 Toujeo® (insulin glargine injection) U-300 Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.256 TREMFYA® (guselkumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.257 TRESIBA® (insulin degludec injection) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.258 Trulicity® (dulaglutide) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.259 TYMLOS™ (abaloparatide) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.260 Tysabri (Natalizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.261 Voxzogo (vosoritide) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.262 VYLEESI (bremelanotide injection) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.263 XEMBIFY (immune globulin subcutaneous, human - klhw) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.264 Xgeva® / RANMARK® (denosumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.265 XULTOPHY® / IDegLira (insulin degludec and liraglutide injection) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.266 XYOSTED (testosterone enanthate) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.267 ZEGALOGUE (dasiglucagon) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.268 Global Subcutaneous Formulation Technologies Market, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.269 Subcutaneous Formulation Technologies Market: Distribution by Type of Payment, 2022-2035 (USD Million)
  • Table 19.270 Subcutaneous Formulation Technologies Market for Milestone Payments, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.271 Subcutaneous Formulation Technologies Market for Upfront Payments, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.272 Subcutaneous Formulation Technologies Market: Distribution by Fundamental Principle, 2022-2035 (USD Million)
  • Table 19.273 Subcutaneous Formulation Technologies Market for Amino Acid Interaction Principles, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.274 Subcutaneous Formulation Technologies Market for Complex Formation Principles, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.275 Subcutaneous Formulation Technologies Market for Encapsulation Principles, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.276 Subcutaneous Formulation Technologies Market for Other Fundamental Principles, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.277 Subcutaneous Formulation Technologies Market: Distribution by End Users, 2022-2035 (USD Million)
  • Table 19.278 Subcutaneous Formulation Technologies Market for Biopharmaceutical Companies, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.279 Subcutaneous Formulation Technologies Market for Biotechnology Companies, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.280 Subcutaneous Formulation Technologies Market for Contract Development and Manufacturing Organizations, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.281 Subcutaneous Formulation Technologies Market for Educational Institutes, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.282 Subcutaneous Formulation Technologies Market for Investors, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.283 Subcutaneous Formulation Technologies Market for Pharmaceutical Companies, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.284 Subcutaneous Formulation Technologies Market for Research Institutes, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.285 Subcutaneous Formulation Technologies Market for Other End Users, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.286 Subcutaneous Formulation Technologies Market: Distribution by Therapeutic Area, 2022 and 2035
  • Table 19.287 Subcutaneous Formulation Technologies Market for Autoimmune Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.288 Subcutaneous Formulation Technologies Market for Genetic Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.289 Subcutaneous Formulation Technologies Market for Infectious Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.290 Subcutaneous Formulation Technologies Market for Metabolic Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.291 Subcutaneous Formulation Technologies Market for Oncological Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.292 Subcutaneous Formulation Technologies Market for Ophthalmic Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.293 Subcutaneous Formulation Technologies Market for Other Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.294 Subcutaneous Formulation Technologies Market: Distribution by Geographical Regions, 2022 and 2035
  • Table 19.295 Subcutaneous Formulation Technologies Market for North America, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.296 Subcutaneous Formulation Technologies Market for Europe, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.297 Subcutaneous Formulation Technologies Market for Asia, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
  • Table 19.298 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.299 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.300 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.301 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.302 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.303 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.304 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.305 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.306 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.307 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.308 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.309 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.310 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.311 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.312 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.313 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.314 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.315 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.316 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.317 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.318 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.319 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.320 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.321 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.322 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.323 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.324 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.325 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs:Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.326 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.327 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.328 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.329 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.330 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.331 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.332 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.333 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.334 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.335 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.336 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.337 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.338 Large Volume Wearable Injectors Market for Non-Insulin Drugs in LatinAmerica, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.339 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.340 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.341 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.342 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.343 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.344 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.345 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.346 Global Large Volume Wearable Injectors Market for Insulin, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.347 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.348 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.349 Large Volume Wearable Injectors Market for Insulin in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.350 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.351 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.352 Large Volume Wearable Injectors Market for Insulin in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.353 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.354 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.355 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.356 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.357 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.358 Large Volume Wearable Injectors Market for Insulin in Latin America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.359 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.360 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.361 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.362 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.363 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
  • Table 19.364 Global Autoinjectors Market, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.365 Global Autoinjectors Market for Anaphylaxis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.366 Global Disposable Autoinjectors Market for Anaphylaxis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.367 Global Intramuscular Autoinjectors Market for Anaphylaxis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.368 Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.369 Global Small Molecule-based Autoinjectors Market for Anaphylaxis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.370 Autoinjectors Market for Anaphylaxis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.371 Autoinjectors Market for Anaphylaxis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.372 Autoinjectors Market for Anaphylaxis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.373 Autoinjectors Market for Anaphylaxis in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.374 Global Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.375 Global Disposable Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.376 Global Reusable Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.377 Global Intramuscular Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.378 Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.379 Global Protein-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.380 Global Peptide-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.381 Global Antibody-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.382 Autoinjectors Market for Multiple Sclerosis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.383 Autoinjectors Market for Multiple Sclerosis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.384 Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.385 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2035 (USD Billion)
  • Table 19.386 Global Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.387 Global Disposable Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.388 Global Subcutaneous Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.389 Global Antibody-based Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.390 Global Small Molecule-based Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.391 Autoinjectors Market for Migraine in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.392 Autoinjectors Market for Migraine in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.393 Autoinjectors Market for Migraine in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.394 Autoinjectors Market for Migraine in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.395 Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.396 Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.397 Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.398 Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.399 Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.400 Global Antibody-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.401 Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.402 Global Small Molecule-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.403 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.404 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.405 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.406 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.407 Global Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.408 Global Disposable Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.409 Global Subcutaneous Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.410 Global Protein-based Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.411 Global Peptide-based Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.412 Autoinjectors Market for Diabetes in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.413 Autoinjectors Market for Diabetes in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.414 Autoinjectors Market for Diabetes in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.415 Autoinjectors Market for Diabetes in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.416 Global Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.417 Global Disposable Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.418 Global Subcutaneous Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.419 Global Intramuscular Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.420 Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.421 Global Protein-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.422 Global Antibody-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.423 Global Small Molecule-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.424 Autoinjectors Market for Other Indications in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.425 Autoinjectors Market for Other Indications in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.426 Autoinjectors Market for Other Indications in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.427 Autoinjectors Market for Other Indications in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.428 Global Autoinjectors Market, 2021-2035 (Million Units)
  • Table 19.429 Global Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
  • Table 19.430 Global Disposable Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
  • Table 19.431 Global Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
  • Table 19.432 Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
  • Table 19.433 Global Small Molecule-based Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
  • Table 19.434 Autoinjectors Market for Anaphylaxis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.435 Autoinjectors Market for Anaphylaxis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.436 Autoinjectors Market for Anaphylaxis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.437 Autoinjectors Market for Anaphylaxis in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.438 Global Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.439 Global Disposable Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.440 Global Reusable Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.441 Global Intramuscular Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.442 Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.443 Global Protein-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.444 Global Peptide-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.445 Global Antibody-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.446 Autoinjectors Market for Multiple Sclerosis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.447 Autoinjectors Market for Multiple Sclerosis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.448 Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.449 Autoinjectors Market for Multiple Sclerosis in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.450 Global Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.451 Global Disposable Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.452 Global Subcutaneous Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.453 Global Antibody-based Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.454 Global Small Molecule-based Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.455 Autoinjectors Market for Migraine in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.456 Autoinjectors Market for Migraine in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.457 Autoinjectors Market for Migraine in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.458 Autoinjectors Market for Migraine in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.459 Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.460 Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.461 Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.462 Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.463 Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.464 Global Antibody-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.465 Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.466 Global Small Molecule-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.467 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.468 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.469 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.470 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.471 Global Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.472 Global Disposable Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.473 Global Subcutaneous Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.474 Global Protein-based Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.475 Global Peptide-based Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.476 Autoinjectors Market for Diabetes in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.477 Autoinjectors Market for Diabetes in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.478 Autoinjectors Market for Diabetes in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.479 Autoinjectors Market for Diabetes in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.480 Global Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.481 Global Disposable Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
  • Table 19.482 Global Subcutaneous Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.483 Global Intramuscular Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.484 Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.485 Global Protein-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.486 Global Antibody-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.487 Global Small Molecule-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.488 Autoinjectors Market for Other Indications in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.489 Autoinjectors Market for Other Indications in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.490 Autoinjectors Market for Other Indications in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.491 Autoinjectors Market for Other Indications in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
  • Table 19.492 Prefilled Syringes Price, 2020-2030: Conservative, Base and Optimistic Scenarios (USD per unit)
  • Table 19.493 Global Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.494 Global Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2020-2030 (Million, Units)
  • Table 19.495 Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, 2020, 2025 and 2030 (USD Million)
  • Table 19.496 Prefilled Syringes Market: Distribution by Type of Chamber System, 2020, 2025 and 2030 (USD Million)
  • Table 19.497 Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, 2020, 2025 and 2030 (USD Million)
  • Table 19.498 Prefilled Syringes Market: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030
  • Table 19.499 Global Needle-free Injection Systems Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.500 Global Needle-free Injection Systems Market: Distribution by Actuation Mechanism, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.501 Global Needle-free Injection Systems Market: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
  • Table 19.502 Global Novel Drug Reconstitution Systems Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.503 Global Dual Chamber Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.504 Dual Chamber Prefilled Syringes Market, 2021 and 2030: Distribution by Physical State of Drug
  • Table 19.505 Dual Chamber Prefilled Syringes Market for Liquid / Powder Drugs, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.506 Dual Chamber Prefilled Syringes Market for Liquid / Liquid Drugs, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.507 Dual Chamber Prefilled Syringes Market, 2021 and2030: Distribution by Type of Fabrication Material Used
  • Table 19.508 Glass Dual Chamber Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.509 Plastic Dual Chamber Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.510 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Volume
  • Table 19.511 Dual Chamber Prefilled Syringes Market for <1 mL Syringes, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.512 Dual Chamber Prefilled Syringes Market for 1-2.5 mL Syringes, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.513 Dual Chamber Prefilled Syringes Market for 2.5-5 mL Syringes, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.514 Dual Chamber Prefilled Syringes Market for >5 mL Syringes, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.515 Dual Chamber Prefilled Syringes Market, 2021 and 2030: Distribution by Geography
  • Table 19.516 Dual Chamber Prefilled Syringes Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.517 Dual Chamber Prefilled Syringes Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.518 Dual Chamber Prefilled Syringes Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.519 Dual Chamber Prefilled Syringes Market in Latin America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.520 Dual Chamber Prefilled Syringes Market in Middle East and Africa, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.521 Global Dual Chamber Cartridges Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.522 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Physical State of Drug
  • Table 19.523 Dual Chamber Cartridges Market for Liquid / Powder Drugs, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.524 Dual Chamber Cartridges Market for Liquid / Liquid Drugs, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.525 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Type of Fabrication Material Used
  • Table 19.526 Glass Dual Chamber Cartridges Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.527 Plastic Dual Chamber Cartridges Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.528 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Volume
  • Table 19.529 Dual Chamber Cartridges Market for <1 mL Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.530 Dual Chamber Cartridges Market for 1-2.5 mL Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.531 Dual Chamber Cartridges Market for 2.5-5 mL Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.532 Dual Chamber Cartridges Market for >5 mL Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.533 Dual Chamber Cartridges Market, 2021-2030: Distribution by Geography
  • Table 19.534 Dual Chamber Cartridges Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.535 Dual Chamber Cartridges Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.536 Dual Chamber Cartridges Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.537 Dual Chamber Cartridges Market in Latin America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.538 Dual Chamber Cartridges Market in Middle East and Africa, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.539 Global Dual / Multi Chamber Infusion Bags Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.540 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Physical State of Drug
  • Table 19.541 Dual / Multi Chamber Infusion Bags Market for Liquid Mixture, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.542 Dual / Multi Chamber Infusion Bags Market for Frozen Mixture, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.543 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Type of Plastic
  • Table 19.544 Dual / Multi Chamber Infusion Bags Market for Ethylene Vinyl Acetate Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.545 Dual / Multi Chamber Infusion Bags Market for Polypropylene Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.546 Dual / Multi Chamber Infusion Bags Market for Polyvinyl Chloride Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.547 Dual / Multi Chamber Infusion Bags Market for Other Plastic Materials Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.548 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Volume
  • Table 19.549 Dual / Multi Chamber Infusion Bags Market for <250 mL Infusion Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.550 Dual / Multi Chamber Infusion Bags Market for 250-500 mL Infusion Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.551 Dual / Multi Chamber Infusion Bags Market for 501-1,000 mL Infusion Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.552 Dual / Multi Chamber Infusion Bags Market for >1,000 mL Infusion Bags, Conservative, Base and Optimistic Scenario, 2021- 2030 (USD Billion)
  • Table 19.553 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Geography
  • Table 19.554 Dual / Multi Chamber Infusion Bags Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.555 Dual / Multi Chamber Infusion Bags Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.556 Dual / Multi Chamber Infusion Bags Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.557 Dual / Multi Chamber Infusion Bags Market in Latin America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
  • Table 19.558 Dual / Multi Chamber Infusion Bags Market in Middle East and Africa, Conservative, Base and Optimistic Scenario, 2021-2030

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. 3D Medicines
  • 2. 89bio
  • 3. AB2 Bio
  • 4. Abbott Laboratories
  • 5. AbbVie
  • 6. Ablynx
  • 7. AC Immune
  • 8. Acceleron Pharma
  • 9. Accord Healthcare
  • 10. Acer Therapeutics
  • 11. ACG Management
  • 12. Activa Brand Products
  • 13. Adisave
  • 14. Adocia
  • 15. Affibody
  • 16. Affinivax
  • 17. Aguettant
  • 18. Aijex Pharma International
  • 19. Ajinomoto Bio-Pharma Services
  • 20. Akcea Therapeutics
  • 21. Akero Therapeutics
  • 22. Akeso
  • 23. Akeso Tiancheng
  • 24. AKRA DERMOJET
  • 25. AktiVax
  • 26. Alder BioPharmaceuticals
  • 27. Alexion
  • 28. Alexion Pharmaceuticals
  • 29. Alkermes
  • 30. Allakos
  • 31. Allergan
  • 32. Alnylam Pharmaceuticals
  • 33. Alopexx Oncology
  • 34. Alphamab
  • 35. Alteogen
  • 36. Altor BioScience
  • 37. ALTuCELL
  • 38. Altus Pharmaceuticals
  • 39. Alvogen
  • 40. ALZA
  • 41. AMAG Pharmaceuticals
  • 42. Amedra Pharmaceuticals
  • 43. Amgen
  • 44. Amgen Astellas BioPharma
  • 45. AnaptysBio
  • 46. Andes Biotechnologies
  • 47. Androsystems
  • 48. Antares Pharma
  • 49. Anterogen
  • 50. Anthera Pharmaceuticals
  • 51. AOP Orphan Pharmaceuticals
  • 52. Apellis Pharmaceuticals
  • 53. Aphios
  • 54. Apobiologix
  • 55. Apotex
  • 56. Araclon Biotech
  • 57. Arecor
  • 58. argenx
  • 59. ARMO BioSciences
  • 60. Arrowhead Pharmaceuticals
  • 61. Arsia Therapeutics
  • 62. ARTE
  • 63. Arthritis Innovation Corporation (AIC)
  • 64. Asahi Kasei
  • 65. Ascendis Pharma
  • 66. ASIT Biotech
  • 67. ASLAN Pharmaceuticals
  • 68. Aspen Pharmacare
  • 69. Astellas Pharma
  • 70. AstraZeneca
  • 71. Athyrium Capital Management
  • 72. Atridia
  • 73. Avadel Pharmaceuticals
  • 74. Avant Medical Corporation
  • 75. Avid Bioservices
  • 76. Avillion
  • 77. Axxia Pharmaceuticals
  • 78. BASF
  • 79. Bavarian Nordic
  • 80. Baxalta
  • 81. Bay City Capital
  • 82. Bayer
  • 83. Becton Dickinson
  • 84. Beijing Dongfang Biotech
  • 85. Beijing Northland Biotech
  • 86. Bespak
  • 87. Beta-Cell
  • 88. Beta-O2 Technologies
  • 89. Bill & Melinda Gates Foundation
  • 90. Bill & Melinda Gates Foundation
  • 91. Bioam Gestion
  • 92. BioAtla
  • 93. BIOCAD
  • 94. Biocorp
  • 95. Biogen
  • 96. Bioject Medical Technologies
  • 97. BioMarin Pharmaceutical
  • 98. Biomay
  • 99. BioMimetix
  • 100. BioValve
  • 101. Bird Rock Bio
  • 102. BJ Bioscience
  • 103. Boehringer Ingelheim
  • 104. Boston Pharmaceuticals
  • 105. Braeburn Pharmaceuticals
  • 106. Bristol-Myers Squibb
  • 107. Britannia Pharmaceuticals
  • 108. Broadfin Capital
  • 109. Cadila Pharmaceuticals
  • 110. Calibr
  • 111. Cam Med
  • 112. Cambridge Antibody Technology
  • 113. Cambridge Consultants
  • 114. Camurus
  • 115. CAPRISA
  • 116. Carbion
  • 117. Catalyst Biosciences
  • 118. CDC Enterprises
  • 119. Celgene
  • 120. Celldex Therapeutics
  • 121. Cellnovo
  • 122. Centocor Ortho Biotech
  • 123. Central Texas Angel Network
  • 124. CeQur
  • 125. Changchun BCHT Biotechnology
  • 126. Chondrial Therapeutics
  • 127. Chugai Pharmaceutical
  • 128. CinnaGen
  • 129. CiVi Biopharma
  • 130. Cleveland BioLabs
  • 131. Clinigen
  • 132. CM Biomaterials
  • 133. CM-CIC Innovation
  • 134. College Diabetes Network
  • 135. Companion Medical
  • 136. Complex Biosystems
  • 137. Copernicus
  • 138. Corbion
  • 139. Corvidia Therapeutics
  • 140. Creative Biolabs
  • 141. Creative BioMart
  • 142. Crescendo Pharmaceuticals
  • 143. Crossject
  • 144. CSL Behring
  • 145. CSPC Pharmaceutical
  • 146. C-Tri
  • 147. Cumberland Pharmaceuticals
  • 148. CuraVac
  • 149. CytoDyn
  • 150. Cytori Therapeutics
  • 151. Daiichi Sankyo
  • 152. Daikyo Seiko
  • 153. DALI Medical Devices
  • 154. D'Antonio Consultants International
  • 155. Debiotech
  • 156. Deerfield Management
  • 157. Delpor
  • 158. DelSiTech
  • 159. Dermira
  • 160. Desentum
  • 161. DiaMedica Therapeutics
  • 162. Diamesco
  • 163. Diasome Pharmaceuticals
  • 164. Dicerna Pharmaceuticals
  • 165. Digital Medics
  • 166. Digna Biotech
  • 167. Dongbao
  • 168. Dr. Reddy's Laboratories
  • 169. DSM Venturing
  • 170. Duoject Medical Systems
  • 171. DURECT
  • 172. Dyax (acquired by Shire)
  • 173. Eagle Pharmaceuticals
  • 174. Eagle Pharmaceuticals
  • 175. Eddingpharm
  • 176. Eiger BioPharmaceuticals
  • 177. Eisai
  • 178. Elcam Medical
  • 179. Elektrofi
  • 180. Eli Lilly
  • 181. EMD Serono
  • 182. Emergent BioSolutions
  • 183. Emperra
  • 184. Enable Injections
  • 185. Endo Pharmaceuticals
  • 186. Enesi Pharma
  • 187. EOC Pharma
  • 188. Epilepsy Foundation
  • 189. Etubics
  • 190. European Pharma Group
  • 191. Ever Supreme Bio Technology
  • 192. Evive Biotech
  • 193. Excelse Bio
  • 194. EyeTech
  • 195. Felton International
  • 196. Ferring Pharmaceuticals
  • 197. Finox Biotech
  • 198. Flamel Technologies
  • 199. Flowonix Medical
  • 200. FluGen
  • 201. Fresenius Kabi
  • 202. FUJIFILM Diosynth Biotechnologies
  • 203. Future Injection Technologies
  • 204. Fuze
  • 205. GALVmed
  • 206. GC Pharma
  • 207. GeneCure Biotechnologies
  • 208. Genentech
  • 209. Generon
  • 210. Genexine
  • 211. Genmab
  • 212. Genocea Biosciences
  • 213. Genor Biopharma
  • 214. GEROPHARM
  • 215. Gerresheimer
  • 216. Gilde Healthcare
  • 217. Gilead Sciences
  • 218. GlaxoSmithKline
  • 219. Globe Medical Tech
  • 220. GlobeImmune
  • 221. Grifols
  • 222. Guangdong Xiangxue Precision Medical Technology
  • 223. HAL Allergy
  • 224. Halozyme Therapeutics
  • 225. Hanall Biopharma
  • 226. Hanmi Pharmaceutical
  • 227. Harbour BioMed
  • 228. Haselmeier
  • 229. Health Decisions
  • 230. Hengrui Therapeutics
  • 231. HengRui USA
  • 232. Hercules Capital
  • 233. Heron Therapeutics
  • 234. Hikma Pharmaceuticals
  • 235. Horizon Therapeutics
  • 236. Hospira
  • 237. Human Genome Sciences
  • 238. IDINVEST Partners
  • 239. ILTOO Pharma
  • 240. Il-Yang Pharmaceutical
  • 241. Immunex
  • 242. ImmunoForge
  • 243. Immunomedics
  • 244. ImmunoVaccine Technologies
  • 245. ImmuPharma
  • 246. ImmusanT
  • 247. Immutep
  • 248. Impax Laboratories
  • 249. Incepta Pharmaceuticals
  • 250. Indivior
  • 251. Inhibrx
  • 252. Injecto
  • 253. INJEX Pharma
  • 254. INmune Bio
  • 255. Inmunotek
  • 256. InnoCore Pharmaceuticals
  • 257. Innovare R&D
  • 258. Innovate UK
  • 259. Innovent Biologics
  • 260. Inolife Sciences
  • 261. Inovio Pharmaceuticals
  • 262. i-novion
  • 263. Insense
  • 264. Insulet
  • 265. Insuline Medical
  • 266. Intarcia Therapeutics
  • 267. Intas Pharmaceuticals
  • 268. Integrity Bio
  • 269. Intrexon
  • 270. IO Biotech
  • 271. Ionis Pharmaceuticals
  • 272. Ipsen
  • 273. ISA Pharmaceuticals
  • 274. ISU Abxis
  • 275. Izana Bioscience
  • 276. Janssen
  • 277. Janssen Biotech
  • 278. Janus Capital
  • 279. JCR Pharmaceuticals
  • 280. JDRF
  • 281. Jiangsu Delfu Medical Device
  • 282. Jiangsu Hengrui Medicine
  • 283. Jiangsu Wan Hai Medical Instruments
  • 284. JO Pharma
  • 285. Johnson & Johnson
  • 286. Juvenile Diabetes Research Foundation
  • 287. Kaléo
  • 288. Kangstem Biotech
  • 289. Kastle Therapeutics
  • 290. KBI Biopharma
  • 291. Kedrion Biopharma
  • 292. Kinevant Sciences
  • 293. King Pharmaceuticals
  • 294. Kingsbury Capital Partners
  • 295. Kiniksa Pharmaceuticals
  • 296. Kitasato Daiichi Sankyo Vaccine
  • 297. Knight Therapeutics
  • 298. Kolltan Pharmaceuticals
  • 299. Kymab
  • 300. Kyowa Hakko Kirin
  • 301. Kyowa Kirin
  • 302. Laboratorios Liomont
  • 303. Lapeyronie Hospital
  • 304. Larimar Therapeutics
  • 305. Lenis Medical
  • 306. LEO Pharma
  • 307. Leukocare Biotechnology
  • 308. LIB Therapeutics
  • 309. Lindy Biosciences
  • 310. Lineage Therapeutics
  • 311. Lundbeck
  • 312. Lupin
  • 313. Luye Pharma
  • 314. Lynkogen
  • 315. Malvern Panalytical
  • 316. Manchester Institute of Biotechnology
  • 317. Maruho
  • 318. Maruishi Pharmaceutical
  • 319. Massachusetts Institute of Technology
  • 320. MaxiVAX
  • 321. McGill University
  • 322. McNair Group
  • 323. Medac Pharma
  • 324. Medical International Technology
  • 325. Medicalchain
  • 326. Medicines Patent Pool (MPP)
  • 327. Medicom Innovation Partner
  • 328. MedImmune
  • 329. MedinCell
  • 330. Medipacs
  • 331. Medison Pharma
  • 332. MedPro
  • 333. Medtronic
  • 334. Medtrum
  • 335. Megapharm
  • 336. Merck
  • 337. Merck KGaA
  • 338. Merck Serono
  • 339. Merieux Développement
  • 340. MGlas
  • 341. MicroVAX
  • 342. Mika Medical
  • 343. MilliporeSigma
  • 344. Miracle Medical
  • 345. Mitsubishi Gas Chemical
  • 346. Mitsubishi Tanabe Pharma
  • 347. MJ Biopharm
  • 348. Momenta Pharmaceuticals
  • 349. Morphogenesis
  • 350. MorphoSys
  • 351. Mundipharma
  • 352. Mylan
  • 353. Nano Precision Medical
  • 354. NantCell
  • 355. National Cancer Institute
  • 356. National Institute of Allergy and Infectious Diseases
  • 357. National Institute of Diabetes and Digestive and Kidney Diseases
  • 358. National Institute of Neurological Disorders and Stroke
  • 359. National Institutes of Health
  • 360. Nektar Therapeutics
  • 361. Nemera
  • 362. Neoleukin Therapeutics
  • 363. Neumedicines
  • 364. Neurimmune
  • 365. NeuroDerm
  • 366. NGM Biopharmaceuticals
  • 367. Ningbo Zhengli Pharmaceutical Packing
  • 368. Nippon Organon
  • 369. Nipro Medical
  • 370. Nordic Group
  • 371. Novartis
  • 372. Novimmune
  • 373. Novo Nordisk
  • 374. NPS Pharmaceuticals
  • 375. Nuance Designs
  • 376. Numab
  • 377. Nuova Ompi
  • 378. OBI Pharma
  • 379. OliPass
  • 380. OliX Pharmaceuticals
  • 381. Omeros
  • 382. Ompi
  • 383. Oncolix
  • 384. Ono Pharmaceutical
  • 385. OPKO Health
  • 386. OrbiMed
  • 387. Orphan Technologies
  • 388. Orphan Technologies
  • 389. Otsuka Pharmaceutical
  • 390. Oval Medical Technologies
  • 391. Owen Mumford
  • 392. Oxford Finance
  • 393. PA Consulting
  • 394. Pacira BioSciences
  • 395. Palmetto Partners
  • 396. Par Pharmaceutical
  • 397. PaxVax
  • 398. Pendiq
  • 399. Penjet
  • 400. Pfizer
  • 401. PharmaJet
  • 402. Pharmakon Advisors
  • 403. PharmaSens
  • 404. Pharmstandard
  • 405. PhaseBio Pharmaceuticals
  • 406. PHC Injection Device Technologies
  • 407. Philogen
  • 408. Phoundry Pharmaceuticals
  • 409. Plas-Tech Engineering
  • 410. Polfa Tarchomin
  • 411. Population Council
  • 412. Portal Instruments
  • 413. Precision NanoSystems
  • 414. Primequal
  • 415. ProJect Pharmaceutics
  • 416. Prolynx
  • 417. Promius Pharma
  • 418. Protagonist Therapeutics
  • 419. ProteoThera
  • 420. Provenance Biopharmaceuticals
  • 421. Pulse NeedleFree Systems
  • 422. QS Medical Technology
  • 423. Qu Biologics
  • 424. RA Capital Management
  • 425. Ra Pharmaceuticals
  • 426. Radius Health
  • 427. Receptos
  • 428. Recon Therapeutics
  • 429. Redmile Group
  • 430. ReForm Biologics
  • 431. Regeneron Pharmaceuticals
  • 432. REMD Biotherapeutics
  • 433. RemeGen
  • 434. Rentschler Biotechnologie
  • 435. Revance Therapeutics
  • 436. Revolutions Medical
  • 437. Rhône-Poulenc Rorer
  • 438. Rhythm Pharmaceuticals
  • 439. RMS Medical Products
  • 440. Roche
  • 441. Rock Springs Capital
  • 442. Roselabs Bioscience
  • 443. ROXALL Medizin
  • 444. R-Pharm
  • 445. Sabby Management
  • 446. Safe Save Medical Cell Sciences & Technology
  • 447. Salix Pharmaceuticals
  • 448. Samsung Bioepis
  • 449. Sandoz
  • 450. Sanofi
  • 451. Sanofi Pasteur
  • 452. Santen Pharmaceutical
  • 453. Schering-Plough
  • 454. Schott
  • 455. Scripps Research Institute
  • 456. Sensile Medical
  • 457. Seqirus
  • 458. Serina Therapeutics
  • 459. Sernova
  • 460. Serum Institute of India
  • 461. Sewa Medicals
  • 462. Shandong Pharmaceutical Glass
  • 463. Shandong Weigao
  • 464. Shandong Zibo Minkang Pharmaceutical Packing
  • 465. Shanghai Dahua Pharmaceutical
  • 466. Shanghai JMT-Bio
  • 467. Shanghai Junshi Biosciences
  • 468. Shanghai Umitai Medical Technology
  • 469. Shenzhen Geno-immune Medical Institute
  • 470. Shenzhen Salubris Pharmaceuticals
  • 471. Shin Yan Sheno Precision Industrial
  • 472. Shionogi
  • 473. Shire
  • 474. SHL Medical
  • 475. Shreya Life Sciences
  • 476. Silicon Valley Bank
  • 477. Sinocelltech
  • 478. SiO2 Medical Products
  • 479. SK Chemicals
  • 480. Société Générale Asset Management
  • 481. Sofinnova Partners
  • 482. Solteam Medical
  • 483. SOOIL Development
  • 484. Sosei Heptares
  • 485. SOTIO
  • 486. Spectrum Pharmaceuticals
  • 487. Square Pharmaceuticals
  • 488. STADA Arzneimittel
  • 489. Statera Biopharma
  • 490. SteadyMed Therapeutics
  • 491. Stemirna Therapeutics
  • 492. Strongbridge Biopharma
  • 493. Subcuject
  • 494. Sumitomo Dainippon Pharma
  • 495. Sun Pharmaceutical Industries
  • 496. Sun Yat-sen University
  • 497. Swedish Orphan Biovitrum
  • 498. Synermore Biologics
  • 499. Synthon Hispania
  • 500. Taisei Kako
  • 501. Taisho Pharmaceutical
  • 502. Takeda Pharmaceutical
  • 503. Talecris Biotherapeutics
  • 504. Tandem Diabetes Care
  • 505. Tasly Transgene Tianjin BioPharmaceutical
  • 506. Technical University of Munich
  • 507. Telegraph Hill Partners
  • 508. TerSera Therapeutics
  • 509. Terumo
  • 510. Tetris Pharma
  • 511. Teva Pharmaceuticals
  • 512. Texan Allergy & Sinus Center
  • 513. Texas Diabetes Institute
  • 514. Texas Emerging Technologies Fund
  • 515. The National Institute for Health and Care Excellence
  • 516. The National Medical Products
  • 517. The National Medical Products Administration
  • 518. The Wyss Institute at Harvard University
  • 519. TheraCyte
  • 520. Theralpha
  • 521. Tianjin SinoBiotech
  • 522. Titan Pharmaceuticals
  • 523. Tonghua Dongbao
  • 524. Torii Pharmaceutical
  • 525. Touche Medical
  • 526. TRACON Pharmaceuticals
  • 527. Transcoject
  • 528. Transgene
  • 529. Travere Therapeutics
  • 530. TREOS Bio
  • 531. TRIO Pharmaceuticals
  • 532. Tyfill Pharmapack
  • 533. TYME Technologies
  • 534. U.S. Medical Instruments
  • 535. UCB Pharma
  • 536. Ultragenyx Pharmaceutical
  • 537. Uman Pharma
  • 538. Uni-Bio Science Group
  • 539. Unilever
  • 540. Unilife
  • 541. Union Medico
  • 542. United BioPharma
  • 543. United Therapeutics
  • 544. University of Colorado
  • 545. University of Texas Health Science Center
  • 546. US WorldMeds
  • 547. Vaccine Research Center (VRC)
  • 548. Valeant Pharmaceuticals
  • 549. Valeritas
  • 550. VectivBio
  • 551. Venrock
  • 552. Ventana Medical Systems
  • 553. Vetter Pharma
  • 554. ViaCyte
  • 555. ViCentra
  • 556. Viela Bio
  • 557. ViiV Healthcare
  • 558. ViroMed
  • 559. ViroPharma
  • 560. Visus Therapeutics
  • 561. Vitaeris
  • 562. Vivo Capital
  • 563. Wanhai Medical
  • 564. West Pharmaceutical Services
  • 565. Wild Basin Investments
  • 566. XBiotech
  • 567. Xellia Pharmaceuticals
  • 568. XEME Biopharma
  • 569. Xencor
  • 570. Xeris Pharmaceuticals
  • 571. YangZhong Wealth Metal
  • 572. Youlyy Industrial
  • 573. Ypsomed
  • 574. Zensun
  • 575. Zogenix
  • 576. Zweite TechnoStar